



(11) **EP 1 809 737 B9**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Description
Claims DE
Numerous spelling errors of minor importance

(51) Int Cl.:
C12N 5/0784 (2010.01) A61K 39/00 (2006.01)

(86) International application number:
PCT/US2005/036304

(87) International publication number:
WO 2006/042177 (20.04.2006 Gazette 2006/16)

(48) Corrigendum issued on:
05.10.2011 Bulletin 2011/40

(45) Date of publication and mention
of the grant of the patent:
24.11.2010 Bulletin 2010/47

(21) Application number: **05804341.5**

(22) Date of filing: **07.10.2005**

(54) **MATURE DENDRITIC CELL COMPOSITIONS AND METHODS FOR CULTURING SAME**
ZUSAMMENSETZUNGEN REIFER DENDRITISCHER ZELLEN UND VERFAHREN ZU DEREN
KULTIVIERUNG
COMPOSITIONS DE CELLULES DENDRITIQUES MATURES ET PROCEDES DE MISE EN
CULTURE CORRESPONDANTS

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR**
Designated Extension States:
AL BA HR MK YU

• **HINOHARA, Atsushi**
Durham, NC 27704 (US)

(74) Representative: **Harrison Goddard Foote**
Belgrave Hall
Belgrave Street
Leeds
LS2 8DD (GB)

(30) Priority: **07.10.2004 US 522512 P**

(43) Date of publication of application:
25.07.2007 Bulletin 2007/30

(56) References cited:
WO-A-02/36141 WO-A-2004/031276
US-A1- 2004 037 807

(60) Divisional application:
10174970.3 / 2 251 418

(73) Proprietor: **Argos Therapeutics, Inc.**
Durham, NC 27704 (US)

• **FARIES M B ET AL: "Calcium signaling inhibits
interleukin-12 production and activates CD83+
dendritic cells that induce Th2 cell development"**
BLOOD, W.B.SAUNDERS COMPANY,
ORLANDO, FL, vol. 98, no. 8, 15 October 2001
(2001-10-15), pages 2489-2497, XP002249512
ISSN: 0006-4971

(72) Inventors:
• **HEALEY, Don**
Rougemont, NC 27572 (US)
• **TCHEREPANOVA, Irina**
Rougemont, NC 27572 (US)
• **ADAMS, Melissa**
Chapel Hill, NC 27517 (US)

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 809 737 B9

- KALADY MATTHEW F ET AL: "Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity." THE JOURNAL OF SURGICAL RESEARCH. JAN 2004, vol. 116, no. 1, January 2004 (2004-01), pages 24-31, XP002383696 ISSN: 0022-4804
- KALADY MATTHEW F ET AL: "Sequential maturation stimuli enhance antigen-specific immunogenicity of RNA-transfected dendritic cells" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03), page 677, XP002383697 & 93RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN FRANCISCO, CALIFORNIA, USA; APRIL 06-10, 2002 ISSN: 0197-016X
- YOSHIDA SEIICHI ET AL: "Generation of dendritic cells from the ventricular fluid in patients with meningeal carcinomatosis." JOURNAL OF NEUROIMMUNOLOGY JUL 2003, vol. 140, no. 1-2, July 2003 (2003-07), pages 172-176, XP002462718 ISSN: 0165-5728
- JONULEIT H ET AL: "PRO-INFLAMMATORY CYTOKINES AND PROSTAGLANDINS INDUCE MATURATION OF POTENT IMMUNOSTIMULATORY DENDRITIC CELLS UNDER FETAL CALF SERUM-FREE CONDITIONS" EUROPEAN JOURNAL OF IMMUNOLOGY, WEINHEIM, DE, vol. 27, no. 12, 1997, pages 3135-3142, XP000906835 ISSN: 0014-2980
- KALADY MATTHEW F ET AL: "Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity." THE JOURNAL OF SURGICAL RESEARCH. JAN 2004, vol. 116, no. 1, January 2004 (2004-01), pages 24-31, XP002383696 ISSN: 0022-4804
- KOYA RICHARD C ET AL: "Potent maturation of monocyte-derived dendritic cells after CD40L lentiviral gene delivery." JOURNAL OF IMMUNOTHERAPY (HAGERSTOWN, MD. : 1997) 2003 SEP-OCT, vol. 26, no. 5, September 2003 (2003-09), pages 451-460, XP008064909 ISSN: 1524-9557
- KALADY MATTHEW F ET AL: "Sequential maturation stimuli enhance antigen-specific immunogenicity of RNA-transfected dendritic cells" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03), page 677, XP002383697 & 93RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN FRANCISCO, CALIFORNIA, USA; APRIL 06-10, 2002 ISSN: 0197-016X
- MOSCA P J ET AL: "A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment." BLOOD. 15 NOV 2000, vol. 96, no. 10, 15 November 2000 (2000-11-15), pages 3499-3504, XP002383698 ISSN: 0006-4971
- SCANDELLA ELKE ET AL: "Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells." BLOOD. 15 AUG 2002, vol. 100, no. 4, 15 August 2002 (2002-08-15), pages 1354-1361, XP002383699 ISSN: 0006-4971
- VIEIRA ET AL: J IMMUNOL, vol. 164, 2000, pages 4507-4512,

Description

CROSS REFERENCE TO RELATED APPLICATIONS

5 [0001] This application claims priority to U.S. provisional application 60/522,512, filed 7 October 2004.

FIELD OF THE INVENTION

10 [0002] The present invention relates to the generation of mature dendritic cells and their use in cell therapy and to educate immune effector cells. The mature dendritic cells can be generated from immature dendritic cells.

BACKGROUND

15 [0003] Cell therapy utilizes modified antigen presenting cells (APCs) or immune effector cells to initiate an immune response in a patient. Antigen presenting cells are central to cell therapy because they initiate the immune response. Indeed, they are the only cells capable of inducing a primary immune response from the T lymphocytes.

20 [0004] Dendritic cells (DC) are the most potent APCs involved in adaptive immunity. They coordinate the initiation of immune responses by naive T cells and B cells and induce antigen-specific cytotoxic T lymphocyte (CTL) responses. DCs are specialized in several ways to prime helper and killer T cells *in vivo*. For example, immature DCs that reside in peripheral tissues are equipped to capture antigens and to produce immunogenic MHC-peptide complexes. In response to maturation-inducing stimuli such as inflammatory cytokines, immature DCs develop into potent T cell stimulators by upregulating adhesion and costimulatory molecules. At the same time, they migrate into secondary lymphoid organs to select and stimulate rare antigen-specific T cells. However, potent stimulation of T cells occurs only after DC maturation, a process that increases the availability of MHC-peptide complexes on the cell surface, in addition to co-stimulatory molecules, that direct the effector function of the responding T-cells. Indeed, immature DCs may be harmful in anti-tumor and other immunotherapies because they can induce immunotolerance rather than immunostimulation.

25 [0005] Co-stimulation is typically necessary for a T cell to produce sufficient cytokine levels that induce clonal expansion. One characteristic of dendritic cells which makes them potent antigen presenting cells is that they are rich in co-stimulatory molecules of the immune response, such as the molecules CD80 and CD86, which activate the molecule CD28, on T lymphocytes. In return, T-helper cells express CD40L, which ligates CD40 on DCs. These mutual interactions between DCs and T-cells leads to 'maturation' of the former, and the development of effector function in the latter. The expression of adhesion molecules, like the molecule CD54 or the molecule CD11a/CD18, facilitate the co-operation between the dendritic cells and the T-cells. Another special characteristic of dendritic cells is to deploy different functions depending on their stage of differentiation. Thus, the capture of the antigen and its transformation are the two principal functions of the immature dendritic cell, whereas its capacities to present the antigen in order to stimulate the T cells increases as the dendritic cells migrate into the tissues and the lymphatic ganglia. This change of functionality corresponds to a maturation of the dendritic cell. Thus, the passage of the immature dendritic cell to the mature dendritic cell represents a fundamental step in the initiation of the immune response. Traditionally, this maturation was followed by monitoring the change of the surface markers on the DCs during this process. Some of the more important cell surface markers characteristic of the different stages of maturation of the dendritic cells are summarized in Table I, below. However, the surface markers can vary depending upon the maturation process.

Table I

Cell type	Surface markers
Hematopoietic stem cell	CD34+
Monocytes	CD14 ⁺⁺ , DR ⁺ , CD86 ⁺ , CD16 ^{+/-} , CD54 ⁺ , CD40 ⁺
Immature dendritic cell	CD14 ^{+/-} , CD16 ⁻ , CD80 ^{+/-} , CD83 ⁻ , CD86 ⁺ , CD1a ⁺ , CD54 ⁺ , DQ ⁺ , DR ⁺⁺
Mature dendritic cell	CD14 ⁻ , CD83 ⁺⁺ , CD86 ⁺⁺ , CD80 ⁺⁺ , DR ⁺⁺⁺ , DQ ⁺⁺ , CD40 ⁺⁺ , CD54 ⁺⁺ , CD1a ^{+/-}

50 [0006] Mature DCs are currently preferred to immature DCs for immunotherapy. Only fully mature DC progeny lack GM-CSF Receptor (GM-CSF-R) and remain stably mature upon removal/in the absence of GM-CSF. Also, mature DCs have been shown to be superior in inducing T cell responses *in vitro* and *in vivo*. In contrast, immature DCs are reported to induce tolerance *in vitro* (Jonuleit et al. (2000) Exp. Med. 192:1213) as well as *in vivo* (Dhodapkar et al. (2001) Exp. Med. 193:233) by inducing regulatory T cells. Mature dendritic cells also are useful to take up and present antigen to T-lymphocytes *in vitro* or *in vivo*. The modified, antigen presenting DCs and/or T cells educated from these modified DCs have many applications, including diagnostic, therapy, vaccination, research, screening and gene delivery.

[0007] It is difficult to isolate mature dendritic cells from peripheral blood because less than 1% of the white blood cells belongs to this category. Mature DCs are also difficult to extract from tissues. This difficulty, in combination with the potential therapeutic benefit of DCs in cell therapy, has driven research and development toward new methods to generate mature dendritic cells using alternative sources. Several methods are reported to produce mature DCs from immature dendritic cells.

[0008] For example, Jonuleit et al. (Eur J Immunol (1997) 12:3135-3142) disclose maturation of immature human DCs by culture in medium containing a cytokine cocktail (IL-1 β , TNF- α , IL-6 and PGE₂).

[0009] WO 95/28479 discloses a process for preparing dendritic cells by isolating peripheral blood cells and enriching for CD34⁺ blood precursor cells, followed by expansion with a combination of hematopoietic growth factors and cytokines.

[0010] European Patent Publication EP-A-0 922 758 discloses the production of mature dendritic cells from immature dendritic cells derived from pluripotential cells having the potential of expressing either macrophage or dendritic cell characteristics. The method requires contacting the immature dendritic cells with a dendritic cell maturation factor containing IFN- γ .

[0011] European Patent Publication EP-B-0 633930 teaches the production of human dendritic cells by first culturing human CD34⁺ hematopoietic cells (i) with GM-CSF, (ii) with TNF- α and IL-3, or (iii) with GM-CSF and TNF- α to induce the formation of CD1a⁺ hematopoietic cells.

[0012] Patent Publication No. 2004/0152191 discloses the maturation of dendritic cells by contacting them with RU 41740.

[0013] U.S. Patent Publication No. 2004/0146492 teaches a process for producing recombinant dendritic cells by transforming hematopoietic stem cells followed by differentiation of the stem cells into dendritic cells by culture in medium containing GM-CSF.

[0014] U.S. Patent Publication No. 2004/0038398 discloses methods for the preparation of substantially purified populations of DCs and monocytes from the peripheral blood of mammals. Myeloid cells are isolated from the mammal and DCs are separated from this population to yield an isolated subpopulation of monocytes. DCs are then enriched by negative selection with anti-CD2 antibodies to remove T cells.

[0015] Although mature DCs are functionally competent and are therefore useful to induce antigen-specific T cells, not all mature DCs are optimized to induce these responses. It has been shown that some mature DCs may also stimulate T helper cells by secreting IL-12. Macatonia et al. (1995) Immunol. 154:507 1; Ahuja et al. (1998) Immunol. 161:868 and Unintford et al. (1999) Immunol. 97:588. IL-12 also has been shown to enhance antigen-specific CD8⁺ T cell response to antigen in an animal model. Schmidt et al. (1999) Immunol. 163:2561.

[0016] Mosca et al. (2000) Blood 96:3499, disclose that culture of DC in AIM V medium containing both soluble CD40L trimer and IFN γ 1b results in increased IL-12 expression in comparison to culture in medium containing only soluble CD40L trimer.

[0017] Koya et al. (2003) J. Immunother. 26(5):451 report that IL-12 expression can be enhanced by transducing immature DCs, in the presence of IFN γ , with a lentiviral vector encoding CD40 Ligand. Greater than 90% of the CD40L transduced DCs expressed CD83 on their cell surface. Unfortunately, lentiviral transduced cells are not suitable for therapeutic purposes, and proviral integration into the genome of the transduced cell can result in leukemia. Furthermore, persistent expression of CD40L may have detrimental effects on APC function and viability.

[0018] This work supplemented the earlier work of Mackey, et al. (1998) J. Immunol. 161:2094 who reported that *in vivo*, DCs require maturation via CD40 to generate anti-tumor immunity. Similarly, Kuniyoshi, J.S. et al. (1999) Cell Immunol. 193:48 have shown that DCs treated with soluble trimeric CD40 Ligand plus IFN- γ stimulated potent T-cell proliferation and induced T cells with augmented antigen-specific lysis. Kalady, M.F. et al. (2004) J. Surg. Res. 116:24, reported that human monocytederived DCs transfected with mRNA encoding melanoma antigen MART-1 or influenza M1 matrix protein exposed to different maturation stimuli added either simultaneously or sequentially showed variability in antigen presentation, IL-12 secretion and immunogenicity of effector T cells raised in the presence of these DCs. Most importantly, this study showed that the application of a 'cytokine cocktail' consisting of IL-1 β , TNF- α , IL-6 and PGE₂, followed by extracellular soluble CD40L protein was superior to applying all the agents simultaneously. However, these authors did not study the combination of IFN- γ signaling with transient CD40L signalling in a sequential process. Faries et al (2001), Blood, 15 October 2001, Vol 98, No 8, reported the culturing of immature dendritic cells with either calcium comophore or interferon - γ , tumor necrosis factor and soluble CD40L. The soluble CD40L is added six hours after addition of IFN- γ and TNF- α . Moreover, despite the production of IL-12 when IFN- γ and CD40L are concomitantly added to the culture medium, the recent prior art shows that the resulting DCs are actually immunosuppressive, rather than pro-inflammatory (Hwu et al. (2000) J. Immunol. 164: 3596 ; Munn et al. (2002) 297:1867; and Grohmann et al. (2003) Trends Immunol. 24:242) due to the induction of an enzyme that metabolized tryptophan resulting in the starvation of responder T-cells that then fail to proliferate. Thus, current literature suggests that the combination of IFN- γ and CD40L should not increase immunopotency. The present invention addresses the long-felt need to provide improved methods for DC maturation and mature DCs with enhanced immunopotency.

SUMMARY OF THE INVENTION

[0019] Applicants have discovered that potent immunostimulation occurs when immature dendritic cells are sequentially signaled with a first signal comprising an interferon gamma receptor (IFN- γ R) agonist followed by a second signal comprising a CD40 agonist. Accordingly, this invention provides a method according to the appended claims.

[0020] In preferred embodiments, the immature DCs are further contacted with PGE₂ and optionally with TNF- α . In alternative embodiments the method further comprises contacting the immature DCs, signaled DCs and/or CCR7⁺ mature dendritic cells with a compound selected from the group consisting of: galactosylceramides, glycosylceramides, galactofuranosylceramides, arabinopyranosylceramides, α -C-galactosylceramides and α -S-galactosylceramides. Preferably the compound is a galactosylceramide. Most preferably, the galactosylceramide is (2S, 3S, 4R)-1-O-(alpha-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol (KRN7000).

[0021] Thus, the invention provides a method for preparing an enriched population of mature dendritic cells (DCs), comprising sequentially signaling immature dendritic cells with a first signal comprising an IFN- γ R agonist and a tumor necrosis factor alpha receptor (TNF- α R) agonist followed by a second signal comprising a CD40 agonist, thereby preparing an enriched population of mature dendritic cells, wherein said signaling is in the absence of an effective amount of IL-1 β or IL-6. Preferably, the immature DCs are further contacted with PGE₂.

[0022] Preferred IFN- γ R agonists are mammalian IFN- γ , preferably human IFN- γ and active fragments thereof. Preferred TNF- α R agonists are mammalian TNF- α , preferably human TNF- α and active fragments thereof. Preferred CD40 agonists are mammalian CD40 Ligands (CD40L), preferably human CD40L and active fragments and variants thereof, as well as agonistic antibodies to CD40 receptor. Signaling can be initiated by providing the signaling agonist in the culture medium, introduction of the agonist into the cell, and/or upon translation within the dendritic cell of an mRNA encoding an agonistic polypeptide. The method can be practiced *in vivo* or *ex vivo*. Dendritic cells matured *ex vivo* according to the methods of the invention can then be administered to the subject to induce or enhance an immune response.

[0023] Each of the dendritic cells can be further modified by the administration of an immunogen to the DC. The DC will take up and process the immunogen, and display it on its cell surface. The immunogen can be delivered *in vivo* or *ex vivo*. The matured, cultured DCs can be administered to a subject to induce or enhance an immune response. In yet a further embodiment, the antigen loaded mature DCs are used to educate naïve immune effector cells.

[0024] Also disclosed although not claimed is a composition comprising *in vitro* matured dendritic cells, such as CD83⁺ CCR7⁻ mature DCs and CD83⁺ CCR7⁺ mature DCs. Mature dendritic cells obtainable from methods of the invention express increased levels of IL-12 in comparison to immature dendritic cells, and/or express less than 500 pg IL-10 per million dendritic cells. The compositions disclosed herein are useful to raise an immune response in a subject by administering to the subject an effective amount of the population.

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

[0025]

SEQ ID NO:1 is a human CD40L cDNA. Nucleotides 40 to 825 represent the coding region, including the ATG translation start codon and the TGA translational stop codon.

SEQ ID NO:2 is an amino acid sequence for full length human CD40L protein.

SEQ ID NO:3 is a human CD40 cDNA. Nucleotides 67 to 522 represent the coding region, including the ATG translation start codon and the TAG translational stop codon.

SEQ ID NO:4 is an amino acid sequence for human CD40 (the receptor for CD40L).

SEQ ID NO:5 is a human IFN- γ cDNA. Nucleotides 109 to 609 represent the coding region, including the ATG translation start codon and the translational stop codon.

SEQ ID NO:6 is an amino acid sequence for human IFN- γ .

SEQ ID NO:7 is a human TNF- α cDNA. Nucleotides 170 to 971 represent the coding region, including the ATG translation start codon and the TGA translational stop codon.

SEQ ID NO:8 is an amino acid sequence for human TNF- α .

SEQ ID NO:9 is a mouse CD40L cDNA. Nucleotides 13 to 795 represent the coding region, including the ATG translation start codon and the TGA translational stop codon.

SEQ ID NO:10 is an amino acid sequence for full length mouse CD40L protein.

SEQ ID NO:11 is a CD40L 5' primer.

SEQ ID NO:12 is a CD40L 3' primer.

SEQ ID NO:13 is the DNA sequence corresponding to an optimized human CD40L mRNA.

SEQ ID NO:14 is the CD40 Receptor 3'UTR.

SEQ ID NO:15 is the untranslated region of final exon of the human beta-actin 3' UTR.

SEQ ID NO:16 is the minimal functional element of the human beta-actin 3' UTR.

SEQ ID NO:17 is the simian rotavirus Gene 6 3'UTR.

SEQ ID NO:18 is the minimal functional element of the simian rotavirus Gene 6 3'UTR.

SEQ ID NO:19 is the human Hsp70 5'UTR (HSPA1A).

SEQ ID NO:20 is the mouse VEGF 5'UTR.

SEQ ID NO:21 is the minimal functional element of the mouse VEGF 5'UTR.

SEQ ID NO:22 is the Spleen Necrosis Virus LTR RU5 Region.

SEQ ID NO:23 is the Tobacco Etch Virus 5' Leader sequence.

SEQ ID NOs:24-25 are HLA-A201 restricted MART-APL peptide, native peptide and PSA-1 peptide, respectively.

BRIEF DESCRIPTION OF THE FIGURES

[0026]

Figure 1 shows that sequential maturation of DCs with IFN- γ then soluble CD40L results in optimal IL-12p70 secretion. DCs were matured with cytokine cocktail, soluble CD40L alone, or with soluble CD40L plus IFN- γ . Pre-incubation of immature DCs with 1000 U/ml of IFN- γ for 18 hrs, followed by addition of soluble CD40L for a further 18 hrs results in maximum IL-12p70 release. Applying soluble CD40L first, followed by IFN- γ is perceived as a negative signal, with minimal IL-12p70 release, accompanied by IL-10.

Figure 2 shows that HELA cells transfected with mRNA encoding CD40L and having a polyA tail of >400 nucleotides express cell surface protein, as defined by FACS analysis with anti-CD40L (CD154) antibody.

Figure 3 shows that IL-12p70 secretion from CD40L mRNA transfected cells is proportional to the size of the transfection payload. DCs were transfected with a titration of CD40L mRNA followed immediately by the addition of 1000 U/ml IFN- γ . At least 4 μ g per million DCs of CD40L mRNA is required to induce significant levels of IL-12p70 release.

Figure 4 shows that at least 100 U/ml of IFN- γ is required to synergize with the CD40L mRNA payload to induce maximal IL-12p70 secretion. DCs were transfected with 4 μ g CD40L mRNA per million cells, and immediately incubated with a titration of IFN- γ . IL-12p70 and IL-10 were measured in culture supernatants after 24hrs.

Figure 5A shows that IL-12p70 secretion induced by CD40L/IFN- γ occurs approximately 24hrs after transfection of DCs and culture in the presence of IFN- γ . DCs were transfected with 4 μ g CD40L mRNA per million cells, and immediately cultured with 1000 U/ml IFN- γ . Supernatants were collected from replica cultures at the designated times, and assayed for IL-12p70 and IL-10 content.

Figure 5B shows that addition of TNF- α to CD40L mRNA transfected DCs results in the generation of IL-12p70, but the level of expression is less than that achieved with IFN- γ as the co-maturation agent.

Figure 5C shows that the use of TNF- α as the co-maturation factor also results in elevated levels of IL-10 compared to the use of IFN- γ .

Figures 6A and 6B show that DCs transfected with mRNA encoding CD40L demonstrate cellular expression as defined by FACS analysis with anti-CD40L (CD154) antibody. In Figure 6A, DCs were transfected with 4 μ g CD40L mRNA per million cells and analyzed at various time points. The majority of CD40L is localized within an intracellular compartment as demonstrated by a 4 hour time point where surface expression is considerably lower. Figure 6B shows that significant intracellular expression is evident at 60 minutes with 27% positive DCs and increasing to 79% by 3 hours.

Figure 6C shows transient expression of CD40L protein post transfection of DC with CD40L encoding mRNA.

Figure 7 shows that DCs transfected with CD40L mRNA and cultured in the presence of IFN- γ secrete IL-12p70 despite the presence of an excess of blocking anti-CD40L antibody, CD40/CD40L interactions operate within an "intracellular" compartment. DCs were transfected 4 μ g CD40L mRNA and immediately cultured with 1000 U/ml IFN- γ in the presence of either 10 or 50 μ g/ml of blocking anti-CD40L antibody. IL-12 p70 release is reduced by only 50%, indicating that intracellular signaling, rather than cell to cell signaling is the primary pathway for the induction of IL-12p70.

Figure 8 shows that DCs transfected with CD40L mRNA and co-cultured with IFN- γ require the presence of PGE₂ to enable chemokine dependent migration. DCs were transfected with a titration of CD40L mRNA and immediately incubated with 1000 U/ml IFN- γ and 1 μ g/ml PGE₂. DCs transfected with eGFP and matured with a cytokine cocktail containing PGE₂ represent a positive control. After 18 hrs of maturation, DCs from each culture condition were tested in "transwell" migration assays against the lymph node homing chemokines, CCL19 and 21. DC migration was proportional to the size of the CD40L mRNA payload.

Figure 9 shows that DCs matured via transfection with CD40L mRNA and cultured in the presence of IFN- γ and PGE₂ invoke efficient T-cell "recall responses" when compared to DCs matured in the presence of the "cytokine cocktail". DCs were co-transfected with 2 μ g flu M1 mRNA per million cells as antigen payload, and 4 μ g eGFP

mRNA control, and subsequently matured with cytokine cocktail. Alternatively, DCs were co-transfected with 2 μ g flu M1 mRNA per million cells as antigen payload, and 4 μ g CD40L mRNA as the maturation payload. These latter cells were immediately cultured in 1000 U/ml IFN- γ and 1 μ g/ml PGE₂ to complete the maturation process. After 24hrs, each DC population was used in ELISpot assays to recruit an anti-flu M1 recall responses, as determined by the frequency of responding T-cells secreting IFN- γ . DCs matured by transfection with CD40L mRNA in the presence of IFN- γ and PGE₂ invoked a more potent anti-flu response.

Figure 10 shows that DCs matured via transfection with CD40L mRNA and cultured in the presence of IFN- γ and PGE₂ invoke efficient "primary T-cell responses" when compared to DCs matured in the presence of the "cytokine cocktail". DCs were transfected with 2 μ g MART-APL mRNA per million cells as antigen payload, and subsequently matured with cytokine cocktail. Alternatively, DCs were co-transfected with 2 μ g MART-APL mRNA per million cells as antigen payload, and 4 μ g CD40L mRNA as the maturation payload. These latter cells were immediately cultured in 1000 U/ml IFN- γ and 1 μ g/ml PGE₂ to complete the maturation process. After 24 hrs, each DC population was used to raise T-cell responses to MART-APL peptide sequences, generated from the transfected MART-APL mRNA payload, by co-culture of autologous naive CD8+ T-cells for 7 days in the presence of 0.2 U/ml of IL-2. After this first round of stimulation, T-cells were harvested and established in IL-2 ELISpot assays, restimulated with the appropriately matured, antigen loaded DCs. DCs matured by transfection with CD40L mRNA in the presence of IFN- γ and PGE₂ invoked a more potent anti-MART-APL response as determined by the frequency of responder CD8+ Tcells secreting IL-2.

Figure 11 shows the induction of cytotoxic T-cells by DCs expressing MART-APL mRNA. Figure 11a shows that maturation of DCs using co-transfection with MART-APL mRNA as source of antigen, and CD40L mRNA, with the addition of soluble interferon- γ /PGE₂ invokes an effective CTL response, whereas Figure 11b shows that DCs transfected with MART-APL mRNA, but matured with a 'cytokine cocktail', do not. T2-PSA: T2 cells pulsed with an HLA-A2 restricted peptide from prostate-specific antigen (PSA) as a negative control target. MART-T2: T2 cells pulsed with the HLA-A2 restricted MART epitope in its native sequence. MART-APL-T2: T2 cells pulsed with the HLA-A2 restricted MART epitope as the preferred 'altered peptide ligand'.

Figure 12 shows the migratory capacity of PME-CD40L matured DCs in transwell assays to the lymph node chemokines, CCL19 and 21. Four independent healthy donors were tested in parallel, with each DC preparation being transfected with 1ug amplified total RCC tumor RNA, along with 4 ug CD40L RNA per million DCs. Migration assays were set up 24 hrs post transfection with the mRNA payloads.

Figure 13 shows the induction of CTL responses from a healthy donor to the melanoma-associated antigen, MART-1. DCs were prepared and loaded with MART-1 RNA and matured via the 'CD40L base process' or DCs were prepared using the PME-CD40L process. DCs and purified CD8 T-cells were co-cultured in a 1:10 ratio, undergoing three rounds of stimulation in the presence of IL-2. The data shows ⁵¹CR release cytotoxic assays using MART-1 peptide pulsed T2 target cells across a range of effector-target ratios.

Figure 14 shows the induction of a fully autologous CTL response to DCs loaded with total amplified RCC tumor RNA, PME-CD40L matured DCs. DCs and purified CD8 T-cells were co-cultured in a 1:10 ratio, undergoing three rounds of stimulation in the presence of IL-2. 5 days after the last stimulation, CD8 T-cells were restimulated with DCs transfected with: total amplified RCC RNA, hTERT RNA, Survivin RNA, G250 RNA or negative control DCs transfected with eGFP RNA. The data is derived from identifying responder T-cells by cell surface staining for the activation marker, CD69, and simultaneously detection of intracellular IFN- γ and IL-2. Intracellular cytokine responses were subdivided to identify IFN- γ single positive (effector cells) from IFN- γ /IL-2 double positive (memory cells).

Figure 15 shows the expansion of NKT-cells (a) and MART-1 reactive CTLs (b) by MART-1 RNA transfected CD40L base process matured DCs pulsed with KRN7000 or vehicle. The data clearly shows that KRN7000 pulsed DC can expand NKT-cells as defined by CD1d/KRN7000 tetramer staining, and that the presence of an expanded population of NKT-cells can increase the concomitant recruitment of primary CTLs to MART-1, as defined by tetramer staining with MART-1/HLA-A2 tetramers.

Figure 16 shows the alignment of the human (SEQ ID NO:1) and mouse (SEQ ID NO:9) CD40L cDNAs. Figures 16A, 16B and 16C represent 3 consecutive pages of the alignment of SEQ ID NO:1 and 2.

Figure 17 shows the alignment of the human (SEQ ID NO:2) and mouse (SEQ ID NO:10) CD40L proteins.

Figure 18 shows the level of IL-12 expression by DC transfected with mRNA transcribed from pCR2.1 CD40L WT Delta X-E plasmid in 100 ug scale (Delta X-E1) or 1 mg scale (Delta X-E2) transcription reactions using mMessage mMachine T7 Ultra kit (Ambion). Reference RNA was transcribed from plasmid pCR2.1 CD40L WT. The transcribed CD40L RNAs were modified by addition of polyA tail using polyA plus kit (Epicentre). RNAs were transfected into DCs. Approximately 20 hrs post transfection the amount of IL-12 was measured in the supernatant of the matured DCs using Elisa Negative: IL-12 expression measure in supernatant of DCs electroporated without any CD40L RNA.

MODES FOR CARRYING OUT THE INVENTION

[0027] Throughout this disclosure, various publications, patents and published patent specifications are referenced by an identifying citation.

[0028] The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. These methods are described in the following publications. See, e.g., Sambrook et al. MOLECULAR CLONING: A LABORATORY MANUAL, 2nd edition (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (Ausubel et al. eds. (1987)); the series METHODS IN ENZYMOLOGY (Academic Press, Inc.); PCR: A PRACTICAL APPROACH (M. MacPherson et al. IRL Press at Oxford University Press (1991)); PCR 2: A PRACTICAL APPROACH (MacPherson, Hames and Taylor eds. (1995)); ANTIBODIES, A LABORATORY MANUAL (Harlow and Lane eds. (1988)); USING ANTIBODIES, A LABORATORY MANUAL (Harlow and Lane eds. (1999)); and ANIMAL CELL CULTURE (Freshney ed. (1987)).

Definitions

[0029] As used in the specification and claims, the singular form "a," "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a cell" includes a plurality of cells, including mixtures thereof.

[0030] As used herein, the term "comprising" is intended to mean that the compositions and methods include the recited elements, but not excluding others. "Consisting essentially of" when used to define compositions and methods, shall mean excluding other elements of any essential significance to the combination. Thus, a composition consisting essentially of the elements as defined herein would not exclude trace contaminants from the isolation and purification method and pharmaceutically acceptable carriers, such as phosphate buffered saline, preservatives, and the like. "Consisting of" shall mean excluding more than trace elements of other ingredients and substantial method steps for administering the compositions of this invention. Embodiments defined by each of these transition terms are within the scope of this invention.

[0031] All numerical designations, e.g., pH, temperature, time, concentration, and molecular weight, including ranges, are approximations which are varied (+) or (-) by increments of 0.1. It is to be understood, although not always explicitly stated, that the reagents described herein are merely exemplary and that equivalents of such are known in the art.

[0032] The term "antigen" is well understood in the art and includes substances which are immunogenic, i.e., immunogen. It will be appreciated that the use of any antigen is envisioned for use in the present invention and thus includes, but is not limited to a self-antigen (whether normal or disease-related), an infectious antigen (e.g., a microbial antigen, viral antigen, etc.), or some other foreign antigen (e.g., a food component, pollen, etc.). The term "antigen" or alternatively, "immunogen" applies to collections of more than one immunogen, so that immune responses to multiple immunogens may be modulated simultaneously. Moreover, the term includes any of a variety of different formulations of immunogen or antigen.

[0033] A "native" or "natural" or "wild-type" antigen is a polypeptide, protein or a fragment which contains an epitope, which has been isolated from a natural biological source, and which can specifically bind to an antigen receptor, when presented as an MHC/peptide complex, in particular a T cell antigen receptor (TCR), in a subject.

[0034] The term "tumor associated antigen" or "TAA" refers to an antigen that is associated with a tumor. Examples of well known TAAs include gp100, MART and MAGE.

[0035] The terms "major histocompatibility complex" or "MHC" refers to a complex of genes encoding cell-surface molecules that are required for antigen presentation to T cells and for rapid graft rejection. In humans, the MHC is also known as the "human leukocyte antigen" or "HLA" complex. The proteins encoded by the MHC are known as "MHC molecules" and are classified into Class I and Class II MHC molecules. Class I MHC molecules include membrane heterodimeric proteins made up of an α chain encoded in the MHC noncovalently linked with the β_2 -microglobulin. Class I MHC molecules are expressed by nearly all nucleated cells and have been shown to function in antigen presentation to CD8⁺ T cells. Class I molecules include HLA-A, B, and C in humans. Class II MHC molecules also include membrane heterodimeric proteins consisting of noncovalently associated α and β chains. Class II MHC molecules are known to function in CD4⁺ T cells and, in humans, include HLA-DP, -DQ, and -DR.

[0036] The term "antigen presenting cells (APCs)" refers to a class of cells capable of presenting one or more antigens in the form of peptide-MHC complex recognizable by specific effector cells of the immune system, and thereby inducing an effective cellular immune response against the antigen or antigens being presented. APCs can be intact whole cells such as macrophages, B-cells, endothelial cells, activated T-cells, and dendritic cells; or other molecules, naturally occurring or synthetic, such as purified MHC Class I molecules complexed to β_2 -microglobulin. While many types of cells may be capable of presenting antigens on their cell surface for T-cell recognition, only dendritic cells have the capacity to present antigens in an efficient amount to activate naive T-cells for cytotoxic T-lymphocyte (CTL) responses.

[0037] The term "dendritic cells (DCs)" refers to a diverse population of morphologically similar cell types found in a

variety of lymphoid and non-lymphoid tissues, Steinman (1991) *Ann. Rev. Immunol.* 9:271-296. Dendritic cells constitute the most potent and preferred APCs in the organism. While the dendritic cells can be differentiated from monocytes, they possess distinct phenotypes. For example, a particular differentiating marker, CD14 antigen, is not found in dendritic cells but is possessed by monocytes. Also, mature dendritic cells are not phagocytic, whereas the monocytes are strongly phagocytosing cells. It has been shown that mature DCs can provide all the signals necessary for T cell activation and proliferation.

[0038] The term "immune effector cells" refers to cells capable of binding an antigen and which mediate an immune response. These cells include, but are not limited to, T cells, B cells, monocytes, macrophages, NK cells and cytotoxic T lymphocytes (CTLs), for example CTL lines, CTL clones, and CTLs from tumor, inflammatory, or other infiltrates.

[0039] A "naïve" immune effector cell is an immune effector cell that has never been exposed to an antigen capable of activating that cell. Activation of naive immune effector cells requires both recognition of the peptide:MHC complex and the simultaneous delivery of a costimulatory signal by a professional APC in order to proliferate and differentiate into antigen-specific armed effector T cells.

[0040] "Immune response" broadly refers to the antigen-specific responses of lymphocytes to foreign substances. Any substance that can elicit an immune response is said to be "immunogenic" and is referred to as an "immunogen". All immunogens are antigens, however, not all antigens are immunogenic. An immune response of this invention can be humoral (via antibody activity) or cell-mediated (via T cell activation).

[0041] As used herein, the term "educated, antigen-specific immune effector cell", is an immune effector cell as defined above, which has previously encountered an antigen. In contrast to its naïve counterpart, activation of an educated, antigen specific immune effector cell does not require a costimulatory signal. Recognition of the peptide:MHC complex is sufficient.

[0042] "Activated", when used in reference to a T cell, implies that the cell is no longer in G₀ phase, and begins to produce one or more of cytotoxins, cytokines and other related membrane-associated proteins characteristic of the cell type (e.g., CD8⁺ or CD4⁺), and is capable of recognizing and binding any target cell that displays the particular peptide/MHC complex on its surface, and releasing its effector molecules.

[0043] As used herein, the term "inducing an immune response in a subject" is a term understood in the art and refers to an increase of at least about 2-fold, or alternatively at least about 5-fold, or alternatively at least about 10-fold, or alternatively at least about 100-fold, or alternatively at least about 500-fold, or alternatively at least about 1000-fold or more in an immune response to an antigen (or epitope) which can be detected or measured, after introducing the antigen (or epitope) into the subject, relative to the immune response (if any) before introduction of the antigen (or epitope) into the subject. An immune response to an antigen (or epitope), includes but is not limited to, production of an antigen-specific (or epitope-specific) antibody, and production of an immune cell expressing on its surface a molecule which specifically binds to an antigen (or epitope). Methods of determining whether an immune response to a given antigen (or epitope) has been induced are well known in the art. For example, antigen-specific antibody can be detected using any of a variety of immunoassays known in the art, including, but not limited to, ELISA, wherein, for example, binding of an antibody in a sample to an immobilized antigen (or epitope) is detected with a detectably-labeled second antibody (e.g., enzyme-labeled mouse anti-human Ig antibody).

[0044] "Co-stimulatory molecules" are involved in the interaction between receptor-ligand pairs expressed on the surface of antigen presenting cells and T cells. Research accumulated over the past several years has demonstrated convincingly that resting T cells require at least two signals for induction of cytokine gene expression and proliferation (Schwartz, R.H. (1990) *Science* 248: 1349-1356 and Jenkins, M.K. (1992) *Immunol. Today* 13:69-73). One signal, the one that confers specificity, can be produced by interaction of the TCR/CD3 complex with an appropriate MHC/peptide complex. The second signal is not antigen specific and is termed the "co-stimulatory" signal. This signal was originally defined as an activity provided by bone-marrow-derived accessory cells such as macrophages and dendritic cells, the so called "professional" APCs. Several molecules have been shown to enhance co-stimulatory activity. These are heat stable antigen (HSA) (Liu, Y. et al. (1992) *J. Exp. Med.* 175:437-445), chondroitin sulfate-modified MHC invariant chain (li-CS) (Naujokas, M.F. et al. (1993) *Cell* 74:257-268), intracellular adhesion molecule 1 (ICAM-1) (Van Seventer, G.A. (1990). *Immunol.* 144:4579-4586), B7-1, and B7-2/B70 (Schwartz, R.H. (1992) *Cell* 71:1065-1068). These molecules each appear to assist co-stimulation by interacting with their cognate ligands on the T cells. Co-stimulatory molecules mediate co-stimulatory signal(s), which are necessary, under normal physiological conditions, to achieve full activation of naïve T cells. One exemplary receptor-ligand pair is the B7 family of co-stimulatory molecule on the surface of APC5 and its counterreceptor CD28 or CTLA-4 on T cells (Freeman, et al. (1993) *Science* 262:909-911; Young, et al. (1992)]. *Clin. Invest.* 90:229 and Nabavi, et al. (1992) *Nature* 360:266-268). Other important co-stimulatory molecules are CD40, and CD54. The term "costimulatory molecule" encompasses any single molecule or combination of molecules which, when acting together with a MHC/peptide complex bound by a TCR on the surface of a T cell, provides a co-stimulatory effect which achieves activation of the T cell that binds the peptide. The term thus encompasses B7, or other co-stimulatory molecule(s) on an antigen-presenting matrix such as an APC, fragments thereof (alone, complexed with another molecule (s), or as part of a fusion protein) which, together with MHC complex, binds to a cognate ligand and results in activation

of the T cell when the TCR on the surface of the T cell specifically binds the peptide. It is intended, although not always explicitly stated, that molecules having similar biological activity as wild-type or purified co-stimulatory molecules (e.g., recombinantly produced or muteins thereof) are intended to be used within the invention.

5 [0045] As used herein, the term "cytokine" refers to any one of the numerous factors that exert a variety of effects on cells, for example, inducing growth or proliferation. Non-limiting examples of cytokines which may be used alone or in combination in the practice of the present invention include, interleukin-2 (IL-2), stem cell factor (SCF), interleukin-3 (IL-3), interleukin-6 (IL-6), interleukin-12 (IL-12), G-CSF, granulocyte macrophage-colony stimulating factor (GM-CSF), interleukin-1 alpha (IL-1 α), interleukin-1L (IL-1L), MIP-11, leukemia inhibitory factor (LIF), c-kit ligand, thrombopoietin (TPO) and flt3 ligand. One embodiment of the present invention includes culture conditions in which an effective amount of IL-1 β and/or IL-6 is excluded from the medium. Cytokines are commercially available from several vendors such as, for example, Genzyme (Framingham, MA), Genentech (South San Francisco, CA), Amgen (Thousand Oaks, CA), R&D Systems (Minneapolis, MN) and Immunex (Seattle, WA). It is intended, although not always explicitly stated, that molecules having similar biological activity as wild-type or purified cytokines (e.g., recombinantly produced or muteins thereof) are intended to be used within the invention.

15 [0046] The terms "polynucleotide", "nucleic acid" and "nucleic acid molecule" are used interchangeably to refer to polymeric forms of nucleotides of any length. The polynucleotides may contain deoxyribonucleotides, ribonucleotides, and/or their analogs. Nucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The term "polynucleotide" includes, for example, single-stranded, double-stranded and triple helical molecules, a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. In addition to a native nucleic acid molecule, a nucleic acid molecule of the present invention may also comprise modified nucleic acid molecules. As used herein, mRNA refers to an RNA that can be translated in a dendritic cell. Such mRNAs typically are capped and have a ribosome binding site (Kozak sequence) and a translational initiation codon.

25 [0047] The term "peptide" is used in its broadest sense to refer to a compound of two or more subunit amino acids, amino acid analogs, or peptidomimetics. The subunits may be linked by peptide bonds. In another embodiment, the subunit may be linked by other bonds, e.g., ester, ether, etc. As used herein the term "amino acid" refers to either natural and/or unnatural or synthetic amino acids, including glycine and both the D and L optical isomers, amino acid analogs and peptidomimetics. A peptide of three or more amino acids is commonly called an oligopeptide if the peptide chain is short. If the peptide chain is long, the peptide is commonly called a polypeptide or a protein.

30 [0048] The term "genetically modified" means containing and/or expressing a foreign gene or nucleic acid sequence which in turn, modifies the genotype or phenotype of the cell or its progeny. In other words, it refers to any addition, deletion or disruption to a cell's endogenous nucleotides.

35 [0049] As used herein, "expression" refers to the processes by which polynucleotides are transcribed into mRNA and mRNA is translated into peptides, polypeptides, or proteins. If the polynucleotide is derived from genomic DNA of an appropriate eukaryotic host expression may include splicing of the mRNA. Regulatory elements required for expression include promoter sequences to bind RNA polymerase and transcription initiation sequences for ribosome binding. For example, a bacterial expression vector includes a promoter such as the lac promoter and for transcription initiation the Shine-Dalgarno sequence and the start codon AUG (Sambrook *et al.* (1989) *supra*). Similarly, a eukaryotic expression vector includes a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome. Such vectors can be obtained commercially or assembled by the sequences described in methods known in the art, for example, the methods herein below for constructing vectors in general.

40 [0050] "Under transcriptional control" is a term understood in the art and indicates that transcription of a polynucleotide sequence, usually a DNA sequence, depends on its being operatively linked to an element which contributes to the initiation of, or promotes, transcription. "Operatively linked" refers to a juxtaposition wherein the elements are in an arrangement allowing them to function.

45 [0051] A "gene delivery vehicle" is defined as any molecule that can carry inserted polynucleotides into a host cell. Examples of gene delivery vehicles are liposomes, biocompatible polymers, including natural polymers and synthetic polymers; lipoproteins; polypeptides; polysaccharides; lipopolysaccharides; artificial viral envelopes; metal particles; and bacteria, or viruses, such as baculovirus, adenovirus and retrovirus, bacteriophage, cosmid, plasmid, fungal vectors and other recombination vehicles typically used in the art which have been described for expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple protein expression.

50 [0052] "Gene delivery," "gene transfer," "transfection" and the like as used herein, are terms referring to the introduction of an exogenous polynucleotide into a host cell, irrespective of the method used for the introduction. Transfection refers to delivery of any nucleic acid to the interior of a cell. Gene delivery refers to the delivery of a nucleic acid that may be integrated into the host cell's genome, or that may replicate independently of the host cell genome. Gene delivery or gene transfer does not refer to introduction of an mRNA into a cell. Transfection methods include a variety of techniques

such as electroporation, protein-based, lipid-based and cationic ion based nucleic acid delivery complexes, viral vectors, "gene gun" delivery and various other techniques known to those of skill in the art. The introduced polynucleotide can be stably maintained in the host cell or may be transiently expressed. In preferred embodiments, an mRNA is introduced into a DC and is transiently expressed. Stable maintenance typically requires that the introduced polynucleotide either contains an origin of replication compatible with the host cell or integrates into a replicon of the host cell such as an extrachromosomal replicon (e.g., a plasmid) or a nuclear or mitochondrial chromosome. A number of vectors are capable of mediating transfer of genes to mammalian cells, as is known in the art and described herein.

[0053] A "viral vector" is defined as a recombinantly produced virus or viral particle that comprises a polynucleotide to be delivered into a host cell, either in vivo, ex vivo or in vitro. Examples of viral vectors include retroviral vectors, adenovirus vectors, adeno-associated virus vectors, alphavirus vectors and the like. Alphavirus vectors, such as Semliki Forest virus-based vectors and Sindbis virus-based vectors, have also been developed for use in gene therapy and immunotherapy. See, Schlesinger and Dubensky (1999) *Curr. Opin. Biotechnol.* 5:434-439 and Zaks et al. (1999) *Nat. Med.* 7:823-827. In aspects where gene transfer is mediated by a retroviral vector, a vector construct refers to the polynucleotide comprising the retroviral genome or part thereof, and a therapeutic gene. As used herein, "retroviral mediated gene transfer" or "retroviral transduction" carries the same meaning and refers to the process by which a gene or nucleic acid sequences are stably transferred into the host cell by virtue of the virus entering the cell and integrating its genome into the host cell genome. The virus can enter the host cell via its normal mechanism of infection or be modified such that it binds to a different host cell surface receptor or ligand to enter the cell. As used herein, "retroviral vector" refers to a viral particle capable of introducing exogenous nucleic acid into a cell through a viral or viral-like entry mechanism.

[0054] Retroviruses carry their genetic information in the form of RNA; however, once the virus infects a cell, the RNA is reverse-transcribed into the DNA form which integrates into the genomic DNA of the infected cell. The integrated DNA form is called a provirus.

[0055] In aspects where gene transfer is mediated by a DNA viral vector, such as an adenovirus (Ad), pseudo adenoviral or adeno-associated virus (MV), vector construct refers to the polynucleotide comprising the viral genome or part thereof, and a transgene. Adenoviruses (Ads) are a relatively well characterized, homogenous group of viruses, including over 50 serotypes. (See, e.g., WO 95/27071). Ads are easy to grow and do not require integration into the host cell genome. Recombinant Ad-derived vectors, particularly those that reduce the potential for recombination and generation of wild-type virus, have also been constructed. (See, WO 95/00655 and WO 95/11984). Wild-type MV has high infectivity and specificity integrating into the host cell's genome. (See, Hermonat and Muzyczka (1984) *Proc. Natl. Acad. Sci. USA* 81: 6466-6470 and Lebkowski et al. (1988) *Mol. Cell. Biol.* 8:3988-3996).

[0056] Vectors that contain both a promoter and a cloning site into which a polynucleotide can be operatively linked are known in the art. Such vectors are capable of transcribing RNA in vitro or in vivo, and are commercially available from sources such as Stratagene (La Jolla, CA) and Promega Biotech (Madison, WI). In order to optimize expression and/or in vitro transcription, it may be necessary to remove, add or alter 5' and/or 3' untranslated portions of the clones to eliminate extra, potential inappropriate alternative translation initiation codons or other sequences that may interfere with or reduce expression, either at the level of transcription or translation. Alternatively, consensus ribosome binding sites can be inserted immediately 5' of the start codon to enhance expression.

[0057] Gene delivery vehicles also include several non-viral vectors, including DNA/liposome complexes, and targeted viral protein-DNA complexes. Liposomes that also comprise a targeting antibody or fragment thereof can be used in the methods of this invention. To enhance delivery to a cell, nucleic acids or proteins of this invention can be conjugated to antibodies or binding fragments thereof which bind cell surface antigens, e.g., TCR, CD3 or CD4.

[0058] "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding between the bases of the nucleotide residues. The hydrogen bonding may occur by Watson-Crick base pairing, Hoogsteen binding, or in any other sequence-specific manner. The complex may comprise two strands forming a duplex structure, three or more strands forming a multi-stranded complex, a single self-hybridizing strand, or any combination of these. A hybridization reaction may constitute a step in a more extensive process, such as the initiation of a PCR reaction, or the enzymatic cleavage of a polynucleotide by a ribozyme.

[0059] Stringent hybridization conditions are as follows: Prehybridization of filters containing a nucleic acid of interest is carried out for 8 hrs to overnight at 65°C in buffer composed of 6xSSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 hrs at 65°C, the preferred hybridization temperature, in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20x10⁶ cpm of ³²P-labeled probe. Subsequently, filter washes are performed at 37°C for 1 h in a solution containing 2xSSC, 0.01% Ficoll, and 0.01% BSA, followed by a wash in 0.1xSSC at 50°C. for 45 min. Following the wash steps, the hybridized probes are detectable by autoradiography. Such methods are well known in the art and cited in Sambrook *et al.*, 1989; and Ausubel *et al.*, 1989.

[0060] A polynucleotide or polynucleotide region (or a polypeptide or polypeptide region) has a certain percentage (for example, 80%, 85%, 90%, or 95%) of "sequence identity" to another sequence means that, when aligned, that

percentage of bases (or amino acids) are the same in comparing the two sequences. This alignment and the percent homology or sequence identity is determined using the well known BLAST alignment program and the default parameters. Alternative programs are BLASTN and BLASTP, using the following default parameters: Genetic code = standard; filter = none; strand = both; cutoff = 60; expect = 10; Matrix = BLOSUM62; Descriptions = 50 sequences; sort by = HIGH SCORE; Databases = non-redundant, GenBank + EMBL + DDBJ + PDB + GenBank CDS translations + SwissProtein + SPupdate + PIR. Details of these programs can be found at the following world wide web address: ncbi.nlm.nih.gov/cgi-bin/BLAST.

[0061] The term "isolated" means separated from constituents, cellular and otherwise, in which the polynucleotide, peptide, polypeptide, protein, antibody, or fragments thereof, are normally associated with in nature. For example, with respect to a polynucleotide, an isolated polynucleotide is one that is separated from the 5' and 3' sequences with which it is normally associated in the chromosome. As is apparent to those of skill in the art, a non-naturally occurring polynucleotide, peptide, polypeptide, proteins, antibody, or fragment(s) thereof, does not require "isolation" to distinguish it from its naturally occurring counterpart. In addition, a "concentrated", "separated" or "diluted" polynucleotide, peptide, polypeptide, protein, antibody, or fragment(s) thereof, is distinguishable from its naturally occurring counterpart in that the concentration or number of molecules per volume is greater than "concentrated" or less than "separated" than that of its naturally occurring counterpart. A polynucleotide, peptide, polypeptide, protein, antibody, or fragment(s) thereof, which differs from the naturally occurring counterpart in its primary sequence or for example, by its glycosylation pattern, need not be present in its isolated form since it is distinguishable from its naturally occurring counterpart by its primary sequence, or alternatively, by another characteristic such as its glycosylation pattern. Although not explicitly stated for each of the inventions disclosed herein, it is to be understood that all of the above embodiments for each of the compositions disclosed below and under the appropriate conditions, are provided by this invention. Thus, a non-naturally occurring polynucleotide is provided as a separate embodiment from the isolated naturally occurring polynucleotide. A protein produced in a bacterial cell is provided as a separate embodiment from the naturally occurring protein isolated from a eukaryotic cell in which it is produced in nature. A mammalian cell, such as dendritic cell is isolated if it is removed from the anatomical site from which it is found in an organism.

[0062] "Host cell," "target cell" or "recipient cell" are intended to include any individual cell or cell culture which can be or have been recipients for vectors or the incorporation of exogenous nucleic acid molecules, polynucleotides and/or proteins. It also is intended to include progeny of a single cell, and the progeny may not necessarily be completely identical (in morphology or in genomic or total DNA complement) to the original parent cell due to natural, accidental, or deliberate mutation. The cells may be prokaryotic or eukaryotic, and include but are not limited to bacterial cells, yeast cells, animal cells, and mammalian cells, e.g., murine, rat, simian or human.

[0063] A "subject" is a vertebrate, preferably a mammal, more preferably a human. Mammals include, but are not limited to, murines, simians, humans, farm animals, sport animals, and pets.

[0064] A "control" is an alternative subject or sample used in an experiment for comparison purpose. A control can be "positive" or "negative". For example, where the purpose of the experiment is to determine a correlation of an immune response with a particular culture condition, it is generally preferable to use a positive control and a negative control.

[0065] By "cancer" is meant the abnormal presence of cells which exhibit relatively autonomous growth, so that a cancer cell exhibits an aberrant growth phenotype characterized by a significant loss of cell proliferation control. Cancerous cells can be benign or malignant. In various embodiments, the cancer affects cells of the bladder, blood, brain, breast, colon, digestive tract, lung, ovaries, pancreas, prostate gland, or skin. The definition of a cancer cell, as used herein, includes not only a primary cancer cell, but also any cell derived from a cancer cell ancestor. This includes metastasized cancer cells, and *in vitro* cultures and cell lines derived from cancer cells. Cancer includes, but is not limited to, solid tumors, liquid tumors, hematologic malignancies, renal cell cancer, melanoma, breast cancer, prostate cancer, testicular cancer, bladder cancer, ovarian cancer, cervical cancer, stomach cancer, esophageal cancer, pancreatic cancer, lung cancer, neuroblastoma, glioblastoma, retinoblastoma, leukemias, myelomas, lymphomas, hepatoma, adenomas, sarcomas, carcinomas, blastomas, etc. When referring to a type of cancer that normally manifests as a solid tumor, a "clinically detectable" tumor is one that is detectable on the basis of tumor mass; e.g., by such procedures as CAT scan, magnetic resonance imaging (MRI), X-ray, ultrasound or palpation. Biochemical or immunologic findings alone may be insufficient to meet this definition.

[0066] The term "culturing" refers to the *in vitro* maintenance, differentiation, and/or propagation of cells or in suitable media. By "enriched" is meant a composition comprising cells present in a greater percentage of total cells than is found in the tissues where they are present in an organism. For example, the enriched cultures and preparations of CD83⁺CCR7⁻ DCs and CD83⁺CCR7⁺ DCs made by the methods of the invention are present in a higher percentage of total cells as compared to their percentage in the tissues where they are present in an organism (e.g., blood, skin, lymph nodes, etc.).

[0067] A "composition" is intended to mean a combination of active agent and another compound or composition, inert (for example, a detectable agent or label) or active, such as an adjuvant.

[0068] A "pharmaceutical composition" is intended to include the combination of an active agent with a carrier, inert

or active, making the composition suitable for diagnostic or therapeutic use *in vitro*, *in vivo* or *ex vivo*.

[0069] As used herein, the term "pharmaceutically acceptable carrier" encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, and emulsions, such as an oil/water or water/oil emulsion, and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see Martin REMINGTON'S PHARM. SCI., 18th Ed. (Mack Publ. Co., Easton (1990)). An "effective amount" is an amount sufficient to effect beneficial or desired results, such as enhanced immune response, treatment, prevention or amelioration of a medical condition (disease, infection, etc). An effective amount can be administered in one or more administrations, applications or dosages. Suitable dosages will vary depending on body weight, age, health, disease or condition to be treated and route of administration. As used herein, "signaling" means contacting an immature or mature dendritic cell with an IFN- γ receptor agonist, a TNF- α receptor agonist, a CD40L polypeptide or other CD40 agonist. In one embodiment, such IFN- γ receptor and/or TNF- α receptor agonists are provided externally, (e.g., in the cell culture medium). In another embodiment, the polypeptide agonist is provided via transfection of an immature or mature dendritic cell with a nucleic acid encoding the polypeptide. Alternatively, a nucleic acid aptamer agonist could be provided in the medium or by transfection. In cases where the polypeptide(s) is provided by transfecting a dendritic cell with a nucleic acid encoding the polypeptide, signaling is effected upon translation of an mRNA encoding the polypeptide, rather than upon transfection with the nucleic acid. In one aspect, this invention provides methods for preparing enriched populations of mature dendritic cells (DCs) that induce potent immunostimulatory responses *in vivo* and/or *in vitro*. As used herein, the term "mature dendritic cells" means dendritic cells that demonstrate elevated cell surface expression of co-stimulator molecule CD83, compared to immature DCs (iDCs). Mature DCs of the invention include both CD83⁺ CCR7⁻ DCs and CD83⁺ CCR7⁺ DCs. The second signal, a CD40 agonist, can be given to either immature CD83⁻ CCR7⁻ DCs, or to CD83⁺ CCR7⁻ mature DCs.

[0070] The literature (Schaft 2005, Bonehill 2004) suggests that post maturation electroporation of DCs with antigen-encoding RNA resulted in DCs with greater potency to invoke immune responses. Therefore, methods were developed to alter the 'CD40L base process' (sequential IFN- γ signaling and CD40L signaling of CD83⁻ iDCs), by altering the timing of the CD40L signaling to CD83⁺ CCR7⁻ mature DCs (post phenotypic maturation). In this embodiment, DCs were first phenotypically matured by adding 'inflammatory mediators', IFN- γ and TNF- α , and optionally PGE₂, to the culture medium, and then electroporating with CD40L mRNA, and optionally antigen-encoding mRNA approximately 12-30 hours (preferably about 18 hrs) later. This novel process was named 'PME-CD40L', for Post Maturation Electroporation with CD40L to produce CD83⁺ CCR7⁺ mature DCs. Cells harvested 4 hrs post electroporation and formulated as a vaccine were shown to mediate maximum immunopotency in *in vitro* assays (see examples). As yet a further enhancement, DCs can be pulsed with an activation ligand for NKT-cells, namely α -galactosylceramide, so as to recruit this population of effector cells to the immune response. NKT-cells display facets of both T-helper and T-cytotoxic cells: NKT-cells can secrete IFN- γ , display CD40L, and can secrete granzyme B, the latter to induce apoptosis in target cells. Thus, NKT-cell recruitment can lead to enhanced DC function by virtue of additional NKT-cell CD40L/DC-CD40 interactions, or amplify cell mediated immune responses by secreting helper cytokines, and/or contributing to a direct lytic effect on target cells.

[0071] After sequential signaling with the first signal (an IFN- γ receptor agonist and/or a TNF- α receptor agonist) to iDCs, and the second signal (a CD40 agonist) to either CD83⁻ CCR7⁻ iDCs, or to CD83⁺ CCR7⁻ mature DCs, the resulting DCs demonstrate (i) elevated cell surface expression of co-stimulator molecules CD80, CD83, and CD86, (ii) are CCR7⁺, and (iii) secrete IL-12 p70 polypeptide or protein, and/or secrete significantly reduced levels (0 to 500 pg/per million DCs) of IL-10. In preferred embodiments, the mature CD83⁺ CCR7⁺ DCs of the invention produce at least 1000 pg IL-12/10⁶ DCs, preferably at least 2000, 3000, 4000, 5000, or 6000 pg IL-12/10⁶ DCs, more preferably at least 7000, 8000, 9000 or 10,000 pg IL-12/10⁶ DCs, and most preferably at least 12,000, 15,000, 17,000 or 20,000 pg IL-12/10⁶ DCs. IL-10 and IL-12 levels can be determined by ELISA of culture supernatants collected at up to 36 hrs post induction of DC maturation from immature DCs. Wierda et al. (2000) Blood 96:2917. Ajdary et al. (2000) Infection and Immunity 68:1760.

[0072] Immature DCs can be isolated or prepared from a suitable tissue source containing DC precursor cells and differentiated *in vitro* to produce immature DC. For example, a suitable tissue source can be one or more of bone marrow cells, peripheral blood progenitor cells (PBPCs), peripheral blood stem cells (PBSCs), and cord blood cells. Preferably, the tissue source is a peripheral blood mononuclear cell (PBMC). The tissue source can be fresh or frozen. In another aspect, the cells or tissue source are pre-treated with an effective amount of a growth factor that promotes growth and differentiation of non-stem or progenitor cells, which are then more easily separated from the cells of interest. These methods are known in the art and described briefly in Romani, et al. (1994) Exp. Med. 180:83 and Caux, C. et al. (1996) Exp. Med. 184:695. In one aspect, the immature DCs are isolated from peripheral blood mononuclear cells (PBMCs). In a preferred embodiment, the PBMCs are treated with an effective amount of granulocyte macrophage colony stimulating factor (GM-CSF) in the presence or absence of interleukin 4 (IL-4) and/or IL-13, so that the PBMCs differentiate into immature DCs. Most preferably, PBMCs are cultured in the presence of GM-CSF and IL-4 for about 4-7 days, preferably about 5-6 days, to produce immature DCs. In preferred embodiments, the first signal is given at day 4, 5, 6, or 7, and most preferably at day 5 or 6. In addition, GM-CSF as well as IL-4 and/or IL-13 may be present in the medium at the


time of the first and/or second signaling.

[0073] To increase the number of dendritic precursor cells in animals, including humans, one can pre-treat subjects with substances which stimulate hematopoiesis. Such substances include, but are not limited to G-CSF, and GM-CSF. The amount of hematopoietic factor to be administered may be determined by one skilled in the art by monitoring the cell differential of individuals to whom the factor is being administered. Typically, dosages of factors such as G-CSF and GM-CSF will be similar to the dosage used to treat individuals recovering from treatment with cytotoxic agents. As an example, GM-CSF or G-CSF can be administered for 4 to 7 days at standard doses prior to removal of source tissue to increase the proportion of dendritic cell precursors. U.S. Patent No. 6,475,483 teaches that dosages of G-CSF of 300 micrograms daily for 5 to 13 days and dosages of GM-CSF of 400 micrograms daily for 4 to 19 days result in significant yields of dendritic cells.

[0074] The methods of the invention produce an enriched population of mature CD83⁺ CCR7⁺ dendritic cells that are potent immunostimulatory agents. Specifically, the invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN- γ R) agonist, and a TNF- α R agonist, to produce IFN- γ R agonist signaled dendritic cells; and (b) signaling said IFN- γ R agonist signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7⁺ mature dendritic cells. The disclosure further includes CD83⁺ CCR7⁻ mature DCs and CD83⁺ CCR7⁺ mature DCs. In preferred embodiments, the CD83⁺ CCR7⁺ mature DCs and/or the CD83⁺ CCR7⁻ mature DCs of the invention transiently express CD40L polypeptide. Preferably, CD40L is predominantly localized intracellularly, rather than on the cell surface. Most preferably, at least 60%, at least 70%, at least 80% or at least 90% of CD40L polypeptide is localized intracellularly.

[0075] For either embodiment (IFN- γ R agonist and TNF- α R agonist as a first signal), the second CD40 agonist signal can be given to either CD83⁻ CCR7⁻ iDCs, or to CD83⁺ CCR7⁻ mature DCs. In a preferred embodiment, the immature DCs and/or mature DCs are contacted with PGE₂. Preferably the cells are contacted with PGE₂ at about the same time that they receive the first signal (an IFN- γ R agonist and TNF- α R agonist). In preferred embodiments, GM-CSF and at least one of IL-4 or IL-13 is present in the medium at the time the dendritic cells receive the first and second signals. In further embodiments, the method further comprises contacting the immature dendritic cells, signaled dendritic cells, and/or CCR7⁺ dendritic cells with a NKT cell ligand that can activate CD1d-restricted NKT cells and consequently potentiate innate and adoptive immunity. In preferred embodiments, the NKT cell ligand is a compound selected from the group consisting of: α -galactosylceramides, α -glucosylceramides, α -6-deoxygalactosylceramides, α -6-deoxygalactofuranosylceramides, β -6-deoxygalactofuranosylceramides, β -arabinosylceramides, α -C-galactosylceramides and α -S-galactosylceramides. A preferred compound is the α -galactosylceramide known as KRN7000 ((2S, 3S, 4R)-1-O-(α -D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol).

[0076] Agelasphins, disclosed in JP patent 3068910, are a class of compounds originally discovered in a marine sponge which have an α -galactosylceramide (α -GalCer) structure and immunostimulating and anti-tumor activity. KRN7000 is a potent synthetic analog of agelasphins, disclosed in U.S. 5,767,092. Additional useful analogs of agelasphins are disclosed U.S. 5,936,076. The structure of KRN7000 is shown below:




[0077] Glycosylceramide analogs of KRN7000 (e.g. α -galactosylceramides, α -glucosylceramides, α -6-deoxygalactosylceramides, α -6-deoxygalactofuranosylceramides, β -6-deoxygalactofuranosylceramides, β -arabinosylceramides) are disclosed in U.S. 5,849,716. U.S. 5,780,441 discloses oligosaccharide (di-, tri-, tetra-, penta-) derivatives of KRN7000. Methods for using KRN7000 and related analogs to produce KRN7000 antigen loaded DCs, and to activate human NKT cells are disclosed in U.S. Ser No. 09/721,768 and U.S. 6,531,453.

[0078] U.S. 5,936,076 discloses α -galactosylceramide compounds represented by the following formula:

5

10


15



wherein the fatty acid chain, R represents:

20

25



where R_2 represents H or OH and X denotes an integer of 0-26 or R represents $-(CH_2)_7CH=CH(CH_2)_7CH_3$ and R_1 represents any one of the substituents defined by the following (a)-(e)

30

- (a) $-CH_2(CH_2)_YCH_3$
- (b) $-CH(OH)(CH_2)_YCH_3$
- (c) $-CH(OH)(CH_2)_YCH(CH_3)_2$
- (d) $-CH=CH(CH_2)_YCH$
- (e) $-CH(OH)(CH_2)_YCH(CH_3)CH_2CH_3$

35

[0079] Wherein Y denotes an integer 5-17.


[0080] WO 03/105769, U.S. 2004/0127429 and Shimiegi J. et al., (2003) J. Exp. Med. 198:1631-1641 disclose the structure of α -C-glycolipids, where the oxygen atom on glycoside bond of α -glycosylceramides such as α -galactosylceramide and α -glucosylceramides is replaced by carbon atom. The structure of a representative compound is shown below.

40

45

C-GalCer


50



[0081] WO 03/016326 disclose KRN7000 analogs with truncated ceramide such as "C4" or "OCH" having the following structure:

55

C4 (OCH)



[0082] U.S. 6,635,622 discloses α -C-, N, or S-Glycolipids, wherein the oxygen atom on glycoside bond of a galactosylceramide is replaced by $-(\text{CH}_2)_a-\text{CH}=\text{CH}-(\text{CH}_2)_{a'}$ -, $-(\text{CH}_2)_a-\text{S}(\text{O})_{0-2}-\text{CH}_2$ -, or $-\text{NHCH}_2$ -, wherein a and a' each denote an integer of 0-5 and a + a' is 5 or less.

[0083] In preferred embodiments, the IFN- γ R agonist is IFN γ or a biologically active fragment thereof. Preferably, the IFN γ is a mammalian IFN γ , most preferably a human IFN γ . The cDNA and amino acid sequence of human IFN γ are shown in SEQ ID NOs: 5 and 6, respectively. Preferably, the IFN γ has the sequence shown in SEQ ID NO:6, or a fragment thereof. In one embodiment, the IFN- γ R agonist comprises a polypeptide having at least 80% sequence identity with SEQ ID NO:6. Preferably, the IFN- γ R agonist has at least 85%, 90%, 95%, 97%, 98% or 99% sequence identity with SEQ ID NO:6. Methods for testing the activity of IFN- γ R agonists are known to those of skill in the art, and some of these methods are described below. Immature DCs can be signaled by adding an IFN- γ R agonist to the culture medium, or by expressing the IFN- γ R agonist in the dendritic cell. In one embodiment, the DC is transfected with an mRNA encoding an IFN- γ R agonist, such as SEQ ID NO:6, or a biologically active fragment thereof. Signaling would then occur upon translation of the mRNA within the dendritic cell. Most preferably, the IFN- γ R agonist is added to the culture medium containing immature DCs. In a preferred embodiment, the culture medium further comprises PGE $_2$ and/or GM-CSF plus IL-4 or IL-13.

[0084] The receptor for IFN- γ has two subunits: IFN- γ R1, the ligand-binding chain (also known as the α chain) and IFN- γ R2, the signal-transducing chain (also known as the β chain or accessory factor 1). These proteins are encoded by separate genes (*IFNGR1* and *IFNGR2*, respectively) that are located on different chromosomes. As the ligand-binding (or α) chains interact with IFN- γ they dimerise and become associated with two signal-transducing (or β) chains. Receptor assembly leads to activation of the Janus kinases JAK1 and JAK2 and phosphorylation of a tyrosine residue on the intracellular domain of IFN- γ R1. This leads to the recruitment and phosphorylation of STAT1 (for 'signal transducers and activators of transcription'), which forms homodimers and translocates to the nucleus to activate a wide range of IFN- γ -responsive genes. After signaling, the ligand-binding chains are internalized and dissociate. The chains are then recycled to the cell surface. Bach et al. (1997) *Ann. Rev. Immunol.* 15, 563-591; and Lammas, Casanova and Kumararatne (2000) *Clin Exp Immunol* 121, 417-425. The crystal structure of the complex of human IFN- γ with the soluble, glycosylated extracellular part of IFN- γ R α (sIFN- γ R α) has been determined at 2.9 Å resolution using multiwavelength anomalous diffraction methods. Thiel et al. *Structure* 8:927-936 (2000).

[0085] In one assay, IFN- γ receptor agonists, such as IFN- γ decrease Na $^+$ -K $^+$ -ATPase activity in a time- and concentration-dependent manner in human intestinal epithelial Caco-2 cells. Na $^+$ -K $^+$ -ATPase activity can be determined as the difference between total and ouabain-sensitive ATPase. Treatment with IFN- γ markedly increases the expression of total and phospho-STAT1, this being accompanied by activation of p38 MAPK. p38 MAP kinase activity can be analyzed by Western blotting using the p38 MAP kinase assay kit. Total and phosphorylated STAT1 protein levels were detected using the PhosphoPlus[®] Stati. The transduction mechanisms set into motion by IFN- γ involve the activation of PKC downstream STAT1 phosphorylation and Raf-1, MEK, ERK2 and p38 MAPK pathways. See Magro et al., *Br J Pharmacol* advance online publication, July 26, 2004; doi:10.1038/sj.bjp.0705895.

[0086] For the purpose of illustration, signaling with IFN- γ receptor agonists and TNF- α receptor agonists can be provided by contacting a cell directly with IFN- γ polypeptides and/or proteins and/or TNF- α polypeptides or proteins, respectively. Alternatively, signaling of a cell with IFN- γ R agonists, TNF- α R agonists as well as CD40 agonists can occur upon translation of mRNA encoding such polypeptides or proteins within the dendritic cell. Thus, signaling occurs upon expression of IFN- γ R agonist, TNF- α R agonist and CD40 agonist polypeptides and/or proteins.

[0087] The second signal used in the methods of the invention is a transient signal with a CD40 agonist. Persistent expression of a CD40 agonist polypeptide, such as constitutive expression of CD40L from a lentiviral vector as described by Koya *et al.*, *supra*, is not considered transient expression. The signal can be considered transient if the medium containing a CD40 agonist is removed from the DCs, or if the DCs are loaded with an mRNA encoding a CD40 agonist. The CD40 agonist signal can also be considered transient if the DCs are loaded/transfected with or with an expression vector encoding a CD40 agonist, provided that either: 1) the promoter driving CD40 agonist expression is not constitutive

in DCs, or 2) the expression vector does not integrate into the DC genome or otherwise replicate in DCs.

[0088] In preferred embodiments, the CD40 agonist is a CD40L polypeptide or a CD40 agonistic antibody. In general, ligands that bind CD40 may act as a CD40 agonist. Applicants have demonstrated that administration of a second signal comprising CD40L to the cells by transfection of immature or mature DCs with CD40L mRNA produces subsequently modified DCs that induce immunostimulatory responses rather than immunosuppressive. In one embodiment, CD40L mRNA transfected dendritic cells are cultured in medium containing IFN γ (and preferentially PGE₂ as well) immediately after transfection and prior to translation of the CD40L mRNA to produce an effective amount of a CD40L signal. In this embodiment, although IFN γ is added after transfection with CD40L mRNA, the dendritic cells receive the IFN γ signal prior to the signal resulting upon translation of the CD40L mRNA. Thus, the order in which the agents are delivered to the cells is important only in that CD40L signaling must occur after IFN- γ signaling. As described in more detail below, the signaling of the DCs can occur *in vivo* or *ex vivo*, or alternatively one or more set may occur *ex vivo* and the remaining steps of the method can occur *in vivo*.

[0089] In one embodiment, the CD40 agonist is an aptamer that binds CD40. Similarly, IFN- γ and TNF- α could be replaced by aptamers, antibodies, and the like, that have a similar biological activity. Most preferably, the CD40 agonist is delivered as mRNA encoding CD40L.

[0090] As used herein, "CD40 Ligand" (CD40L) shall encompass any polypeptide or protein that specifically recognizes and activates the CD40 receptor and activates its biological activity. The term includes transmembrane and soluble forms of CD40L. In preferred embodiments, the CD40 agonist is a mammalian CD40L, preferably a human CD40L. Alignments of the human and mouse cDNAs and proteins are shown in Figures 16 and 17, respectively. A human CD40L cDNA and the corresponding amino acid sequence are shown in SEQ ID NOS:1 and 2, respectively. The open reading frame for CD40L is represented by nucleotides 40 to 822 of SEQ ID NO.1, while the TGA stop codon is at position 823 to 825. Also useful in the methods of the invention are truncated CD40L (residues 47 to 261 of SEQ ID NO:2, encoded by nucleotide residues 178 to 825 of SEQ ID NO:1) and CD40L fragments encoded by nucleotides 43 to 825 of SEQ ID NO:1, 181 to 825 of SEQ ID NO:1, 193 to 825 of SEQ ID NO:1, 376 to 825 of SEQ ID NO:1, 379 to 825 of SEQ ID NO:1 and 400 to 825 of SEQ ID NO:1. In preferred embodiments, the CD40L polypeptide is selected from the group consisting of: a) a polypeptide comprising SEQ ID NO:2; b) a polypeptide comprising amino acid residues 47 through 261 of SEQ ID NO:2; c) a polypeptide comprising amino acid residues 51 through 261 of SEQ ID NO:2; d) a polypeptide comprising amino acid residues 120 through 261 of SEQ ID NO:2; e) a polypeptide comprising amino acid residues 113 through 261 of SEQ ID NO:2; f) a polypeptide comprising amino acid residues 112 through 261 of SEQ ID NO:2; g) a polypeptide comprising SEQ ID NO:10; h) a polypeptide comprising amino acid residues 35 through 261 of SEQ ID NO:2; i) a polypeptide comprising amino acid residues 34 through 225 of SEQ ID NO:2; j) a polypeptide comprising amino acid residues 113 through 225 of SEQ ID NO:2; k) a polypeptide comprising amino acid residues 120 through 225 of SEQ ID NO:2; and l) a fragment of the polypeptide of any of (a) through (k), wherein said fragment binds CD40.

[0091] Preferably, the CD40L polypeptide is encoded by an mRNA comprising a polynucleotide selected from the group consisting of: a) a polynucleotide of SEQ ID NO:1; b) a polynucleotide comprising nucleotides 40 to 822 of SEQ ID NO:1; c) a polynucleotide comprising nucleotides 178 to 822 of SEQ ID NO:1; d) a polynucleotide comprising nucleotides 190 to 822 of SEQ ID NO:1; e) a polynucleotide comprising nucleotides 397 to 822 of SEQ ID NO:1; f) a polynucleotide comprising nucleotides 376 to 822 of SEQ ID NO:1; g) a polynucleotide of SEQ ID NO:9; h) a polynucleotide of SEQ ID NO:13; i) a polynucleotide having at least 80% sequence identity with any polynucleotide of (a) through (h); j) a polynucleotide hybridizing under stringent conditions to any polynucleotide of (a) through (h); and k) a polynucleotide of (a) through (j), further comprising a 3' untranslated sequence selected from the group consisting of the nucleic acids of SEQ ID NO:14, 15, 16, 17 or 18, and/or a 5' untranslated sequence selected from the group consisting of the nucleic acids of SEQ ID NO:19, 20, 21, 22, or 23.

[0092] Alternatively, the CD40L polypeptide is a polypeptide having at least 77% sequence identity to a polypeptide selected from the group consisting of: a) a polypeptide comprising SEQ ID NO:2; b) a polypeptide comprising amino acid residues 47 through 261 of SEQ ID NO:2; c) a polypeptide comprising amino acid residues 51 through 261 of SEQ ID NO:2; d) a polypeptide comprising amino acid residues 120 through 261 of SEQ ID NO:2; e) a polypeptide comprising amino acid residues 113 through 261 of SEQ ID NO:2; f) a polypeptide comprising amino acid residues 112 through 261 of SEQ ID NO:2; g) a polypeptide comprising SEQ ID NO:10; h) a polypeptide comprising amino acid residues 35 through 261 of SEQ ID NO:2; i) a polypeptide comprising amino acid residues 34 through 225 of SEQ ID NO:2; j) a polypeptide comprising amino acid residues 113 through 225 of SEQ ID NO:2; k) a polypeptide comprising amino acid residues 120 through 225 of SEQ ID NO:2; and l) a fragment of the polypeptide of any of (a) through (k), wherein said fragment binds CD40.

[0093] CD40 was first characterized as a receptor expressed on B lymphocytes. Schonbeck and Libby (2001) Cell Mol. Life Sci. 58:4. It was later discovered that engagement of B-cell CD40 with CD40L expressed on activated T-cells is essential for T-cell dependent B-cell activation (i.e. proliferation, immunoglobulin secretion, and class switching). It was subsequently revealed that functional CD40 is expressed on a variety of cell types other than B-cells, including hematopoietic progenitor cells, T lymphocytes, basophils, eosinophils, monocytes/macrophages, dendritic cells, epithe-

lial cells, endothelial cells, smooth muscle cells, keratinocytes, fibroblasts and carcinomas. Schonbeck and Libby (2001) supra.

[0094] The CD40 Ligand was cloned in 1993 and reported by Gauchat, et al. (1993) FEBS Lett. 315:259. Graf *et al.* mapped it to chromosome Xq26.3-q27.1 (Graf, et al. (1992) Eur. J. Immunol. 22: 3191-3194). Shorter soluble forms of the cell-associated full-length 39 kDa form of CD40 Ligand have been described with molecular weights of 33, and 18 kDa. Graf, et al. (1995) Eur. J. Immunol. 25: 1749; Ludewig, et al. (1996) Eur. J. Immunol. 26: 3137; Wykes, et al. (1998) Eur. J. Immunol. 28:548. The 18 kDa soluble form generated via intracellular proteolytic cleavage, which lacks the cytoplasmic tail, the transmembrane region and parts of the extracellular domain, but conserves the CD40 binding domain retains the ability to bind to CD40 receptor and therefore is an example of a CD40 receptor signaling agent. Graf, *et al.* (1995) supra.

[0095] U.S. Patent No. 5,981,724 discloses DNA sequences encoding human CD40 Ligand (CD40L) as well as vectors, and transformed host cells for the purpose of producing CD40L polypeptides. U.S. Patent No. 5,962,406 discloses DNA sequences encoding soluble forms of human CD40L.

[0096] Exemplary sequences of mammalian homologs to CD40L have the following Genbank accession numbers: NM_204733 (*Gallus gallus* (chicken)); DQ054533 (*Ovis aries* (sheep)); Z48469 (*Bos taurus* (cow)); AY333790 (*Canis familiaris* (dog)); Macaca nemestrina (pig-tailed macaque)); AF344844 (*Callithrix jacchus* (white-tufted-ear marmoset)); AF34481 (*Cercopithecus torquatus atys* (sooty mangabey)); AF344860 (*Aotus trivirgatus* (douroucoulis)); AF344859 (*Macaca mulatta* (rhesus monkey)); AF116582 (*Rattus norvegicus* (Norway rat)); and AF079105 (*Felis catus* (cat)).

[0097] The CD40 receptor can also be activated by use of CD40 agonist antibodies, antibody fragments, derivatives and variants thereof. CD40 agonist antibodies can be purchased from commercial vendors such as Mabtech (Nacka, Sweden). Examples and methods to generate these agents are also provided infra. The literature also provides examples of CD40 agonist antibodies and antibody fragments. See, e.g., Osada, *et al.* (2002) **25**(2):176 and Ledbetter, J.A. et al. (1997) Crit. Reviews in Immunol. 17:427.

[0098] As noted above, the agent having the biological activity of CD40L can be a polypeptide translated from an exogenous polynucleotide (mRNA or DNA) encoding CD40L. For example, the CD40L mRNA has the sequence of SEQ ID NO.: 1 or SEQ ID NO.:3. Alternatively, the cells are signaled with an effective amount of CD40L protein and/or polypeptide, for example, those having the sequence of SEQ ID NO.: 2 or SEQ ID NO.:4. Modified CD40L can also be used in the methods of this invention. For example, CD40L includes those molecules that have been altered through addition, subtraction, or substitution, either conservatively or non-conservatively, of any number of amino acids, provided that the resulting protein binds CD40 on the surface of DC. A "conservative alteration" is one that results in an alternative amino acid of similar charge density, hydrophilicity or hydrophobicity, size, and/or configuration (e.g., Val for Ile). In comparison, a "nonconservative alteration" is one that results in an alternative amino acid of differing charge density, hydrophilicity or hydrophobicity, size and/or configuration (e.g., Val for Phe). The means of making such modifications are well-known in the art and also can be accomplished by means of commercially available kits and vectors (for example, those available from New England Biolabs, Inc., Beverly, Mass.; Clontech, Palo Alto, Calif.).

[0099] When the agents are delivered as polynucleotides or genes encoding the agents, an effective amount of the polynucleotide can be replicated by any method known in the art. PCR technology is one means to replicate DNA and is the subject matter of United States Patent Nos. 4,683,195; 4,800,159; 4,754,065; and 4,683,202 and described in PCR: THE POLYMERASE CHAIN REACTION (Mullis *et al.* eds, Birkhauser Press, Boston (1994)) and references cited therein. Additional methods to generate polynucleotides are provided infra.

[0100] In embodiments of the invention, wherein immature dendritic cells are stimulated with an agonist of TNF- α receptor, followed by stimulation with a CD40 agonist, the method is performed in the absence of an effective amount of interleukin 1-beta (IL-1 β) and or interleukin 6 (IL-6). Methods for detecting the presence of proteins such as IL-1 β and IL-6 are known in the art.

[0101] One of skill in the art can determine when the object of the method has been met by sampling a cell or small population of DCs from the population for the presence of mature DCs expressing CD40L mRNA and/or CD40L polypeptide. In a further aspect, the mature CD83⁺ CCR7⁺ DCs of the invention express interleukin 12 (IL-12) p35 protein. In a further aspect, mature CD83⁺ CCR7⁺ DCs express IL-12 p70 protein, and/or express limited IL-10 (not more than 500 pg/ml/10⁶ DCs).

[0102] The steps of the method can be practiced *in vivo* or *ex vivo*. When practiced *ex vivo*, the method can be practiced in an open or closed system. Methods and systems for culturing and enriching cell populations are known in the art. See, examples 1 and 2 of U.S. Patent Publication No. 2004/0072347. See also U.S. Patent Publication No. 2003/0235908, which describes closed systems for cell expansion.

[0103] In a further embodiment, the above method is modified by the addition of delivering to the immature or mature DCs an effective amount of an antigen which will be then be processed and presented by the mature DCs. Thus, the methods of the invention further comprise introducing into iDCs, signaled DCs or CCR7⁺ mature DCs one or more antigens or a polynucleotide(s) encoding one or more antigens to produce an antigen-loaded CCR7⁺ mature DCs. The antigen or antigen-encoding polynucleotide can be introduced prior to said first signal. Alternatively, the antigen or

antigen-encoding polynucleotide is delivered subsequent to said first signal and prior to said second signal. In another embodiment, the antigen or polynucleotide is delivered subsequent to said second signal or substantially concurrent with said second signal.

[0104] For example, antigens include, but are not limited to, pathogens, pathogen lysates, pathogen extracts, pathogen polypeptides, viral particles, bacteria, proteins, polypeptides, cancer cells, cancer cell lysates, cancer cell extracts, cancer cell specific polypeptides. Antigens can be naturally occurring or recombinantly produced. The immunogens can be delivered to the cells as polypeptides, proteins or as nucleic acids using methods known in the art which are briefly described infra. Preferably, one or more polynucleotides encoding one or more antigens are introduced into the iDCs, signaled DCs or CCR7⁺ mature DCs. The polynucleotide can be introduced into the DCs by methods known to those of skill in the art. In a preferred embodiment, the polynucleotide is introduced by electroporation. Most preferably, the polynucleotide is an mRNA. In preferred embodiments, the antigen or antigen encoding mRNA is introduced together with an mRNA encoding a CD40 agonist or substantially concurrent with CD40 agonist signaling.

[0105] The methods can be further modified by contacting the cell with an effective amount of a cytokine or co-stimulatory molecule, e.g., GM-CSF, IL-4 and PGE₂. In embodiments where the immature DCs are signaled with a TNF α R agonist followed by signaling with CD40 agonist, effective amounts of IL-1 β and/or IL-6 are specifically excluded from the culture.

[0106] The antigen may be delivered in its "natural" form in that no human intervention was involved in preparing the antigen or inducing it to enter the environment in which it encounters the APC. Alternatively or additionally, the antigen may comprise a crude preparation, for example of the type that is commonly administered in a conventional allergy shot or in a tumor lysate. The antigen may alternatively be substantially purified, e.g., at least about 90% pure.

[0107] Where the antigen is a peptide, it may be generated, for example, by proteolytic cleavage of isolated proteins. Any of a variety of cleavage agents may be utilized including, but not limited to, pepsin, cyanogen bromide, trypsin, chymotrypsin, etc. Alternatively, peptides may be chemically synthesized, preferably on an automated synthesizer such as is available in the art. Also, recombinant techniques may be employed to create a nucleic acid encoding the peptide of interest, and to express that peptide under desired conditions.

[0108] The antigen can alternatively have a structure that is distinct from any naturally-occurring compound. In certain embodiments of the invention, the antigen is a "modified antigen" in that the antigen has a structure that is substantially identical to that of a naturally-occurring antigen but that includes one or more deviations from the precise structure of the naturally-occurring compound. For instance, where the naturally-occurring antigen is a protein or polypeptide antigen, a modified antigen as compared with that protein or polypeptide antigen would have an amino acid sequence that differs from that of the naturally-occurring antigen in the addition, substitution, or deletion of one or more amino acids, and/or would include one or more amino acids that differ from the corresponding amino acid in the naturally-occurring antigen by the addition, substitution, or deletion of one or more chemical moieties covalently linked to the amino acid. In one aspect, the naturally-occurring and modified antigens share at least one region of at least 5 amino acids that are at least approximately 75% identical. Those of ordinary skill in the art will appreciate that, in comparing two amino acid sequences to determine the extent of their identity, the spacing between stretches (i.e., regions of at least two) of identical amino acids need not always be precisely preserved. Naturally-occurring and modified protein or polypeptide antigens can show at least approximately 80% identity, more alternatively 85%, 90%, 95%, or greater than 99% identity in amino acid sequence for at least one region of at least 5 amino acids. Often, it may be useful for a much longer region (e.g., 10, 20, 50, or 100 or more amino acids) of amino acid sequence to show the designated degree of identity.

[0109] In preferred embodiments, the antigen is delivered as a polynucleotide or gene encoding the antigen, so that expression of the gene results in antigen production either in the individual being treated (when delivered *in vivo*) or the cell culture system (when delivered *in vitro*). Techniques for generating nucleic acids including an expressible gene, and for introducing such nucleic acids into an expression system in which any protein encoded by the expressible gene will be produced are known in the art and briefly described infra. Preferably, an mRNA encoding the antigen is introduced into the DC.

[0110] In one embodiment, the immunogen is delivered prior to said first signal, wherein the first signal is an IFN γ R agonist and TNF- α R. Alternatively, the immunogen is delivered subsequent to said first signal and prior to said second signal, or the immunogen is delivered subsequent to said second signal. In another embodiment, the immunogen is delivered substantially concurrent with said second signal.

[0111] The amount of antigen to be employed in any particular composition or application will depend on the nature of the particular antigen and of the application for which it is being used, as will readily be appreciated by those of skill in the art.

[0112] The antigen-loaded dendritic cells are useful for raising an immune response to the antigen(s). Thus, in one aspect, the invention provides a method of raising an immune response in a subject comprising administering to the subject an effective amount of the immunogen loaded CCR7⁺ mature DCs. The loaded DCs may be allogeneic or autologous to the subject.

[0113] The disclosure further includes a method of stimulating immune effector cells, comprising culturing said cells

in the presence of an antigen loaded CCR7⁺ mature DCs produced by the methods of invention to produce stimulated immune effector cells. The disclosure also includes a method of enhancing immunity in a subject comprising administering to the subject an effective amount of such stimulated immune effector cells.

5 **[0114]** An effective amount of a cytokine and/or co-stimulatory molecule can be delivered to the cells or patient, *in vitro* or *in vivo*. These agents can be delivered as polypeptides, proteins or alternatively, as the polynucleotides or genes encoding them. Cytokines, co-stimulatory molecules and chemokines can be provided as impure preparations (e.g., isolates of cells expressing a cytokine gene, either endogenous or exogenous to the cell) or in a "purified" form. Purified preparations are preferably at least about 90% pure, or alternatively, at least about 95% pure, or yet further, at least about 99% pure. Alternatively, genes encoding the cytokines or inducing agents may be provided, so that gene expression results in cytokine or inducing agent production either in the individual being treated or in another expression system (e.g., an *in vitro* transcription/translation system or a host cell) from which expressed cytokine or inducing agent can be obtained for administration to the individual.

10 **[0115]** Where both cytokine and antigen are to be delivered to an individual, they may be provided together or separately. When they are delivered as polypeptides or proteins, they can be delivered in a common encapsulation device or by means of physical association such as covalent linkage, hydrogen bonding, hydrophobic interaction, van der Waals interaction, etc. In an alternative embodiment, the compounds are provided together, genes encoding both are provided. For example, genes for both may be provided as part of the same nucleic acid molecule. In some embodiments, this nucleic acid molecule may be prepared so that both factors are expressed from a single contiguous polynucleotide, as a fusion protein in which the cytokine and the antigen are covalently linked to one another via a peptide bond. Alternatively or additionally, the genes may be linked to the same or equivalent control sequences, so that both genes become expressed within the individual in response to the same stimuli. A wide variety of different control sequences, active in different host cells under different conditions are known in the art. These control sequences, including constitutive control sequences, inducible control sequences, and repressible control sequences, can be used in accordance with the present invention, though inducible or repressible sequences are particularly preferred for applications in which additional control
25 over the timing of gene expression is desired.

[0116] It is appreciated by those of skill in the art that administration of cytokine and/or antigen may optionally be combined with the administration of any other desired immune system modulatory factor such as, for example, an adjuvant or other immunomodulatory compound.

30 **[0117]** Antigens can also be delivered in the form of polynucleotides or genes encoding the antigens. The antigens can also be modified by linking a portion of sequence from a first polypeptide (e.g., a first antigen) to a portion of sequence from a second polypeptide (e.g., a second antigen, a signal sequence, a transmembrane domain, a purification handle, etc.) by means of a peptide bond. Those of ordinary skill in the art will appreciate the diversity of such fusion proteins for use in accordance with the present invention. Recombinant techniques further allow for the ready modification of the amino acid sequence of polypeptide or protein antigens, by substitution, deletion, addition, or inversion of amino acid sequences.

35 **[0118]** Where the immunogen is a fragment of an antigen, it may be generated, for example, by proteolytic cleavage of isolated proteins. Any of a variety of cleavage agents may be utilized including, but not limited to, pepsin, cyanogen bromide, trypsin, chymotrypsin, etc. Alternatively, peptides may be chemically synthesized, preferably on an automated synthesizer such as is available in the art (see, for example, Stewart et al., *Solid Phase Peptide Synthesis*, 2d. Ed., Pierce Chemical Co., 1984. Also, recombinant techniques may be employed to create a nucleic acid encoding the peptide of interest, and to express that peptide under desired conditions (e.g., in a host cell or an *in vitro* expression system from which it can readily be purified).

40 **[0119]** In preferred embodiments, the antigen is from a cancer cell or a pathogen. Preferably, the neoplastic cell is a renal cancer cell, a multiple myeloma cell or a melanoma cell. Preferred pathogens are HIV and HCV. In preferred embodiments, the antigen is delivered to the antigen presenting cell in the form of RNA isolated or derived from a neoplastic cell or a pathogen. Methods for RT-PCR of RNA extracted from any cell (e.g., a neoplastic cell or pathogen cell), and *in vitro* transcription are disclosed in copending PCT/US05/32710 (WO2006/031870).

45 **[0120]** The antigen employed in accordance with the present invention may be a naturally-occurring compound or may alternatively have a structure that is distinct from any naturally-occurring compound. In certain embodiments of the invention, the antigen is a "modified antigen" in that the antigen has a structure that is substantially identical to that of a naturally-occurring antigen but that includes one or more deviations from the precise structure of the naturally-occurring compound.

50 **[0121]** Also disclosed herein are the enriched populations of mature DCs prepared by any of the methods described herein. Mature DCs prepared by the methods of the invention have enhanced immunostimulatory characteristics. In another aspect, the invention provides a method for storing an enriched population of mature DCs, comprising contacting an enriched dendritic cell population of the invention with a suitable cryopreservative under suitable conditions.

55 **[0122]** The compositions described herein are useful to raise an immune response in a subject by administering to the subject an effective amount of the enriched population of cells, e.g., DCs, modified DCs, or educated immune effector

cells. The cells can be allogeneic or autologous. They can be administered to a subject to raise or induce an immune response in a subject comprising administering to the subject an effective amount of the enriched populations as described above. The cells can be allogeneic or autologous to the subject. They can also be used to educate immune effector cells such as T cells by culturing the immune effector cell in the presence and at the expense of a mature DC of this invention. The educated effector cells can also be used to enhance immunity in a subject by delivering to the subject an effective amount of these cells.

Methods for Generating and Delivering Polynucleotides

[0123] Certain embodiments of this invention require the use of polynucleotides. These can be generated and replicated using any method known in the art, e.g., one of skill in the art can use the sequences provided herein and a commercial DNA synthesizer to replicate the DNA. Alternatively, they can be obtained by providing the linear sequence of the polynucleotide, appropriate primer molecules, chemicals such as enzymes and instructions for their replication and chemically replicating or linking the nucleotides in the proper orientation to obtain the polynucleotides. In a separate embodiment, these polynucleotides are further isolated. Still further, one of skill in the art can insert the polynucleotide into a suitable replication vector and insert the vector into a suitable host cell (prokaryotic or eukaryotic) for replication and amplification. The DNA so amplified can be isolated from the cell by methods well known to those of skill in the art. A process for obtaining polynucleotides by this method is further provided herein as well as the polynucleotides so obtained.

[0124] In one embodiment, the agent (e.g., CD40L) is delivered as mRNA. RNA can be obtained by first inserting a DNA polynucleotide into a suitable host cell or preferably, by *in vitro* transcription. The DNA can be inserted by any appropriate method, e.g., by the use of an appropriate gene delivery vehicle (e.g., liposome, plasmid or vector) or by electroporation. When the cell replicates and the DNA is transcribed into RNA; the RNA can then be isolated using methods well known to those of skill in the art, for example, as set forth in Sambrook *et al.* (1989) *supra*. For instance, mRNA can be isolated using various lytic enzymes or chemical solutions according to the procedures set forth in Sambrook, *et al.* (1989) *supra* or extracted by nucleic-acid-binding resins following the accompanying instructions provided by manufactures.

[0125] In preferred embodiments the CD40L expression cassette contains a promoter suitable for *in vitro* transcription, such as the T7 promoter or SP6 promoter. Preferably, the *in vitro* transcribed CD40L or CD40 agonist mRNA is optimized for stability and efficiency of translation. For example, SEQ ID NO:13 represents an optimized CD40L mRNA, wherein ATG codons in the 5' untranslated region have been altered to avoid incorrect initiation of translation.

[0126] mRNA stability and/or translational efficiency can also be increased by including 3'UTRs and or 5'UTRs in the mRNA. Preferred examples of 3'UTRs include those from human CD40, β -actin and rotavirus gene 6. Referred examples of 5'UTRs include CD40L, and the translational enhancers in the 5'UTRs of Hsp70, VEGF, spleen necrosis virus RU5, and tobacco etch virus.

[0127] For example, CD40L expression is normally regulated in part by 3'UTR-mediated mRNA instability, and therefore a large portion of the CD40L 3'UTR is not included in the current CD40L mRNA. CD40L is not normally expressed in DCs. In contrast, the CD40 Receptor is expressed in DCs and there is no evidence in the literature to indicate that its expression is regulated post-transcriptionally, particularly at the level of mRNA stability. Including the CD40 Receptor 3'UTR (SEQ ID NO:14, or an active fragment thereof) at the 3' end or region of the CD40L mRNA would give the RNA 3' untranslated sequence similar to naturally occurring CD40 messages without imparting any unwanted regulatory activity.

[0128] Beta-Actin is an abundantly expressed gene in human non-muscle cells. The human beta-actin promoter has been widely used to drive gene expression in mammalian cell lines and transgenic mice. Inclusion of the beta-actin 3'UTR plus flanking region has been demonstrated to further increase the level of mRNA accumulation from gene expression constructs containing the beta-actin promoter.

[0129] Qin and Gunning (1997) *Journal of Biochemical and Biophysical Methods* 36 pp. 63-72. SEQ ID NO:15 represents the untranslated region of the final exon of the human beta-actin 3' UTR. SEQ ID NO:16 shows the minimal region of this 3'UTR.

[0130] The 3'UTR of the simian rotavirus gene 6 (SEQ ID NO:17) mRNA functions as an enhancer of translation in its capped, non-polyadenylated viral transcript. The 3'UTR has also been shown to enhance translation of a heterologous reporter mRNA in Rabbit reticulocyte lysates. Yang *et al.*, 2004 *Archives of Virology* 149:303-321. The minimal functional element of this 3'UTR is shown in SEQ ID NO: 18

[0131] The 5' UTR of the human hsp70 gene (SEQ ID NO:19) has been shown to increase translation of reporter mRNAs in the absence of stress induction and without dramatically influencing the message stability. Enhancer function has been demonstrated in a number of human cell lines. Vivinus, *et al.*, 2001 *European Journal of Biochemistry* 268: 1908-1917.

[0132] The mouse VEGF 5' UTR (SEQ ID NO:20) enhances translation of a monocistronic reporter RNA and also

has IRES (Internal Ribosome Entry Site) activity. Its enhancer activity has been demonstrated in rat, hamster and human cell lines. The full length 5'UTR is 1014 nucleotides, but a 163 nucleotide mutant version (SEQ ID NO:21) was shown to be more active. Stein et al., 1998 Molecular and Cellular Biology 18:3112-3119.

[0133] The Spleen Necrosis Virus (SNV) is an avian retrovirus. The RU5 region of the viral 5' LTR (SEQ ID NO:22) stimulates translation efficiency of a non-viral reporter RNA in human 293 cells. Roberts and Boris-Lawrie 2000 Journal of Virology 74:8111-8118.

[0134] The 143 nucleotide 5' leader of the tobacco etch virus RNA (SEQ ID NO:23) promotes cap-independent translation of reporter mRNAs in plant and animal cell lines. Although the leader sequence does not further enhance the translation of capped transcripts, the cap-independent CD40L expression in dendritic cells is a very attractive alternative to *in vitro* capping. Gallie et al. (1995) Gene 165:233-238. Niepel and Gallie (1999) Journal of Virology 73:9080-9088. Gallie, Journal of Virology (2001) 75:12141-12152.

[0135] Dendritic cells can be transfected with nucleic acids by methods known in the art, which include, but are not limited to calcium phosphate precipitation, microinjection or electroporation. They can be added alone or in combination with a suitable carrier, e.g., a pharmaceutically acceptable carrier such as phosphate buffered saline. Alternatively or additionally, the nucleic acid can be incorporated into an expression or insertion vector for incorporation into the cells. Vectors that contain both a promoter and a cloning site into which a polynucleotide can be operatively linked are known in the art. Such vectors are capable of transcribing RNA *in vitro* or *in vivo*, and are commercially available from sources such as Stratagene (La Jolla, CA) and Promega Biotech (Madison, WI). In order to optimize expression and/or *in vitro* transcription, it may be necessary to remove, add or alter 5' and/or 3' untranslated portions of the clones to eliminate extra, potential inappropriate alternative translation initiation codons or other sequences that may interfere with or reduce expression, either at the level of transcription or translation. Alternatively, consensus ribosome binding sites can be inserted immediately 5' of the start codon to enhance expression. Examples of vectors are viruses, such as baculovirus and retrovirus, bacteriophage, adenovirus, adeno-associated virus, cosmid, plasmid, fungal vectors and other recombination vehicles typically used in the art which have been described for expression in a variety of eukaryotic and prokaryotic hosts, and may be used for gene therapy as well as for simple protein expression.

[0136] Among these are several non-viral vectors, including DNA/liposome complexes, and targeted viral protein DNA complexes. To enhance delivery to a cell, the nucleic acid or proteins of this invention can be conjugated to antibodies or binding fragments thereof which bind cell surface antigens. Liposomes that also comprise a targeting antibody or fragment thereof can be used in the methods of this invention. This invention also provides the targeting complexes for use in the methods disclosed herein.

[0137] Polynucleotides are inserted into vector genomes using methods known in the art. For example, insert and vector DNA can be contacted, under suitable conditions, with a restriction enzyme to create complementary ends on each molecule that can pair with each other and be joined together with a ligase. Alternatively, synthetic nucleic acid linkers can be ligated to the termini of restricted polynucleotide. These synthetic linkers contain nucleic acid sequences that correspond to a particular restriction site in the vector DNA. Additionally, an oligonucleotide containing a termination codon and an appropriate restriction site can be ligated for insertion into a vector containing, for example, some or all of the following: a selectable marker gene, such as the neomycin gene for selection of stable or transient transfectants in mammalian cells; enhancer/promoter sequences from the immediate early gene of human CMV for high levels of transcription; transcription termination and RNA processing signals from SV40 for mRNA stability; SV40 polyoma origins of replication and ColE1 for proper episomal replication; versatile multiple cloning sites; and T7 and SP6 RNA promoters for *in vitro* transcription of sense and antisense RNA. Other means are known and available in the art.

Preparation and Isolation of Proteins and Polypeptides

[0138] Polypeptides and proteins are necessary components of various methods of this invention. The proteins and polypeptides can be obtained by chemical synthesis using a commercially available automated peptide synthesizer such as those manufactured by Perkin Elmer/Applied Biosystems, Inc., Model 430A or 431A, Foster City, CA, USA. The synthesized protein or polypeptide can be precipitated and further purified, for example by high performance liquid chromatography (HPLC). Alternatively, the proteins and polypeptides can be obtained by known recombinant methods as described herein using the host cell and vector systems described below.

[0139] It is well known to those skilled in the art that modifications can be made to any peptide to provide it with altered properties. As used herein the term "amino acid" refers to either natural and/or unnatural or synthetic amino acids, including glycine and both the D and L optical isomers, and amino acid analogs and peptidomimetics. A peptide of three or more amino acids is commonly called an oligopeptide if the peptide chain is short. If the peptide chain is long, the peptide is commonly called a polypeptide or a protein. Peptides for use in this invention can be modified to include unnatural amino acids. Thus, the peptides may comprise D-amino acids, a combination of D- and L-amino acids, and various "designer" amino acids (e.g., β -methyl amino acids, C- α -methyl amino acids, and N- α -methyl amino acids, etc.) to convey special properties to peptides. Additionally, by assigning specific amino acids at specific coupling steps,

peptides with α -helices β turns, β sheets, γ -turns, and cyclic peptides can be generated. In a further embodiment, subunits of peptides that confer useful chemical and structural properties will be chosen. For example, peptides comprising D-amino acids may be resistant to L-amino acid-specific proteases *in vivo*. Modified compounds with D-amino acids may be synthesized with the amino acids aligned in reverse order to produce the peptides of the invention as retro-inverso peptides. In addition, the present invention envisions preparing peptides that have better defined structural properties, and the use of peptidomimetics, and peptidomimetic bonds, such as ester bonds, to prepare peptides with novel properties. In another embodiment, a peptide may be generated that incorporates a reduced peptide bond, *i.e.*, $R_1-CH_2NH-R_2$, where R_1 , and R_2 are amino acid residues or sequences. A reduced peptide bond may be introduced as a dipeptide subunit. Such a molecule would be resistant to peptide bond hydrolysis, *e.g.*, protease activity. Such molecules would provide peptides with unique function and activity, such as extended half-lives *in vivo* due to resistance to metabolic breakdown, or protease activity. Furthermore, it is well known that in certain systems constrained peptides show enhanced functional activity (Hruby (1982) Life Sciences 31:189-199 and Hruby et al. (1990) Biochem 3. 268:249-262); the present invention provides a method to produce a constrained peptide that incorporates random sequences at all other positions.

15 Methods for Isolating Stem Cells

[0140] Many methods are known in the art for the isolation and expansion of CD34⁺ stem cells for *in vitro* expansion and differentiation into dendritic cells. See for example, U.S. 5,199,942, the contents of which is incorporated by reference. The following descriptions are for the purpose of illustration only and in no way are intended to limit the scope of the invention.

[0141] CD34⁺ stem cells can be isolated from bone marrow cells or by panning the bone marrow cells or other sources with antibodies which bind unwanted cells, such as CD4⁺ and CD8⁺ (T cells), CD45⁺ (panB cells) and GR-1. For a detailed description of this protocol see, Inaba, et al. (1992) 3. Exp. Med. 176:1693-1702. Human CD34⁺ cells can be obtained from a variety of sources, including cord blood, bone marrow explants, and mobilized peripheral blood. Purification of CD34⁺ cells can be accomplished by antibody affinity procedures. See, for example, Paczesny et al. (2004) 3 Exp Med. 199: 1503-11; Ho, et al. (1995) Stem Cells 13 (suppl. 3):100-105; Brenner (1993) Journal of Hematotherapy 2:7-17; and Yu, et al. (1995) PNAS 92:699-703.

30 Differentiating Stem Cells into Immature Dendritic Cells

[0142] CD34⁺ stem cells can be differentiated into dendritic cells by incubating the cells with the appropriate cytokines. Inaba *et al.* (1994) *supra*, described the *in vitro* differentiation of murine stem cells into dendritic cells by incubating the stem cells with murine GM-CSF. In brief, isolated stem cells are incubated with between 1 and 200 ng/ml murine GM-CSF, and preferably about 20 ng/ml GM-CSF in standard RPMI growth medium. The media is changed with fresh media about once every other day. After approximately 5-7 days in culture, a large percentage of cells are dendritic, as assessed by expression of surface markers and morphology. Dendritic cells are isolated by fluorescence activated cell sorting (FACS) or by other standard methods.

[0143] Murine CD34⁺ stem cells can be differentiated into dendritic cells by culturing the cells with murine GM-CSF. Typically, the concentration of GM-CSF in culture is at least about 0.2 ng/ml, and preferably at least about 1 ng/ml. Often the range will be between about 20 ng/ml and 200 ng/ml. In many preferred embodiments, the dose will be about 100 ng/ml. IL-4 is optionally added in similar ranges for making murine DCs.

[0144] Human CD34⁺ hematopoietic stem cells are preferably differentiated *in vitro* by culturing the cells with human GM-CSF and TNF- α . See for example, Szabolcs, *et al.* (1995) 154:5851-5861. Human GM-CSF is used in similar ranges, and TNF- α can also be added to facilitate differentiation. TNF- α is also typically added in about the same ranges. Optionally, SCF or other proliferation ligand (*e.g.*, Flt3) is added in similar dose ranges to differentiate human DCs.

[0145] As is apparent to those of skill in the art, dose ranges for differentiating stem cells and monocytes into dendritic cells are approximate. Different suppliers and different lots of cytokine from the same supplier vary in the activity of the cytokine. One of skill can easily titrate each cytokine which is used to determine the optimal dose for any particular cytokine.

50 Differentiation of Monocytes into Dendritic Cells

[0146] DCs can be generated from frequent, but non-proliferating CD14⁺ precursors (monocytes) in peripheral blood by culture in medium containing GM-CSF and IL-4 or GM-CSF and IL-13 (see, *e.g.*, WO 97/29182). This method is described in Sallusto and Lanzavecchia (1994) J. Exp. Med. 179:1109 and Romani et al. (1994) J. Exp. Med. 180:83. Briefly, CD14⁺ precursors are abundant so that pretreatment of patients with cytokines such as G-CSF (used to increase CD34⁺ cells and more committed precursors in peripheral blood) is reported to be unnecessary in most cases (Romani et al. (1996) J. Immunol. Methods 196:137). Others have reported that DCs generated by this approach appear rather homogenous and can be produced in an immature state or fully differentiated or mature. It was shown that it is possible

to avoid non-human proteins such as FCS (fetal calf serum), and to obtain fully and irreversibly mature and stable DCs by using autologous monocyte conditioned medium as maturation stimulus (Romani et al. (1996) Immunol. Methods 196:137; Bender et al. (1996) J. Immunol. Methods 196:121). However, in contrast to the instant invention, these studies did not result in mature DC having increased levels of IL-12 and/or decreased levels of IL-10.

Antigen Loading

[0147] Methods of loading dendritic cells with antigens are known to those of skill in the art. In one embodiment, the dendritic cells are cultured in medium containing the antigen. The DCs then take up and process the antigen on the cell surface in association with MHC molecules. Preferably, the DCs are loaded with antigen by transfection with a nucleic acid encoding the antigen. Methods of transfecting DCs are known to those of skill in the art.

Isolation of and Expansion of T Cells

[0148] In some methods of this invention, T cells are isolated from mammals so that they can be educated (or activated) by the mature, modified DC *in vitro*. In one method, Ficoll-Hypaque density gradient centrifugation is used to separate PBMC from red blood cells and neutrophils according to established procedures. Cells are washed with modified AIM-V (which consists of AIM-V (GIBCO) with 2 mM glutamine, 10 µg/ml gentamicin sulfate, 50 µg/ml streptomycin) supplemented with 1% fetal bovine serum (FBS). T cells are enriched by negative or positive selection with appropriate monoclonal antibodies coupled to columns or magnetic beads according to standard techniques. An aliquot of cells is analyzed for cell surface phenotype including CD4, CD8, CD3 and CD14. For the purpose of illustration only, cells are washed and resuspended at a concentration of about 5×10^5 cells per ml of AIM-V modified as above and containing 5% FBS and 100 U/ml recombinant IL-2 (rIL-2) (supplemented AIM-V). Where the cells are isolated from and HIV⁺ patient, 25 nM CD4-PE40 (a recombinant protein consisting of the HIV-1-binding CD4 domain linked to the translocation and ADP-ribosylation domains of *Pseudomonas aeruginosa* exotoxin A), or other similar recombinant cytotoxic molecule which selectively hybridizes to HIV is added to the cell cultures for the remainder of the cell expansion to selectively remove HIV infected cells from the culture. CD4-PE40 has been shown to inhibit p24 production in HIV-infected cell cultures and to selectively kill HIV-1-infected cells.

[0149] To stimulate proliferation, OKT3 monoclonal antibody (Ortho Diagnostics) can be added to a concentration of 10 ng/ml and the cells are plated in 24 well plates with 0.5 ml per well. The cells are cultured at a temperature of about 37°c in a humidified incubator with 5% CO₂ for 48 hours. Media is aspirated from the cells and 1 ml of vector-containing supernatant (described below) supplemented with 5 µl/ml of protamine sulfate, 100 U/ml rIL-2, 100 U/ml penicillin, 0.25 µg/ml amphotericin B/ml and an additional 100 µg/ml streptomycin (25 nM CD4-PE40 can be added).

Cell Isolation and Characterization

[0150] In another aspect, cell surface markers can be used to isolate the cells necessary to practice the method of this invention. For example, human stem cells typically express CD34 antigen while DCs express MHC molecules and costimulatory molecules (e.g., B7-1 and B7-2), a lack of markers specific for granulocytes, NK cells, B cells, and T cells. The expression of surface markers facilitates identification and purification of these cells. These methods of identification and isolation include FACS, column chromatography, panning with magnetic beads, western blots, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, and the like, and various immunological methods such as fluid or gel precipitin reactions, immunodiffusion (single or double), immunoelectrophoresis, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, and the like. For a review of immunological and immunoassay procedures in general, see Stites and Terr (eds.) 1991 Basic and Clinical Immunology (7th ed.) and Paul supra. For a discussion of how to make antibodies to selected antigens see Harlow and Lane (1989) supra.

[0151] Cell isolation or immunoassays for detection of cells during cell purification can be performed in any of several configurations, e.g., those reviewed in Maggio (ed.) (1980) Enzyme Immunoassay CRC Press, Boca Raton, Fla.; Tijan (1985) "Practice and Theory of Enzyme Immunoassays," Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Publishers B.V., Amsterdam; Harlow and Lane, supra; Chan (ed.) (1987) Immunoassay: A Practical Guide Academic Press, Orlando, Fla.; Price and Newman (eds.) (1991) Principles and Practice of Immunoassays Stockton Press, NY; and Ngo (ed.) (1988) Non-isotopic Immunoassays Plenum Press, NY.

[0152] Cells can be isolated and characterized by flow cytometry methods such a FACS analysis. A wide variety of flow-cytometry methods are known. For a general overview of fluorescence activated flow cytometry see, for example, Abbas et al. (1991) Cellular and Molecular immunology W.B. Saunders Company, particularly chapter 3, and Kuby (1992) Immunology W.H. Freeman and Company, particularly chapter 6. FACS machines are available, e.g., from Becton Dickinson.

[0153] Labeling agents which can be used to label cell antigen include, but are not limited to monoclonal antibodies, polyclonal antibodies, proteins, or other polymers such as affinity matrices, carbohydrates or lipids. Detection proceeds by any known method, such as immunoblotting, western blot analysis, tracking of radioactive or bioluminescent markers, capillary electrophoresis, or other methods which track a molecule based upon size, charge or affinity.

Antibodies

[0154] Certain aspects of this method require the use of antibodies. Such antibodies can be monoclonal or polyclonal. They can be antibody derivatives or antibody variants. They can be chimeric, humanized, or totally human. Using a protein or a polypeptide one of skill in the art can generate additionally antibodies which specifically bind to the receptor. A functional fragment or derivative of an antibody also can be used including Fab, Fab', Fab2, Fab'2, and single chain variable regions. Antibodies can be produced in cell culture, in phage, or in various animals, including but not limited to cows, rabbits, goats, mice, rats, hamsters, guinea pigs, sheep, dogs, cats, monkeys, chimpanzees, apes, etc. So long as the fragment or derivative retains specificity of binding for the protein or fragment thereof it can be used. Antibodies can be tested for specificity of binding by comparing binding to appropriate antigen to binding to irrelevant antigen or antigen mixture under a given set of conditions. If the antibody binds to the appropriate antigen at least 2, 5, 7, and preferably 10 times more than to irrelevant antigen or antigen mixture then it is considered to be specific.

[0155] Techniques for making such partially to fully human antibodies are known in the art and any such techniques can be used. According to one embodiment, fully human antibody sequences are made in a transgenic mouse which has been engineered to express human heavy and light chain antibody genes. Multiple strains of such transgenic mice have been made which can produce different classes of antibodies. B cells from transgenic mice which are producing a desirable antibody can be fused to make hybridoma cell lines for continuous production of the desired antibody. See for example, Russel et al. (2000) *Infection and Immunity* April 2000: 1820-1826; Gallo et al. (2000) *European J. of Immun.* 30:534-540; Green (1999) *J. of Immun. Methods* 231:11-23; Yang et al. (1999A) *J. of Leukocyte Biology* 66: 401-410; Yang (1999B) *Cancer Research* 59(6):1236-1243; Jakobovits (1998) *Advanced Drug Delivery Reviews* 31: 33-42; Green and Jakobovits (1998) *Exp. Med.* 188(3):483-495; Jakobovits (1998) *Exp. Opin. Invest. Drugs* 7(4):607-614; Tsuda et al. (1997) *Genomics* 42:413-421; Sherman-Gold (1997). *Genetic Engineering News* 17:14; Mendez et al. (1997) *Nature Genetics* 15:146-156; Jakobovits (1996) *WEIR'S HANDBOOK OF EXPERIMENTAL IMMUNOLOGY, THE INTEGRATED IMMUNE SYSTEM VOL. IV*, 194.1-194.7; Jakobovits (1995) *Current Opinion in Biotechnology* 6: 561-566; Mendez et al. (1995) *Genomics* 26:294-307; Jakobovits (1994) *Current Biology* 4:761-763; Arbones et al. (1994) *Immunity* 1:247-260; Jakobovits (1993) *Nature* 362:255-258; Jakobovits et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:2551-2555; Kucherlapati, et al. U.S. Patent No. 6,075,181.

[0156] Antibodies can also be made using phage display techniques. Such techniques can be used to isolate an initial antibody or to generate variants with altered specificity or avidity characteristics. Single chain Fv can also be used as is convenient. They can be made from vaccinated transgenic mice, if desired.

[0157] The antibodies of this invention also can be modified to create chimeric antibodies. Chimeric antibodies are those in which the various domains of the antibodies' heavy and light chains are coded for by DNA from more than one species. See, e.g., U.S. Patent No.: 4,816,567.

[0158] The term "antibody variant" also includes "diabodies" which are small antibody fragments with two antigen-binding sites, wherein fragments comprise a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VH VL). See for example, EP 404,097; WO 93/11161; and Hollinger et al., (1993) *Proc. Natl. Acad. Sci. USA* 90:6444-6448. By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. See also, U.S. Patent No. 6,632,926 to Chen et al. which discloses antibody variants that have one or more amino acids inserted into a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen. The term also includes post-translational modification to linear polypeptide sequence of the antibody or fragment. The term "antibody variant" further includes "linear antibodies". The procedure for making such variants is known in the art and described in Zapata et al. (1995) *Protein Eng.* 8(10):1057-1062. Briefly, these antibodies comprise a pair of tandem Fd segments (VH ~CH 1-VH -CH1) which form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.

Methods to Detect Nucleic Acids

[0159] Various methods are known for quantifying the expression of a gene of interest (e.g. CD40L and/or IL-12p35) and include but are not limited to hybridization assays (Northern blot analysis) and PCR based hybridization assays. In assaying for an alteration in mRNA level such as IL-12 p35 mRNA or CD40L mRNA, the nucleic acid contained in a sample can be first extracted. For instance, mRNA can be isolated using various lytic enzymes or chemical solutions

according to the procedures set forth in Sambrook *et al.* (1989), *supra* or extracted by commercially available nucleic-acid-binding resins following the accompanying instructions provided by the manufacturers. The mRNA contained in the extracted nucleic acid sample can then be detected by hybridization (e.g., Northern blot analysis) and/or amplification procedures using nucleic acid probes and/or primers, respectively, according to standard procedures.

5 **[0160]** Nucleic acid molecules having at least 10 nucleotides and exhibiting sequence complementarity or homology to the nucleic acid to be detected can be used as hybridization probes or primers in the diagnostic methods. It is known in the art that a "perfectly matched" probe is not needed for a specific hybridization. Minor changes in probe sequence achieved by substitution, deletion or insertion of a small number of bases do not affect the hybridization specificity. In general, as much as 20% base-pair mismatch (when optimally aligned) can be tolerated. For example, a probe useful for detecting CD40L mRNA is at least about 80% identical to the homologous region of comparable size contained in a previously identified sequence, e.g., see SEQ ID NOS: 1 or 3. Alternatively, the probe is at least 85% or even at least 90% identical to the corresponding gene sequence after alignment of the homologous region. The total size of fragment, as well as the size of the complementary stretches, will depend on the intended use or application of the particular nucleic acid segment. Smaller fragments of the gene will generally find use in hybridization embodiments, wherein the length of the complementary region may be varied, such as between about 10 and about 100 nucleotides, or even full length according to the complementary sequences one wishes to detect.

10 **[0161]** Nucleotide probes having complementary sequences over stretches greater than about 10 nucleotides in length will increase stability and selectivity of the hybrid, and thereby improving the specificity of particular hybrid molecules obtained. One can design nucleic acid molecules having gene-complementary stretches of more than about 25 and even more preferably more than about 50 nucleotides in length, or even longer where desired. Such fragments may be readily prepared by, for example, directly synthesizing the fragment by chemical means, by application of nucleic acid reproduction technology, such as the PCRTM technology with two priming oligonucleotides as described in U.S. Patent No. 4,603,102 or by introducing selected sequences into recombinant vectors for recombinant production.

15 **[0162]** In certain embodiments, it will be advantageous to employ nucleic acid sequences of the present invention in combination with an appropriate means, such as a label, for detecting hybridization and therefore complementary sequences. A wide variety of appropriate indicator means are known in the art, including fluorescent, radioactive, enzymatic or other ligands, such as avidin/biotin, which are capable of giving a detectable signal. A fluorescent label or an enzyme tag, such as urease, alkaline phosphatase or peroxidase, instead of radioactive or other environmental undesirable reagents can also be used. In the case of enzyme tags, colorimetric indicator substrates are known which can be employed to provide a means visible to the human eye or spectrophotometrically, to identify specific hybridization with complementary nucleic acid-containing samples.

20 **[0163]** Hybridization reactions can be performed under conditions of different "stringency". Relevant conditions include temperature, ionic strength, time of incubation, the presence of additional solutes in the reaction mixture such as formamide, and the washing procedure. Higher stringency conditions are those conditions, such as higher temperature and lower sodium ion concentration, which require higher minimum complementarity between hybridizing elements for a stable hybridization complex to form. Conditions that increase the stringency of a hybridization reaction are widely known and published in the art. See, Sambrook, *et al.* (1989) *supra*. One can also utilize to detect and quantify mRNA level or its expression using quantitative PCR or high throughput analysis such as Serial Analysis of Gene Expression (SAGE) as described in Velculescu *et al.* (1995) *Science* 270:484-487. Briefly, the method comprises isolating multiple mRNAs from cell or tissue samples suspected of containing the transcript. Optionally, the gene transcripts can be converted to cDNA. A sampling of the gene transcripts are subjected to sequence-specific analysis and quantified. These gene transcript sequence abundances are compared against reference database sequence abundances including normal data sets for diseased and healthy patients. The patient has the disease(s) with which the patient's data set most closely correlates and for this application, includes the differential of the transcript.

25 **[0164]** In certain aspects, it may be necessary to use polynucleotides as nucleotide probes or primers for the amplification and detection of genes or gene transcripts. A primer useful for detecting differentially expressed mRNA is at least about 80% identical to the homologous region of comparable size of a gene or polynucleotide. For the purpose of this invention, amplification means any method employing a primer-dependent polymerase capable of replicating a target sequence with reasonable fidelity. Amplification may be carried out by natural or recombinant DNA-polymerases such as T7 DNA polymerase, Klenow fragment of *E. coli* DNA polymerase, and reverse transcriptase.

30 **[0165]** General procedures for PCR are taught in MacPherson *et al.*, PCR: A PRACTICAL APPROACH, (IRL Press at Oxford University Press (1991)). However, PCR conditions used for each application reaction are empirically determined. A number of parameters influence the success of a reaction. Among them are annealing temperature and time, extension time, Mg²⁺ ATP concentration, pH, and the relative concentration of primers, templates, and deoxyribonucleotides.

35 **[0166]** After amplification, the resulting DNA fragments can be detected by agarose gel electrophoresis followed by visualization with ethidium bromide staining and ultraviolet illumination. A specific amplification of differentially expressed genes of interest can be verified by demonstrating that the amplified DNA fragment has the predicted size, exhibits the

predicated restriction digestion pattern, and/or hybridizes to the correct cloned DNA sequence. Other methods for detecting gene expression are known to those skilled in the art. See, for example, International PCI Application No. WO 97/10365, U.S. Patent numbers 5,405,783, 5,412,087 and 5,445,934, 5,405,783; 5,412,087; 5,445,934; 5,578,832; 5,631,734; and LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGY, Vol. 24: Hybridization with Nucleic Acid Probes, Tijssen, ed. Elsevier, N.Y. (1993).

Methods for Detecting and Quantifying Protein or Polypeptides

[0167] A variety of techniques are available in the art for protein analysis and include, but are not limited to radioimmunoassays, ELISA (enzyme linked immunoradiometric assays), "sandwich" immunoassays, immunoradiometric assays, *in situ* immunoassays (using e.g., colloidal gold, enzyme or radioisotope labels), western blot analysis, immunoprecipitation assays, immunofluorescent assays and PAGE-SDS.

Ex Vivo Therapy

[0168] As noted above, this invention also provides *ex vivo* therapeutic methods using the dendritic cells or educated T cells produced by the methods of this invention. For example, dendritic cells are transformed with an immunogen can be used to activate cytotoxic and helper T cells *in vitro*. Alternatively, the transformed dendritic cells are introduced into a mammal to activate the T cells *in vivo*. Yet further, T cells educated *in vitro* can be introduced into a mammal where they are cytotoxic against target cells bearing antigenic peptides corresponding to those the T cells are activated to recognize on class I MHC molecules. These target cells are typically cancer cells, or infected cells which express unique antigenic peptides on their MHC class I surfaces.

[0169] Similarly, helper T-cells, which recognize antigenic peptides in the context of MHC class II, can also be stimulated by the DCs of the invention, which comprise antigenic peptides both in the context of class I and class II MHC. Helper T-cells also stimulate an immune response against a target cell. As with cytotoxic T cells, helper T-cells are stimulated with the recombinant DCs *in vitro* or *in vivo*.

[0170] The dendritic cells and T cells can be isolated from the mammal into which the DCs and/or activated T cells are to be administered. Alternatively, the cells can be allogeneic provided from a donor or stored in a cell bank (e.g., a blood bank).

In Vivo Therapy

[0171] T cells or dendritic cells produced by the methods of this invention can be administered directly to the subject to produce T cells active against a selected immunogen. Administration can be by methods known in the art to successfully deliver a cell into ultimate contact with a subject's blood or tissue cells.

[0172] The cells are administered in any suitable manner, often with pharmaceutically acceptable carriers. Suitable methods of administering cells in the context of the present invention to a subject are available, and, although more than one route can be used to administer a particular cell composition, a particular route can often provide a more immediate and more effective reaction than another route. Preferred routes of administration include, but are not limited to intradermal and intravenous administration.

[0173] Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention. Most typically, quality controls (microbiology, clonogenic assays, viability tests), are performed and the cells are reinfused back to the subject, preceded by the administration of diphenhydramine and hydrocortisone. See, for example, Korbling et al. (1986) Blood 67:529-532 and Haas et al. (1990) Exp. Hematol. 18:94-98.

[0174] Formulations suitable for parenteral administration, such as, for example, by intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, intranodal and subcutaneous routes, and carriers include aqueous isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. Intradermal and intravenous administration are the preferred method of administration for DCs or T cells of the invention.

[0175] The dose of cells (e.g., activated T cells, or dendritic cells) administered to a subject is in an effective amount, effective to achieve the desired beneficial therapeutic response in the subject over time, or to inhibit growth of cancer cells, or to inhibit infection.

[0176] For the purpose of illustration only, the method can be practiced by obtaining and saving blood samples from the subject prior to infusion for subsequent analysis and comparison. Generally at least about 10^4 to 10^6 and typically, between 1×10^8 and 1×10^{10} cells are infused intravenously or intraperitoneally into a 70 kg patient over roughly 60-120

minutes. In one aspect, administration is by intravenous infusion. Vital signs and oxygen saturation by pulse oximetry are closely monitored. Blood samples are obtained 5 minutes and 1 hour following infusion and saved for analysis. Cell re-infusions are repeated roughly every month for a total of 10-12 treatments in a one year period. After the first treatment, infusions can be performed on an outpatient basis at the discretion of the clinician. If the re-infusion is given as an outpatient, the participant is monitored for at least 4 hours following the therapy.

[0177] For administration, cells of the present invention can be administered at a rate determined by the effective dose, the LD-50 (or other measure of toxicity) of the cell type, and the side-effects of the cell type at various concentrations, as applied to the mass and overall health of the subject. Administration can be accomplished via single or divided doses.

[0178] The cells of this invention can supplement other treatments for a condition by known conventional therapy, including cytotoxic agents, nucleotide analogues and biologic response modifiers. Similarly, biological response modifiers are optionally added for treatment by the DCs or activated T cells of the invention. For example, the cells are optionally administered with an adjuvant, or cytokine such as GM-CSF, IL-12 or IL-2.

In Vitro Assays and Kits

[0179] The present disclosure provides commercially valuable kits to practice the maturation methods of the invention. The kit may comprise IFN γ polypeptide, or an expression cassette for expressing IFN γ mRNA in vivo or in vitro, and CD40L polypeptide, or an expression cassette for expressing CD40L mRNA in vivo or in vitro expression of CD40L. Alternatively, the kit may comprise TNF α polypeptide, or an expression cassette for expressing TNF α mRNA in vivo or in vitro, and CD40L polypeptide, or an expression cassette for expressing CD40L mRNA in vivo or in vitro expression of CD40L. The kits may further comprise a RNA polymerase for in vitro transcription.

Methods to Assess Immunogenicity

[0180] The immunogenicity of the antigen presenting cells or educated T cells produced by the methods of the invention can be determined by well known methodologies including, but not limited to the following:

⁵¹Cr-release lysis assay. Lysis of peptide-pulsed ⁵¹Cr-labeled targets by antigen-specific T cells can be compared. "More active" compositions will show greater lysis of targets as a function of time. The kinetics of lysis as well as overall target lysis at a fixed timepoint (e.g., 4 hours) may be used to evaluate performance. Ware et al. (1983) 3. Immunol. 131:1312.

Cytokine-release assay. Analysis of the types and quantities of cytokines secreted by T cells upon contacting modified APCs can be a measure of functional activity. Cytokines can be measured by ELISA or ELISPOT assays to determine the rate and total amount of cytokine production. Fujihashi et al. (1993) J. Immunol. Meth. 160:181; Tanquay and Killian (1994) Lymphokine Cytokine Res. 13:259.

In vitro T cell education. The compositions of the invention can be assayed for the ability to elicit reactive T cell populations from normal donor or patient-derived PBMC. In this system, elicited T cells can be tested for lytic activity, cytokine-release, polyclonality, and cross-reactivity to the antigenic epitope. Parkhurst et al. (1996) Immunol. 157: 2539.

Transgenic animal models. Immunogenicity can be assessed *in vivo* by vaccinating HLA transgenic mice with the compositions of the invention and determining the nature and magnitude of the induced immune response. Alternatively, the hu-PBL-SCID mouse model allows reconstitution of a human immune system in a mouse by adoptive transfer of human PBL. These animals may be vaccinated with the compositions and analyzed for immune response as previously mentioned in Shirai et al. (1995) J. Immunol. 154:2733; Mosier et al. (1993) Proc. Natl. Acad. Sci. USA 90:2443.

Proliferation Assays. T cells will proliferate in response to reactive compositions. Proliferation can be monitored quantitatively by measuring, for example, ³H-thymidine uptake. Caruso et al. (1997) Cytometry 27:71.

Primate models. A non-human primate (chimpanzee) model system can be utilized to monitor *in vivo* immunogenicities of HLA-restricted ligands. It has been demonstrated that chimpanzees share overlapping MHC-ligand specificities with human MHC molecules thus allowing one to test HLA-restricted ligands for relative *in vivo* immunogenicity. Bertoni et al. (1998) Immunol. 161:4447.

Monitoring TCR Signal Transduction Events. Several intracellular signal transduction events (*e.g.*, phosphorylation) are associated with successful TCR engagement by MHC-ligand complexes. The qualitative and quantitative analysis of these events have been correlated with the relative abilities of compositions to activate effector cells through TCR engagement. Salazar et al. (2000) *Tnt. J. Cancer* 85:829; Isakov et al. (1995) *J. Exp. Med.* 181:375).

[0181] In accordance with the above description, the following examples are intended to illustrate, but not limit, the various aspects of this invention.

Experimental Examples

Reagents

[0182] Histopaque 1077 and Tween 20 were purchased from Sigma (St Louis, MO). PBS and X-VIVO 15 were purchased from Cambrex (East Rutherford, NJ). AIM-V medium, Iscove's modified Dulbecco's medium and RPMI 1640 medium along with Trypan Blue and Fetal Bovine Serum (FBS) were purchased from Invitrogen (Carlsbad, CA). Viaspan was purchased from Dupont Pharma Labs (Wilmington, DE). GM-CSF, IL-4, TNF- α , IL-1 β , IL-6 and IFN- γ were all purchased from R&D Systems (Minneapolis, MN). PGE₂ was purchased from Cayman Chemicals (Ann Arbor, CA). Soluble CD40L was purchased from Alexis Biochemicals (San Diego CA). Human AB serum was purchased from Valley Biochemical (Winchester, VA).

[0183] Chemokines CCL19 and CCL21 were purchased from Peprotech (Rocky Hill, NJ). Phenotyping antibodies (HLA-ABC, HLA-DR, CD80, CD86, CD83, CD14, and negative isotype controls), ELISpot antibody pairs (IFN- γ and IL-2) ELISA sets (IL-12 and IL-10) and streptavidin-HRP were all purchased from BD Pharmingen (San Diego, CA) along with BD Opt EIA reagent set B pH9.5. AEC peroxidase substrate was purchased from Vector Labs (Vector Labs, Burlingame, CA). Blocking anti-CD40L antibody was purchased from eBioscience. CD1d/ α -galactosylceramide (KRN7000) tetramer and native KRN7000 were kind gifts from Kirin Brewery, Pharmaceuticals Division, Tokyo, Japan. MART-1/HLA-A201 tetramers were purchased from Beckman-Coulter (Miami, FL)

DC generation

[0184] Human PBMCs were isolated from Leukapheresis collections from healthy volunteers provided by Life Blood (Memphis, Tennessee). PBMCs were prepared by Ficoll-Histopaque density centrifugation and washed four times in PBS at room temperature. 2×10^8 PBMCs were re-suspended in 30 ml AIM-V medium and allowed to adhere to 150 cm³ plastic flasks for 2 hours at 37°C. Non-adherent cells were removed and remaining cells cultured in X-VIVO 15 medium, supplemented with GM-CSF (1000 U/ml) and IL-4 (1000 U/ml), for 5-6 days at 37°C, 5% CO₂.

Cloning of CD40L

[0185] T cells were stimulated with PMA in RPMI for 1 hr. Cells were harvested and washed with PBS once. Total RNA was extracted using QIAGEN RNeasy procedure. One microgram of total RNA from activated T cells was taken into one tube RT-PCR reaction using Gene Amp Gold kit (Applied Bioscience) using a high fidelity Advantage Polymerase (Clontech). Gene specific primers for CD40L sequence correspond to bases 47 and 859 of CD40L sequence CD40L 5' primer: 5'-GCATCATCGAAACATACAACC-3' (SEQ ID NO. 11) and CD40 3' primer: 5'-GTATTATGAAGACTCCCAGCG-3' (SEQ ID NO. 12). The PCR fragment was purified and subcloned into pCR2.1 vector using T4 DNA ligase (Invitrogen). Sequence analysis of the CD40L open reading frame and alignment with a GenBank consensus sequence revealed presence of two mutations. One mutation was conservative and did not lead to amino acid change. Another substitution resulted in a functional amino acid change Asn-Ser. Site directed mutagenesis was performed to correct the non-conservative amino acid change back to asparagine. Briefly, 10-40 ng of CD40L PCR2.1 plasmid DNA was used in site directed mutagenesis using custom 5' phosphorylated and HPLC purified primers (QIAGEN), PFU Ultra enzyme with accompanying 10X PCR buffer (Stratagene) and dNTPS (Clontech) Following the PCR reaction, Dpn I restriction enzyme (Promega) was added and incubated for 1 hour at 37°C to digest away parental template. Five microliters of this reaction was then transformed into Oneshot MACH T1R competent cells (Invitrogen) and plated out on freshly made ampicillin containing LB plates. Six colonies were selected and grown as 3 mL cultures overnight in LB containing ampicillin. DNA was isolated using plasmid miniprep (QIAGEN). An aliquot of purified DNA for each clone was submitted to the University of North Carolina (UNC) sequencing facility for sequence analysis of the CD40L open reading frame using M13F and M13R primers (Invitrogen). All the clones were then aligned to a consensus GenBank Sequence for CD40L using DNASTAR Seqman analysis software. Clone #2 (renamed CD40L WT PCR 2.1) was selected for containing the correct mutagenized bases.

Generation of mRNAs for transfection of DCs

[0186] CD40L WT PCR 2.1 plasmid was linearized using SpeI restriction enzyme and purified by phenol/chloroform extraction followed by ethanol precipitation. The linear template was reconstituted in water and transcribed *in vitro* using mMessage mMachine T7 Ultra kits (Ambion) following the manufacturer's directions. An aliquot of RNA was saved for final analysis prior to proceeding to polyadenylation reaction. Polyadenylated RNA was purified using RNeasy column (QIAGEN) following protocol for RNA cleanup. RNA was eluted in water and stored in individual size aliquots below -150°C. PolyA tail length was determined by the comparative analysis of non-polyadenylated RNA and final product using RNA Bioanalyzer 2100.

Electroporation of DCs

[0187] Prior to electroporation, DCs were harvested and washed in PBS and then re-suspended in chilled Viaspan® (Barr Laboratories) at 4×10^7 /ml in 0.5 ml or 2.5×10^7 /ml in 0.2 ml and placed on ice. DCs were mixed with mRNA (1 or 2 $\mu\text{g}/10^6$ for mRNA encoding antigen and 4 $\mu\text{g}/10^6$ for CD40L mRNA) and placed in a 4 mm gap electroporation cuvette and electroporated using Biorad apparatus. Immediately after electroporation, DCs were washed in X-VIVO 15 medium and finally re-suspended in X-VIVO 15 supplemented with GM-CSF (800 U/ml) and IL-4 (500 U/ml) at 1×10^6 /ml and cultured for either 4 or 24 hours at 37°C in low adherence six well plates (BD Biosciences, Franklin Lakes, NJ). Additional maturation stimuli, described below, were also added at this point.

DC maturation - CD40L base process.

[0188] Following electroporation, DCs transfected with CD40L mRNA were treated with IFN- γ (1000 U/ml) or TNF- α (10 ng/ml) or a combination of IFN- γ and PGE₂ (1 $\mu\text{g}/\text{ml}$). By comparison, immature DCs were transfected with various antigen-encoding mRNAs and were then treated with a "cytokine cocktail" comprising of TNF- α (10 ng/ml), IL-1 β (10 ng/ml), IL-6 (100 ng/ml) and PGE₂ (1 $\mu\text{g}/\text{ml}$) or soluble CD40L (200 ng/ml) plus enhancer (1 $\mu\text{g}/\text{ml}$) with either simultaneous or sequential addition of 1000 U/ml IFN- γ .

DC maturation - PME-CD40L process.

[0189] Immature DCs were phenotypically matured on Day 5 of culture with TNF- α (10 ng/ml), IFN- γ (1000 U/ml) and PGE₂ (1 $\mu\text{g}/\text{ml}$). On day 6, DCs were harvested and electroporated with antigen and CD40L mRNA as described above, and cultured in X-VIVO 15 media containing 800 U/ml GM-CSF and 500 U/ml IL-4 for 4 hrs prior to harvest, or formulation for vaccine production.

DC maturation with the CD40L base process, in combination with α -galactosylceramide (KRN7000)

[0190] 100 ng/ml of KRN7000 was pulsed onto the CD40L base process DCs immediately post electroporation in combination with 500 U/ml IFN- γ and 1 $\mu\text{g}/\text{ml}$ PGE₂, for 24 hrs of culture.

Flow Cytometry analysis of DCs

[0191] 10^6 DCs were harvested and re-suspended in chilled PBS/ 1% FCS. Phycoerythrin (PE) or FITC conjugated antibodies specific for MHC molecules (HLA-ABC, HLA-DR), co-stimulatory molecules (CD80, CD86), maturation markers (CD83) and monocyte markers (CD14) were mixed with 1×10^5 DCs per well in a 96 well plates (BD Biosciences) and incubated at 4°C for a minimum of 15 minutes. Isotype matched antibodies were used as controls. After thorough washing, fluorescence analysis was performed with a FACScalibur flow cytometer (BD Biosciences) using CellQuest software (BD Biosciences).

[0192] Intracellular expression of CD40L was determined as follows: 2×10^5 DCs or HeLa cells were harvested at various time points post transfection with CD40L mRNA and re-suspended in 250 μL of Cytofix/Cytoperm solution (BD Biosciences) for a minimum of 10 minutes up to 2 hours at 4°C. Cells were washed twice with 2 ml staining buffer (PBS, BSA, NaN₃, and EDTA), re-suspended in 0.5 ml staining buffer and stored over night at 4°C. Cells were re-suspended in 2.0 ml Perm/Wash solution (BD Biosciences) for 15 minutes, centrifuged and re-suspended in 100 μL Perm/Wash solution. 20 μL of mouse anti-human CD40L PE and anti-human CD40 APC (BD Biosciences) or mouse IgG1 PE and IgG1 APC (BD Biosciences) was added to each DC preparation collected and permeabilized at each time point, and incubated at 4°C for 30 minutes in the dark. Cells were washed twice with 1 ml Perm/Wash solution and re-suspended in staining buffer prior to flow cytometric analysis.

[0193] Intracellular cytokine staining (ICS) was performed as follows: 1×10^6 /ml primed CD8+ T cells, removed from

co-culture on day 19 and re-stimulated in 200 μ l R10 media with PME DC targets (RCC, survivin, G250, hTERT or eGFP) at 37°C; 5% CO₂ for 1 hour prior to the addition of brefeldin A (BD GolgiPlug, Cat No. 555029) at 1 μ l/ml. Cells incubated at 37°C for a further 16 hours. Cells were washed and resuspended in 150 μ l FACS buffer with 5 μ l CD8 per CP-cy5.5 (BD 341051) and incubated at 4°C. After 30 minutes cells were washed twice and resuspended in 2% para-formaldehyde (PFA). Cells were subsequently washed after 10 minutes, and then permeabilized in 0.1% saponin for 10 minutes at room temperature (RT), prior to incubation with 2 μ l of blocking antibody, Mouse IgG1 pure (BD 349040). After 10 minutes incubation at RT, 0.5 μ l IFN- γ - APC (BD 554681), 10 μ l IL-2-FITC (BD 554702) and 10 μ l CD69-PE (BD 555531) antibodies were added to each sample tube. Samples were incubated for 30 minutes in the dark at RT. Cells were resuspended in 2% PFA following a final wash in 0.1 % saponin. Analysis undertaken by FACS cytometry, collecting 100,000 events.

CD40L functional analysis when expressed from mRNA in HeLa cells

[0194] HeLa cells were grown in 10% FBS/DMEM and then harvested and electroporated in 4 mm cuvettes with GFP and CD40L RNA (20 μ g each/5x10⁶ cells). Post-transfection recovery was ~70% and the cells were plated in 6 well dishes and allowed to grow overnight. Following the overnight incubation, transfected HELA cells were harvested by scraping and stained with either mouse IgG1-PE or anti-human CD40L-PE (both from BD Biosciences, San Diego, CA) to look for cell surface expression of CD40L. 2 x 10⁵ cells/tube were stained with 10 μ g/ml of antibody in 1% FBS/PBS for 30 minutes at 4°C. The cells were analyzed using a FACScaliber flow cytometer and Cellquest software (BD Biosciences). To analyze the function of the HeLa expressed CD40L, 1 x 10⁶ immature dendritic cells were co-cultured with 1 x 10⁶ HeLa cells in 5% huAB serum/RPMI supplemented with 1000 U/ml of IFN- γ (R&D Systems, Minneapolis, MN) in 6 well dishes (2 mls total volume) overnight. A blocking CD40L monoclonal antibody (24-31 from eBioscience) was included at 10 μ g/ml in matched wells to confirm that cell surface expression of the protein was required for stimulating the dendritic cells. The culture supernatant was harvested after 18-24 hours and expression of the cytokines IL-10 and IL-12 analyzed by ELISA (BD Biosciences).

Migration Assay

[0195] Chemotaxis of DCs was measured by migration through a 8 μ m pore size polycarbonate filter in 24 well transwell chambers (corning Costar, Acton, MA). 5% human AB serum in Iscoves modified Dulbecco's medium or AIM-V medium containing 3-300 ng/ml CCL19, 5-250 ng/ml CCL21, a combination of both or medium alone was added to the lower chamber. 1-5 x 10⁵ DCs in 0.1 ml were added to the upper chamber and incubated for 2-3 hours at 37°C. Lower chamber harvested into 5ml tubes (BD Biosciences) and re-suspended in 0.1 ml PBS and viable cell counts undertaken using trypan blue.

ELISpot

[0196] PVDF membrane ELISpot plates (Millipore, Ballerica, MA) were coated with 5 μ g/mL monoclonal anti-IFN- γ or anti-IL-2 capture antibody (BD Pharmingen, San Diego, CA) and incubated at 4°C for 24 hours. After incubation, plates were washed with PBS/0.05% Tween 20, and blocked with 5% human AB serum/RPMI 1640 medium for 1 hour. PBMCs, T-cells, or CD8 enriched T cells, were plated at 1x10⁵cells/well and mRNA transfected, antigen-loaded DC targets at 1x10⁴cells/well for a 10:1 effector:target ratio, and incubated at 37°C, 5% CO₂ for a minimum of 16 hours.

[0197] Following incubation, plates were washed 6 times, and anti-IFN- γ detection antibody (BD Pharmingen) or anti-IL-2 detection antibody (BD Pharmingen) was added to the appropriate plates at 1 μ g/ml for 2 hours. After a further six washes, Streptavidin-HRP (BD Pharmingen) was added to each well for 1 hour. Finally, after another wash cycle, color development was undertaken with AEC Peroxidase Substrate for 5-15 minutes and stopped with water. The plates were left to air dry prior to analysis on CTL Immunospot Plate Reader (CTL, Cleveland, OH).

ELISA

[0198] The method as laid out by BD Pharmingen for IL-12 and IL-10 ELISA sets (BD Pharmingen) using BD Opt EIA reagent set B pH 9.5. Briefly, ELISA plates (BD Biosciences) were coated with anti-IL-12p70 or anti-IL-10 ELISA capture antibody in coating buffer for 24 hours at 4°C. Plates underwent blocking with 200 μ l per well 10% FCS/PBS for one hour prior to the addition of standards (BD Pharmingen) and supernatant samples, in duplicate, at 100 μ l per well and incubated at room temperature for 2 hours. Plates were washed and anti-cytokine detection antibody added, incubated for one hour, the plates washed and solutions replaced with 100 μ l of streptavidin-HRP and further incubated for one hour at room temperature. Again plates were washed and color development substrates applied for 10-20 minutes, followed by cessation of color development with stop solution. Plate analysis undertaken using Bio-Tek instruments

ELx800 plate reader with KC junior software (Winooski, VT). The results show the number of picograms/ml/10⁶ DCs. Because the assays were set up so that 1 ml corresponds to 10⁶ DCs, the results can also be expressed as number of picograms/10⁶ DCs. For example, 3000 pg/ml/10⁶ DCs is equivalent to 3000 pg/10⁶ DCs.

5 **CTL induction**

[0199] Mature dendritic cells transfected with mRNAs were co-cultured with CD8 purified T-cells. All co-cultures were performed in R-10 media (10% FBS, RPMI-1640 supplemented with 10 mM HEPES pH 7.4, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 2 mM sodium glutamate, 55 μM β-mercaptoethanol). All cell culture reagents were from Invitrogen (Carlsbad, CA). CD8⁺ cells were purified using the CD8⁺ T Cell Isolation kit II (Miltenyi Biotec, Auburn, CA) from non-adherent cells harvested from the monocyte adherence step. The CD8⁺ cells are mixed with dendritic cells prepared as described above at 10:1 CD8⁺:DC. For the first seven days the cells were cultured in media supplemented with 0.2 U/ml IL-2 (R&D Systems, Minneapolis, MN) and then aliquoted into 24-well tissue culture dishes at 1 ml (1x10⁶ CD8⁺ cells)/well. Following this initial seven day incubation the CD8⁺ cells were harvested, counted and re-cultured with fresh DC stimulators at 10:1 in media supplemented with 5 U/ml IL-2. Again the cells were cultured for one week and then restimulated with fresh DC and 20 U/ml IL-2. CTL assays were performed 3 or 7 days following the third stimulation.

20 **CTL assay**

[0200] T2 cells were previously pulsed with 10 μg/ml of either the HLA-A201 restricted MART-APL peptide (LAGIGILTV; SEQ ID NO:24) or native peptide (AAGIGILTV; SEQ ID NO:25) or PSA-1 peptide (FLTPKKLQCV; SEQ ID NO:26) by overnight incubation in FBS/RPMI media, and washed prior to use as CTL targets. Dendritic cell targets were transfected with either GFP mRNA, MART-1 APL mRNA, Flu-M1 mRNA, as described above and incubated overnight without maturation. Pulsed T2 cells were incubated with 100 μCi of Na⁵¹Cr (Perkin-Elmer Life and Analytical Sciences, Inc., Boston, MA) for 90 minutes at 37° C. Excess ⁵¹Cr was washed away and 5000 labeled targets incubated with various E:T ratios of CD8⁺ cells for 4 hours. Non-specific lysis was reduced by the addition of unpulsed T2 cells at 25,000 cells per well. Released ⁵¹Cr was measured in the supernatant by scintillation counting. Total release was calculated by addition of 1% Triton X-100 to the targets while spontaneous release was calculated by addition of media alone. Percent lysis was calculated using the formula (sample cpm released-spontaneous cpm)/(total cpm released- spontaneous cpm released).

Induction of MART-1 specific CTLs employing KRN7000-pulsed CD40L base process matured DC

[0201] DCs were generated as described above, employing the 'CD40L base process', and loaded with mRNA encoding MART-1. Post electroporation, DCs were incubated with KRN7000, IFN-γ and PGE₂. DCs and PBMCs were co-cultured at a 1:10 ratio in the presence of 20 U/ml IL-2. PBMCs were restimulated three times under the same conditions, and the frequency of CTL induction determined by staining with MART-1/A2 tetramers, and the expansion of NKT-cells enumerated using KRN7000/CD1d tetramers by FACS.

Results of Experimental Examples

Sequential maturation with Interferon-γ and CD40L optimizes IL-12p70 secretion

[0202] Immature DCs were prepared by 6 day culture of adherent cells PBMCs in X-VIVO 15 media, inclusive of GM-CSF and IL-4. DCs were recovered on Day 6 and electroporated with 2 μg of eGFP encoding mRNA per million DCs, and matured for 36 hrs with "cytokine cocktail". Alternatively, maturation was achieved by culturing the DCs in the presence of IFN-γ and soluble CD40L, applied simultaneously, or sequentially. DCs were monitored for increased expression of co-stimulatory molecules, but most importantly for the secretion of IL-12p70 versus IL-10. Figure 1 shows that DCs matured with the cytokine cocktail secrete excess IL-10 in comparison to IL-12p70 into the culture supernatant over the 36 hr culture period. By contrast, DCs matured simultaneously with soluble CD40L plus IFN-γ secrete excess IL-12p70. However, sequential application of IFN-γ for 18 hrs, followed by the addition of soluble CD40L directly to the culture, and an additional 18hr culture period resulted in significantly enhanced levels of IL-12p70 secretion. Unexpectedly, the application of soluble CD40L, followed by IFN-γ, prevented significant secretion of IL-12p70. In conclusion, the sequential delivery of an innate stimulus to "prime" DC maturation (IFN-γ), followed by a surrogate T-helper cell signal delivered by soluble CD40L, optimizes DC maturation for IL-12p70 secretion.

Co-culture of HeLa cells, transfected with mRNA encoding CD40L, with immature DCs results in the induction of DC derived IL-12p70.

[0203] Figure 2 shows that HeLa cells transfected with mRNA encoding CD40L results in significant cell surface expression of CD40L protein after 24 hrs of culture, as defined by an anti-CD40L antibody and flow cytometry. CD40L mRNA transfected HeLa cells were co-cultured with immature DCs, in the presence of 1000 U/ml IFN- γ . Table II shows that HeLa cells transfected with an extended poly-A tail (> 400 'A's) are capable of inducing significant IL-12p70 secretion when cultured with immature DCs over the 18 hr culture period. Importantly, the inclusion of a blocking anti-CD40L antibody prevents IL-12p70 secretion, and confirms the identity and functional importance of protein encoded by the transfected mRNA sequence.

TABLE II

HeLa cells transfected with CD40L encoding mRNA, when co-cultured with immature DCs in the presence of IFN- γ , results in the secretion of IL-12p70. Inclusion of 'blocking' anti-CD40L antibody in the culture prevents the induction of IL-12p70.		
	Immature DCs IL-12p70 (pg/ml)	"Cocktail" matured and reactivated DCs IL-12p70 (pg/ml)
DC's alone	-	4.9
(a) HeLa/ > 400 polyA + IFN- γ	372	26.3
(b) HeLa/ > 400 polyA + IFN- γ + 24-31	-	2.5

(a) HeLa cells were transfected with 4 μ g of CD40L mRNA bearing greater than 400 nucleotide poly-A tail, and incubated with DCs in the presence of IFN- γ .
 (b) As (a) but in the presence of blocking anti-CD40L antibody (24-31).

Dendritic cells transfected with CD40L mRNA, and cultured in the presence of IFN- γ secrete IL-12p70.

[0204] Immature DCs were harvested after 6 days in culture with GM-CSF and IL-4, and transfected with a titration of CD40L mRNA (400-polyA), and immediately cultured in the presence of 1000 U/ml IFN- γ . Figure 3 shows that supernatants harvested after 18 hrs of culture contain excess IL-12p70 over IL-10, and that at least 4 μ g of CD40L mRNA per million DCs is required for optimal cytokine secretion. Increasing the CD40L mRNA payload above 4 μ g per million DCs results in a significant reduction in DC yield post maturation (data not shown). In a parallel experiment, immature DCs were transfected with 4 μ g CD40L mRNA per million cells, and a titration of IFN- γ immediately applied to the cultures. Figure 4 shows that at least 100 U/ml of IFN- γ is required to support optimal induction of IL-12p70. Figure 5a shows that IL-12p70 appears at detectable levels 6 to 8 hrs post transfection and coculture with IFN- γ , with optimal accumulation in the culture supernatant being recorded between 20 and 24 hrs. By contrast, the substitution of 10 ng/ml TNF- α for IFN- γ also supports IL-12 production, but at reduced levels (Figure 5b). Moreover, IFN- γ results in concomitantly lower levels of IL-10 production than does TNF- α . (Figure 5c)

Induction of IL-12p70 by DCs transfected with CD40L mRNA is dependent on "intracellular signaling" as opposed to cell-cell interactions.

[0205] Figure 2 demonstrates that CD40L protein translated from mRNA can be expressed on the cell surface of the transfected cells, and that the protein retains the ability to appropriately signal DCs for IL-12p70 secretion as a consequence of its interaction with its counterpart on DCs, namely CD40. To determine the cellular distribution of CD40L in transfected DCs, and to confirm its functional identity, DCs were harvested at various time points post transfection, the presence of CD40L on the cell surface, or intracellular compartments was determined. Figures 6a and 6b show that the majority of CD40L is localized within an intracellular compartment, and that significant protein expression (27% DCs CD40L positive) was not apparent until 60 minutes post transfection. Thus, although IFN- γ is applied immediately post transfection, the delivery of the maturation events is *sequential*, with the IFN- γ signal preceding that of CD40L. As shown in Figure 1, sequential maturation of DCs with IFN- γ and CD40L optimizes for IL-12p70 secretion. In addition, Figure 7 shows that CD40L transfected and IFN- γ treated DCs, when cultured in the presence of excess blocking anti-CD40L antibody for 18hrs post transfection, still secrete significant levels of IL-12p70. This data shows that CD40L/CD40 interactions, which are required for IL-12p70 production in this system, can take place within the intracellular compartment.

Frequency of CD40L positive cells over time

[0206] Immature DCs were transfected with 4 μg CD40L mRNA per 10^6 DC, and co-matured with 1000 U/ml IFN- γ . Alternatively, and by way of negative control for CD40L staining, immature DCs were matured with 'cytokine cocktail'. Maximum frequency of expression is achieved around 3 to 4 hrs post transfection with CD40L RNA (see Figure 6b), although 80% of DCs express CD40L when the cells are fixed and permeabilized, cell surface staining only detects approximately 15% of the DCs (Figure 6c). This data shows that the bulk of the CD40L protein is retained within the DC, and is not expressed at the cell surface. CD40L protein is transiently expressed, with the majority of DCs becoming CD40L negative 26 hrs post transfection. The expression of CD40, the cognate receptor molecule for CD40L, is not altered by transfection of DCs with mRNA encoding CD40L, when compared to DCs receiving 'cytokine cocktail' only.

PGE₂ is required to induce DC migration on maturation with CD40L and IFN- γ

[0207] In addition to the capacity to secrete IL-12p70 and exhibit a mature phenotype, typically defined as cells expressing elevated levels of co-stimulatory molecules such as CD80, CD83 and CD86 (see Table III), DCs must display the capacity to migrate, if they are going to be capable of homing to a lymph node *in vivo*. Several studies have shown that PGE₂ primes mature DCs for migration (Luft et al. (2002) Blood 100: 1362, Scandella et al. (2002) Blood 100: 1354). Figure 8 shows that the inclusion of 1 $\mu\text{g}/\text{ml}$ PGE₂, in addition to IFN- γ , enables the maturing DCs to migrate, and that the acquisition of this migratory potential is proportional to the CD40L mRNA payload. Thus, CD40L contributes to not only the maturing DC phenotype, and dominant IL-12p70 profile (see Table II), but also to priming for migration. By contrast, DCs matured by transfection with CD40L mRNA and cultured in the presence of IFN- γ , but in the absence of PGE₂, fail to migrate (data not shown), despite displaying significant cell surface expression of the chemokine receptor, CCR7.

TABLE III

Phenotypic analysis and secreted cytokine profile of DCs undergoing maturation induced by either 'Cytokine Cocktail', or CD40L plus IFN- γ and PGE₂

	Immature DC	(a) Flu/eGFP mRNA	(b) Mart-APL mRNA	(c) Flu/CD40L mRNA	(d) Mart-APL/CD40L mRNA
DC markers		Cytokine Cocktail	Cytokine Cocktail	IFN-g/PGE₂	IFN-g/PGE₂
HLA-ABC	99.7%	98.6%	99.5%	99.9%	99.9%
HLA-DR	95.0%	99.6%	99.7%	99.8%	99.5%
CD83	23.2%	98.3%	99.2%	99.6%	99.3%
CD14	0.3%	1.7%	2.9%	3.2%	4.9%
CD56	2.8%	3.3%	3.2%	2.8%	2.1%
CD19	1.8%	1.1%	2.1%	3.2%	3.2%
CD3	2.8%	2.4%	3.1%	2.8%	3.1 %
CD86	59.3%	99.7%	100.0%	100.0%	100.0%
CD80	28.8%	99.0%	99.5%	99.2%	99.5%
CD1a	51.6%	49.1%	52.2%	48.6%	49.9%
CD209	95.8%	95.5%	96.1%	96.4%	95.9%
CCR7	3.2%	47.4%	35.5%	35.4%	36.2%
(e) IL-12 (pg/ml)	N/A	27.5	59.0	1456.3	1350.0
(f) IL-10 (pg/ml)	N/A	948.8	810.0	187.7	165.5

[0208] DCs were prepared from adherent monocytes and cultured for 6 days in GM-CSF/IL-4. On harvesting, DCs

were transfected with various mRNA payloads and subjected to maturation for a further 24 hrs. DCs were again harvested, and the cells stained for various cell surface markers, particularly those associated with increased function, namely co-stimulation and migration. Supernatants from the maturation cultures were collected and subjected to IL-12p70 and IL-10 cytokine analysis.

(a) DCs were transfected with 2 μ g per million cells with flu mRNA as antigen-encoding payload, in addition to 4 μ g per million cells eGFP mRNA. eGFP mRNA allows for confirmation of transfection by FACS, and to act as a substitute control for the 4 μ g per million cells CD40L mRNA maturation payload, in the alternate process. These flu/eGFP transfected DCs were matured in the presence of the "cytokine cocktail".

(b) DCs were transfected with 2 μ g per million cells with MART-APL mRNA as antigen-encoding payload, and subjected to maturation with the "cytokine cocktail".

(c) DCs were transfected with 2 μ g per million cells with flu mRNA as antigen-encoding payload, concomitant with 4 μ g per million cells CD40L mRNA as the maturation payload. These cells were immediately placed in culture with IFN- γ and PGE₂ as described in materials and methods.

(d) DCs were transfected with 2 μ g per million cells with MART-APL as antigen-encoding payload, concomitant with 4 μ g per million cells CD40L mRNA as the maturation payload. These cells were immediately placed in culture with IFN- γ and PGE₂ as described in materials and methods.

(e) IL-12p70 secretion from DCs undergoing maturation.

(f) IL-10 secretion from DCs undergoing maturation.

DCs sequentially matured via transfection with CD40L mRNA and IFN- γ /PGE₂ invoke potent T-cell recall responses.

[0209] To determine the "immunopotency" of DCs matured via CD40L mRNA transfection and IFN- γ /PGE₂, DCs were co-transfected with 2 μ g mRNA encoding flu matrix protein per million DCs in addition to the CD40L mRNA and IFN- γ /PGE₂ culture environment. 18hrs post transfection, DCs were harvested, washed, and co-cultured with autologous T-cells in IFN- γ ELISpot assays. Figure 9 shows that DCs matured via CD40L/IFN- γ /PGE₂ display increased immunopotency, compared to DCs transfected with flu mRNA and matured with 'cytokine cocktail', as defined by the frequency of flu-specific IFN- γ spots in the assay.

DCs sequentially matured via transfection with CD40L mRNA and IFN- γ /PGE₂ invoke primary responses.

[0210] Recall responses, such as that described in Figure 9, are less dependent on the presence of DCs expressing optimized co-stimulatory molecules and supporting cytokine environments. Therefore, DCs were tested for their ability to invoke primary immune responses to the melanoma associate antigen, MART-1, to which many healthy donors maintain a high naive T-cell precursor frequency. As HLA-A201 donors were preferentially used, DCs were transfected with an mRNA encoding MART-1 in which the A2 restricted determinant was optimized by mutation of the mRNA sequence by site directed mutagenesis, such that the alanine at position 27 was substituted by leucine, and here referred to as MART-APL (Valmori, D et al (1998) J. Immunol. 160:1750). DCs co-transfected with 2 μ g MART-APL mRNA with 4 μ g CD40L mRNA and immediately pulsed with IFN- γ /PGE₂ for 18 hrs were compared to DCs loaded solely with MART-APL, and matured overnight with the "cytokine cocktail". Antigen-loaded and matured DCs were added to purified autologous CD8⁺ T-cells, and cultured for 7 days in the presence of 0.2 U/ml human IL-2. After this period, T-cells were recovered and co-cultured with a second round of antigen-loaded DC stimulators as appropriate in an IL-2 ELISpot assay. Figure 10 shows that CD8⁺ T-cells cultured in the presence of DCs matured via CD40L and IFN- γ /PGE₂ results in a highly significant increase in T-cells capable of IL-2 secretion in a specific response to the optimized MART-APL epitope originally encoded within the MART-APL mRNA sequence. In conclusion, DCs exposed to sequential maturation via IFN- γ /PGE₂ and CD40L are significantly more potent at raising primary immune responses than DCs matured with the currently accepted standard "cytokine cocktail". Moreover, Figure 11 shows that CTLs generated with MART-APL loaded DCs matured with the 'cytokine cocktail' fail to mediate CD4-independent CD8-mediated cytotoxicity against T2 cells pulsed with the appropriate HLA-A2 restricted MART-APL peptide (Figure 11b). By contrast, CTLs generated on CD40L/IFN- γ /PGE₂ matured DCs are fully active, and kill the MART-APL peptide pulsed T2 targets (Figure 11a).

Phenotypic analysis of immature DCs maturing under the PME-CD40L process

[0211] DCs were matured on Day 5 with the PME-CD40L process described herein. Specifically monocytes were cultured in medium GM-CSF and IL-4 for 5 days to produce immature CD83⁻ DCs. On day 5, the immature DCs were fed with medium containing TNF α , IFN γ and PGE₂ (TIP). On day 6, the post TIP phenotype was determined (see Table IV). As shown in Table IV, the majority of cells were positive for CD80, CD83, CD86 and CD209. These DCs were also CCR7 negative (data not shown). The low percentage of CD14⁺ cells represent monocytes that did not differentiate into dendritic cells. On day 6, the CD83⁺ CCR7⁻ DCs were co-transfected (via electroporation) with 1 μ g mRNA prepared from amplified renal cell carcinoma RNA and 4 μ g CD40L mRNA per million cells. CD40L expression was measured at 4 hours post transfection. The cells were cryopreserved in liquid nitrogen at 4 hrs post transfection. The post thaw recovery and viability were measured immediately after thawing, and at 24 hours post thawing. As can be seen, at 24 hours post thaw, the majority of DCs became CCR7⁺. The CCR7⁺ DCs were also positive for CD80, CD83 and CD86. The results of 3 separate runs are shown in Table IV.

TABLE IV

Run data	Run 1	Run 2	Run 3
Seeding density per flask	200 x 10 ⁶	200 x 10 ⁶	200 x 10 ⁶
Number of flasks seeded	18	20	20
Post TIP Recovery (%)	8	24	15
Post TIP Viability (%)	97	95	93
Number of cuvettes	14	15 (limited)	15 (limited)
4hr post electroporation Recovery (%)	64	43	73
4hr post electroporation Viability (%)	91	89	85
Number of vaccine doses from Run	13	9	15
Post thaw Recovery (%)	86	94	85
Post thaw Viability (%)	88	88	78
Predicted doses per 30 flasks	21	28	30
4hr CD40L expression			
	84	76	49
Post TIP DC phenotype			
% CD14	0.8	0.5	12
% CD80	100	100	98
% CD83	99	92	82
% CD86	100	100	100
% CD209	98	99	100
mDC phenotype (post thaw)			
% CD14	3	0.3	1.4
% CD80	99	100	100
% CD83	100	100	98
% CD86	100	100	100
% CD209	98	100	100
% CCR7	53	12	32
24hr post thaw % CCR7			
	93	93	95
24hr post thaw 'washout'			

(continued)

Run data	Run 1	Run 2	Run 3
% viability	50	67	63
% recovery	36	46	73
24hr post thaw transwell migration			
% Migration - media control	1.1	0.78	1.2
% Migration - 100ng/ml CCL19 and 21	74	107	70

DCs matured via the PME-CD40L process are highly migratory in response to lymph node homing chemokines, CCL19 and 21.

[0212] PME-CD40L matured DCs were assayed for migration in response to chemokines, CCL19 and 21, twenty-four hours after co-transfection with total amplified RCC RNA and CD40L RNA. Figure 12 shows that using four independent donors, that PME-CD40L matured DCs are highly migratory, consistent with the very high level of CCR7 expression achieved 24 hrs post electroporation with the PME-CD40L process (see Table IV).

DCs matured via the PME-CD40L process show significantly enhanced immunopotency over DCs matured with the 'CD40L base process'.

[0213] Despite the induction of primary immune responses by the 'CD40L base process', the 'post maturation electroporation-CD40L' process, whereby DCs are first matured with TNF- α , IFN- γ and PGE₂, prior to electroporation with CD40L plus antigen-encoding mRNA, results in a significant improvement in CTL activity using the MART antigen model system. (Figure 13). In addition, the PME-CD40L process was tested for the induction of IFN- γ and IL-2 responses using fully autologous materials derived from a renal cell carcinoma patient: patient DCs were prepared as described above for the PME-CD40L process, and electroporated with autologous total amplified RCC tumor RNA. The antigen loaded DCs were cultured with autologous patient CD8 T-cells, and the resulting responder CTL were studied by intracellular cytokine staining in response to the eliciting DC, and to individual DCs transfected with the tumor-associated antigens, hTERT, Survivin and the RCC specific antigen, G250. DCs transfected with eGFP encoding mRNA were used as negative control stimulators. Figure 14 shows that patient T-cells responded to the total amplified RCC RNA loaded DCs, and also to the three tumor-associated antigens, with both IFN- γ and IL-2 frequencies higher than that induced by the eGFP mRNA transfected negative control. (Response to eGFP subtracted from total response to each RCC associated DC target)

DCs matured by the 'base CD40L process' and pulsed with KRN7000 can recruit NKT-cells which enhance the induction of primary CTLs.

[0214] MART-1 mRNA-loaded, CD40L base process matured DC, pulsed with KRN7000, increase the frequency of NKT-cells in PBMC cultures versus the same mature RNA loaded DCs pulsed with vehicle in place of KRN7000, as defined by CD1d/KRN7000-tetramer staining (Figure 15a). Using tetramer analysis for responder CTL (MART-1/HLA-A2), the presence of KRN7000 pulsed onto MART-1 mRNA transfected DC significantly increases the frequency of MART reactive T-cells (Figure 15b). Thus, the expansion of NKT-cells in the PBMC cultures provides an amplification loop, probably achieved by NKT-cell derived 'help', that can support primary CD8 CTL development.

Optimization of CD40L mRNA

[0215] The CD40L RNA used in the original DC experiments demonstrating a preferred way of maturation was transcribed from plasmid template pCR2.1 CD40L WT. The preferred CD40L RNA contains an ARCA cap analog and polyA tail. The plasmid pCR2.1 CD40L WT was modified by removal of an XbaI - EcoRV fragment located 5' of the initiator ATG codon. The fragment encompassed 32 nucleotides of vector sequence and contained three cryptic potential initiator ATG codons. The rationale for this modification was that these additional ATG's might interfere with efficient initiation of CD40L translation by competing with the accurate CD40L translation initiation site. Coding sequence of the CD40L remained unaffected by these modifications. CD40L RNA transcribed from the modified plasmid template performed better than the current CD40L reference standard in two independent DC transfection experiments as measured by

EP 1 809 737 B9

induction of IL-12 expression. The modified plasmid is referred to as pCR2.1 CD40L WT Delta X-E.

[0216] In addition we wished to determine whether expression of the CD40L RNA can be further optimized by placing the CD40L 5' untranslated region directly upstream of the CD40L initiator codon. The pCR2.1 CD40L WT Delta X-E plasmid was further modified by the insertion of 39 bp CD40L 5' untranslated sequence located immediately upstream of the CD40L translation start site. RNA transcribed from this plasmid did not perform as well as the RNA described from CD40L WT Delta X-E but rather, performed similarly to the current CD40L transcribed from pCR2.1 CD40L WT (Figure 18). Therefore the pCR2.1 CD40L WT Delta X-E plasmid is the preferred plasmid. The DNA sequence corresponding to the CD40L RNA transcribed from the pCR2.1 CD40L WT Delta X-E plasmid is shown in SEQ ID NO:11. The ATG start codon begins at position 41.

SEQUENCE LISTING

[0217]

<110> Argos Therapeutics, Inc.
Kirin Beer Kabushiki Kaisha
Healey, Don
Tcherepanova, Irina
Adams, Melissa
Hinohara, Atsushi

<120> MATURE DENDRITIC CELL COMPOSITIONS AND METHODS FOR CULTURING SAME

<130> MER030W0

<150> US 60/522,512

<151> 2004-10-07

<160> 26

<170> PatentIn version 3.3

<210> 1

<211> 1816

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (40)..(825)

<400> 1

	cttctctgcc agaagatacc atttcaactt taacacagc atg atc gaa aca tac	54
	Met Ile Glu Thr Tyr	
	1 5	
5	aac caa act tct ccc cga tct gcg gcc act gga ctg ccc atc agc atg	102
	Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly Leu Pro Ile Ser Met	
	10 10	
10	aaa att ttt atg tat tta ctt act gtt ttt ctt atc acc cag atg att	150
	Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu Ile Thr Gln Met Ile	
	25 30 35	
15	ggg tca gca ctt ttt gct gtg tat ctt cat aga agg ttg gac aag ata	198
	Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg Arg Leu Asp Lys Ile	
	40 45 50	
15	gaa gat gaa agg aat ctt cat gaa gat ttt gta ttc atg aaa acg ata	246
	Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val Phe Met Lys Thr Ile	
	55 60 65	
20	cag aga tgc aac aca gga gaa aga tcc tta tcc tta ctg aac tgt gag	294
	Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser Leu Leu Asn Cys Glu	
	70 75 80 85	
20	gag att aaa agc cag ttt gaa ggc ttt gtg aag gat ata atg tta aac	342
	Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys Asp Ile Met Leu Asn	
	90 95 100	
25	aaa gag gag acg aag aaa gaa aac agc ttt gaa atg caa aaa ggt gat	390
	Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu Met Gln Lys Gly Asp	
	105 110 115	
30	cag aat cct caa att gcg gca cat gtc ata agt gag gcc agc agt aaa	438

	Gln	Asn	Pro	Gln	Ile	Ala	Ala	His	Val	Ile	Ser	Glu	Ala	Ser	Ser	Lys	
			120					125					130				
5	aca	aca	tct	gtg	tta	cag	tgg	gct	gaa	aaa	gga	tac	tac	acc	atg	agc	486
	Thr	Thr	Ser	Val	Leu	Gln	Trp	Ala	Glu	Lys	Gly	Tyr	Tyr	Thr	Met	Ser	
			135				140					145					
10	aac	aac	ttg	gta	acc	ctg	gaa	aat	ggg	aaa	cag	ctg	acc	gtt	aaa	aga	534
	Asn	Asn	Leu	Val	Thr	Leu	Glu	Asn	Gly	Lys	Gln	Leu	Thr	Val	Lys	Arg	
			150			155					160				165		
15	caa	gga	ctc	tat	tat	atc	tat	gcc	caa	gtc	acc	ttc	tgt	tcc	aat	cgg	582
	Gln	Gly	Leu	Tyr	Tyr	Ile	Tyr	Ala	Gln	Val	Thr	Phe	Cys	Ser	Asn	Arg	
				170						175					180		
20	gaa	gct	tcg	agt	caa	gct	cca	ttt	ata	gcc	agc	ctc	tgc	cta	aag	tcc	630
	Glu	Ala	Ser	Ser	Gln	Ala	Pro	Phe	Ile	Ala	Ser	Leu	Cys	Leu	Lys	Ser	
				185					190					195			
25	ccc	ggt	aga	ttc	gag	aga	atc	tta	ctc	aga	gct	gca	aat	acc	cac	agt	678
	Pro	Gly	Arg	Phe	Glu	Arg	Ile	Leu	Leu	Arg	Ala	Ala	Asn	Thr	His	Ser	
			200					205					210				
30	tcc	gcc	aaa	cct	tgc	ggg	caa	caa	tcc	att	cac	ttg	gga	gga	gta	ttt	726
	Ser	Ala	Lys	Pro	Cys	Gly	Gln	Gln	Ser	Ile	His	Leu	Gly	Gly	Val	Phe	
							220					225					
35	gaa	ttg	caa	cca	ggt	gct	tcg	gtg	ttt	gtc	aat	gtg	act	gat	cca	agc	774
	Glu	Leu	Gln	Pro	Gly	Ala	Ser	Val	Phe	Val	Asn	Val	Thr	Asp	Pro	Ser	
						235					240					245	
40	caa	gtg	agc	cat	ggc	act	ggc	ttc	acg	tcc	ttt	ggc	tta	ctc	aaa	ctc	822
	Gln	Val	Ser	His	Gly	Thr	Gly	Phe	Thr	Ser	Phe	Gly	Leu	Leu	Lys	Leu	
					250					255					260		
45	tga	acagtgtcac	cttgcaggct	gtgggtggagc	tgacgctggg	agtccttcata											875
50	atacagcaca	gcggttaagc	ccaccccctg	ttaactgcct	atttataacc	ctaggatcct											935
55	ccttatggag	aactatztat	tatacactcc	aaggcatgta	gaactgtaat	aagtgaatta											995
60	caggtcacat	gaaacaaaa	cgggccctgc	tccataagag	cttatatatic	tgaagcagca											1055
65	acccactga	tcagacatc	cagagagtcc	tatgaaaaga	caaggccatt	atgcacaggt											1115
70	tgaattctga	gtaaacagca	gataacttgc	caagttcagt	tttgtttctt	tcgctgcagt											1175
75	gtctttccat	ggataatgca	tttgatttat	cagtgaagat	gcagaagga	aatggggagc											1235
80	ctcagctcac	attcagttat	ggttgactct	gggttcctat	ggccttgttg	gagggggcca											1295
85	ggctctagaa	cgtctaacac	agtggagaac	cgaaccccc	cccccccc	ccgccaccct											1355
90	ctcggacagt	tattcattct	ctttcaatct	ctctctctcc	atctctctct	ttcagttctct											1415
95	ctctctcaac	ctctttcttc	caatctctct	ttctcaatct	ctctgtttcc	ctttgtcagt											1475
100	ctttccctc	ccccagtctc	tcttctcaat	ccccctttct	aacacacaca	cacacacaca											1535
105	cacacacaca	cacacacaca	cacacacaca	cacacacaca	cacacagagt	caggccgttg											1595
110	ctagtcagtt	ctcttctttc	caccctgtcc	ctatctctac	cactatagat	gaggggtgagg											1655

agtagggagt gcagccctga gcctgccac tcctcattac gaaatgactg tatttaaagg 1715
 aaatctattg tatctacctg cagtctccat tgtttccaga gtgaacttgt aattatcttg 1775
 5 ttatttattt tttgaataat aaagacctct taacattaa a 1816

<210> 2

<211> 261

10 <212> PRT

<213> Homo sapiens

<400> 2

15

Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly
 1 5 10 15

Leu Pro Ile Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu
 20 25 30

20

Ile Thr Gln Met Ile Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg
 35 40 45

Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val
 50 55 60

25

Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser
 65 70 75 80

Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys
 85 90 95

30

Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu
 100 105 110

Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser
 115 120 125

35

Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly
 130 135 140

Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln
 145 150 155 160

40

Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr
 165 170 175

Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser
 180 185 190

45

Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala
 195 200 205

Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His
 210 215 220

50

Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn
 225 230 235 240

Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe
 245 250 255

55

Gly Leu Leu Lys Leu
 260

<210> 3
 <211> 1570
 <212> DNA
 <213> Homo sapiens

5

<220>
 <221> CDS
 <222> (67)..(522)

10

<400> 3

```

ggcaggggag tcagcagagg cctcgctcgg gcgcccagtg gtctgcccgc ctggtctcac      60
ctcgcc atg gtt cgt ctg cct ctg cag tgc gtc ctc tgg ggc tgc ttg      108
  Met Val Arg Leu Pro Leu Gln Cys Val Leu Trp Gly Cys Leu
    1           5           10
ctg acc gct gtc cat cca gaa cca ccc act gca tgc aga gaa aaa cag      156
Leu Thr Ala Val His Pro Glu Pro Pro Thr Ala Cys Arg Glu Lys Gln
 15           20           25           30
tac cta ata aac agt cag tgc tgt tct ttg tgc cag cca gga cag aaa      204
Tyr Leu Ile Asn Ser Gln Cys Cys Ser Leu Cys Gln Pro Gly Gln Lys
           35           40           45
ctg gtg agt gac tgc aca gag ttc act gaa acg gaa tgc ctt cct tgc      252
Leu Val Ser Asp Cys Thr Glu Phe Thr Glu Thr Glu Cys Leu Pro Cys
           50           55           60
ggg gaa agc gaa ttc cta gac acc tgg aac aga gag aca cac ttc cac      300
Gly Glu Ser Glu Phe Leu Asp Thr Trp Asn Arg Glu Thr His Phe His
           65           70           75
cag cac aaa tac tgc gac ccc aac cta ggg ctt cgg gtc cag cag aag      348
Gln His Lys Tyr Cys Asp Pro Asn Leu Gly Leu Arg Val Gln Gln Lys
           80           85           90
ggc acc tca gaa aca gac acc atc tgc acc tgt gaa gaa ggc tgg cac      396
Gly Thr Ser Glu Thr Asp Thr Ile Cys Thr Cys Glu Glu Gly Trp His
 95           100           105           110
tgt acg agt gag gcc tgt gag agc tgt gtc ctg cac cgc tca tgc tcg      444
Cys Thr Ser Glu Ala Cys Glu Ser Cys Val Leu His Arg Ser Cys Ser
           115           120           125
ccc ggc ttt ggg gtc aag cag att gac atc tgc cag cca cat ttc ccc      492
Pro Gly Phe Gly Val Lys Gln Ile Asp Ile Cys Gln Pro His Phe Pro
           130           135           140
aag gac cgc ggt ttg aac ctt ctg atg tag atgagctctg acattggaag      542
Lys Asp Arg Gly Leu Asn Leu Leu Met
           145           150
attctggagt ctgacaagtc acagcagggt gagggtaggg agaaactgca ggtgaggggt      602
gcatgctgaa gtcttgattt ctccagggtcc ccaggatcgg ctgagagccc tgggtggtgat      662
ccccatcatc ttcgggatcc tgtttgccat cctcttggtg ctggtcttta tcaaaaaggt      722
ggccaagaag ccaaccaata aggcccccca cccaagcag gaaccccagg agatcaattt      782
tcccgacgat cttcctggct ccaacactgc tgctccagtg caggagactt tacatggatg      842
    
```

55

ccaaccggtc acccaggagg atggcaaaga gagtcgcatc tcagtgcagg agagacagtg 902
 5 aggctgcacc caccaggag tgtggccacg tgggcaaaca ggcagttggc cagagagcct 962
 ggtgctgctg ctgctgtggc gtgaggggtga ggggctggca ctgactgggc atagctcccc 1022
 gcttctgcct gcaccctgc agtttagaca ggagacctgg cactggatgc agaaacagtt 1082
 10 caccttgaag aacctctcac ttcaccctgg agcccatcca gtctcccaac ttgtattaaa 1142
 gacagaggca gaagtttggg ggtgggtggtg ttgggggtatg gtttagtaat atccaccaga 1202
 ccttccgatc cagcagtttg gtgcccagag aggcatcatg gtggcttccc tgcgcccagg 1262
 15 aagccatata cacagatgcc cattgcagca ttgtttgtga tagtgaacaa ctggaagctg 1322
 cttaactgtc catcagcagg agactggcta aataaaatta gaatatattt atacaacaga 1382
 atctcaaaaa cactgttgag taaggaaaaa aaggcatgct gctgaatgat gggatggaa 1442
 20 ctttttaaaa aagtacatgc ttttatgtat gtatattgcc tatggatata tgtataaata 1502
 caatatgcat catatattga taaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1562
 aaaaaaaaaa 1570

25 <210> 4
 <211> 151
 <212> PRT
 <213> Homo sapiens

30 <400> 4

Met Val Arg Leu Pro Leu Gln Cys Val Leu Trp Gly Cys Leu Leu Thr
 1 5 10 15
 35 Ala Val His Pro Glu Pro Pro Thr Ala Cys Arg Glu Lys Gln Tyr Leu
 20 25 30
 Ile Asn Ser Gln Cys Cys Ser Leu Cys Gln Pro Gly Gln Lys Leu Val
 35 40 45
 40 Ser Asp Cys Thr Glu Phe Thr Glu Thr Glu Cys Leu Pro Cys Gly Glu
 50 55 60
 Ser Glu Phe Leu Asp Thr Trp Asn Arg Glu Thr His Phe His Gln His
 65 70 75 80
 45 Lys Tyr Cys Asp Pro Asn Leu Gly Leu Arg Val Gln Gln Lys Gly Thr
 85 90 95
 Ser Glu Thr Asp Thr Ile Cys Thr Cys Glu Glu Gly Trp His Cys Thr
 100 105 110
 50 Ser Glu Ala Cys Glu Ser Cys Val Leu His Arg Ser Cys Ser Pro Gly
 115 120 125
 Phe Gly Val Lys Gln Ile Asp Ile Cys Gln Pro His Phe Pro Lys Asp
 130 135 140
 55 Arg Gly Leu Asn Leu Leu Met
 145 150

<210> 5
 <211> 1193
 <212> DNA
 <213> Homo sapiens

5

<220>
 <221> CDS
 <222> (109)..(609)

10

<400> 5

	tgaagatcag ctattagaag agaaagatca gttaagtcct ttggacctga tcagcttgat	60
15	acaagaacta ctgatttcaa cttctttggc ttaattctct cggaaacg atg aaa tat Met Lys Tyr 1	117
	aca agt tat atc ttg gct ttt cag ctc tgc atc gtt ttg ggt tct ctt Thr Ser Tyr Ile Leu Ala Phe Gln Leu Cys Ile Val Leu Gly Ser Leu 5 10 15	165
20	ggc tgt tac tgc cag gac cca tat gta aaa gaa gca gaa aac ctt aag Gly Cys Tyr Cys Gln Asp Pro Tyr Val Lys Glu Ala Glu Asn Leu Lys 20 25 30 35	213
25	aaa tat ttt aat gca ggt cat tca gat gta gcg gat aat gga act ctt Lys Tyr Phe Asn Ala Gly His Ser Asp Val Ala Asp Asn Gly Thr Leu 40 45 50	261
	ttc tta ggc att ttg aag aat tgg aaa gag gag agt gac aga aaa ata Phe Leu Gly Ile Leu Lys Asn Trp Lys Glu Glu Ser Asp Arg Lys Ile 55 60 65	309
30	atg cag agc caa att gtc tcc ttt tac ttc aaa ctt ttt aaa aac ttt Met Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Phe Lys Asn Phe 70 75 80	357
35	aaa gat gac cag agc atc caa aag agt gtg gag acc atc aag gaa gac Lys Asp Asp Gln Ser Ile Gln Lys Ser Val Glu Thr Ile Lys Glu Asp 85 90 95	405
	atg aat gtc aag ttt ttc aat agc aac aaa aag aaa cga gat gac ttc Met Asn Val Lys Phe Phe Asn Ser Asn Lys Lys Lys Arg Asp Asp Phe 100 105 110 115	453
40	gaa aag ctg act aat tat tcg gta act gac ttg aat gtc caa cgc aaa Glu Lys Leu Thr Asn Tyr Ser Val Thr Asp Leu Asn Val Gln Arg Lys 120 125 130	501
45	gca ata cat gaa ctc atc caa gtg atg gct gaa ctg tcg cca gca gct Ala Ile His Glu Leu Ile Gln Val Met Ala Glu Leu Ser Pro Ala Ala 135 140 145	549
	aaa aca ggg aag cga aaa agg agt cag atg ctg ttt caa ggt cga aga Lys Thr Gly Lys Arg Lys Arg Ser Gln Met Leu Phe Gln Gly Arg Arg 150 155 160	597
50	gca tcc cag taa tggttgtcct gcctgcaata tttgaatttt aaatctaaat Ala Ser Gln 165	649
	ctatttatta atatttaaca ttatttatat ggggaatata tttttagact catcaatcaa	709
55	ataagtatit ataatagcaa cttttgtgta atgaaaatga atatctatta atatatgtat	769

tatttataat tcctatatcc tgtgactgtc tcaactaatc ctttgttttc tgactaatta 829
 ggcaaggcta tgtgattaca aggcctttatc tcaggggcca actaggcagc caacctaagc 889
 5 aagatcccat gggttgtgtg tttatttcac ttgatgatac aatgaacact tataagttaa 949
 gtgatactat ccagttactg ccggtttgaa aatatgcctg caatctgagc cagtgcctta 1009
 atggcatgtc agacagaact tgaatgtgtc aggtgaccct gatgaaaaca tagcatctca 1069
 10 ggagatttca tgcctggtgc ttccaaatat tgttgacaac tgtgactgta cccaaatgga 1129
 aagtaactca tttgttaaaa ttatcaatat ctaatatata tgaataaagt gtaagttcac 1189
 aact 1193

15 <210> 6
 <211> 166
 <212> PRT
 <213> Homo sapiens
 20 <400> 6

25 Met Lys Tyr Thr Ser Tyr Ile Leu Ala Phe Gln Leu Cys Ile Val Leu
 1 5 10
 Gly Ser Leu Gly Cys Tyr Cys Gln Asp Pro Tyr Val Lys Glu Ala Glu
 20
 30 Asn Leu Lys Lys Tyr Phe Asn Ala Gly His Ser Asp Val Ala Asp Asn
 35 35 40 45
 Gly Thr Leu Phe Leu Gly Ile Leu Lys Asn Trp Lys Glu Glu Ser Asp
 50 55 60
 35 Arg Lys Ile Met Gln Ser Gln Ile Val Ser Phe Tyr Phe Lys Leu Phe
 65 70 75 80
 Lys Asn Phe Lys Asp Asp Gln Ser Ile Gln Lys Ser Val Glu Thr Ile
 85 90 95
 40 Lys Glu Asp Met Asn Val Lys Phe Phe Asn Ser Asn Lys Lys Lys Arg
 100 105 110
 Asp Asp Phe Glu Lys Leu Thr Asn Tyr Ser Val Thr Asp Leu Asn Val
 115 120 125
 45 Gln Arg Lys Ala Ile His Glu Leu Ile Gln Val Met Ala Glu Leu Ser
 130 135 140
 Pro Ala Ala Lys Thr Gly Lys Arg Lys Arg Ser Gln Met Leu Phe Gln
 145 150 155 160
 50 Gly Arg Arg Ala Ser Gln
 165

55 <210> 7
 <211> 1669
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> CDS

<222> (170)..(871)

<400> 7

5	ctcccctcagc aaggacagca gaggaccagc taagagggag agaagcaact acagaccccc	60
	cctgaaaaca accctcagac gccacatccc ctgacaagct gccaggcagg ttctcttctct	120
10	ctcacatact gaccacggc tccaccctct ctcccctgga aaggacacc atg agc act	178
		Met Ser Thr 1
	gaa agc atg atc cgg gac gtg gag ctg gcc gag gag gcg ctc ccc aag	226
	Glu Ser Met Ile Arg Asp Val Glu Leu Ala Glu Glu Ala Leu Pro Lys	
	5 10 15	
15	aag aca ggg ggg ccc cag ggc tcc agg cgg tgc ttg ttc ctc agc ctc	274
	Lys Thr Gly Gly Pro Gln Gly Ser Arg Arg Cys Leu Phe Leu Ser Leu	
	20 25 30 35	
20	ttc tcc ttc ctg atc gtg gca ggc gcc acc acg ctc ttc tgc ctg ctg	322
	Phe Ser Phe Leu Ile Val Ala Gly Ala Thr Thr Leu Phe Cys Leu Leu	
	40 45 50	
	cac ttt gga gtg atc ggc ccc cag agg gaa gag ttc ccc agg gac ctc	370
	His Phe Gly Val Ile Gly Pro Gln Arg Glu Glu Phe Pro Arg Asp Leu	
	55 60 65	
25	tct cta atc agc cct ctg gcc cag gca gtc aga tca tct tct cga acc	418
	Ser Leu Ile Ser Pro Leu Ala Gln Ala Val Arg Ser Ser Arg Thr	
	70 75 80	
	ccg agt gac aag cct gta gcc cat gtt gta gca aac cct caa gct gag	466
	Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro Gln Ala Glu	
	85 90 95	
30	ggg cag ctc cag tgg ctg aac cgc cgg gcc aat gcc ctc ctg gcc aat	514
	Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu Leu Ala Asn	
	100 105 110 115	
35	ggc gtg gag ctg aga gat aac cag ctg gtg gtg cca tca gag ggc ctg	562
	Gly Val Glu Leu Arg Asp Asn Gln Leu Val Val Pro Ser Glu Gly Leu	
	120 125 130	
40	tac ctc atc tac tcc cag gtc ctc ttc aag ggc caa ggc tgc ccc tcc	610
	Tyr Leu Ile Tyr Ser Gln Val Leu Phe Lys Gly Gln Gly Cys Pro Ser	
	135 140 145	
	acc cat gtg ctc ctc acc cac acc atc agc cgc atc gcc gtc tcc tac	658
	Thr His Val Leu Leu Thr His Thr Ile Ser Arg Ile Ala Val Ser Tyr	
	150 155 160	
45	cag acc aag gtc aac ctc ctc tct gcc atc aag agc ccc tgc cag agg	706
	Gln Thr Lys Val Asn Leu Leu Ser Ala Ile Lys Ser Pro Cys Gln Arg	
	165 170 175	
50	gag acc cca gag ggg gct gag gcc aag ccc tgg tat gag ccc atc tat	754
	Glu Thr Pro Glu Gly Ala Glu Ala Lys Pro Trp Tyr Glu Pro Ile Tyr	
	180 185 190 195	
55	ctg gga ggg gtc ttc cag ctg gag aag ggt gac cga ctc agc gct gag	802
	Leu Gly Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu Ser Ala Glu	
	200 205 210	

atc aat cgg ccc gac tat ctc gac ttt gcc gag tct ggg cag gtc tac 850
 Ile Asn Arg Pro Asp Tyr Leu Asp Phe Ala Glu Ser Gly Gln Val Tyr
 215 220 225

5 ttt ggg atc att gcc ctg tga ggaggacgaa catccaacct tcccaaacgc 901
 Phe Gly Ile Ile Ala Leu
 230

ctcccctgcc ccaatccctt tattaccccc tccttcagac accctcaacc tcttctggct 961
 10 caaaaagaga attgggggct tagggctgga acccaagctt agaactttaa gcaacaagac 1021
 caccacttcg aaacctggga ttcaggaatg tgtggcctgc acagtgaagt gctggcaacc 1081
 actaagaatt caaactgggg cctccagaac tcaactggggc ctacagcttt gatccctgac 1141
 15 atctggaatc tggagaccag ggagcctttg gttctggcca gaatgctgca ggacttgaga 1201
 agacctcacc tagaaattga cacaagtgga ccttaggcct tcctctctcc agatgtttcc 1261
 agacttcctt gagacacgga gccagccct ccccatggag ccagctccct ctatttatgt 1321
 20 ttgcacttgt gattatttat tatttattta ttatttattt atttacagat gaatgtattt 1381
 atttgggaga ccgggggatc ctgggggacc caatgtagga gctgccttgg ctcagacatg 1441
 ttttccgtga aaacggagct gaacaatagg ctgttcccat gtagccccct ggcctctgtg 1501
 25 ccttcttttg attatgtttt ttaaaatatt tatctgatta agttgtctaa acaatgctga 1561
 tttggtgacc aactgtcact cattgctgag cctctgctcc ccaggggagt tgtgtctgta 1621
 atcgccctac tattcagtgg cgagaaataa agtttgctta gaaaagaa 1669

30 <210> 8
 <211> 233
 <212> PRT
 <213> Homo sapiens

35 <400> 8

40 Met Ser Thr Glu Ser Met Ile Arg Asp Val Glu Leu Ala Glu Glu Ala
 1 5 10 15
 Leu Pro Lys Lys Thr Gly Gly Pro Gln Gly Ser Arg Arg Cys Leu Phe
 20 25 30

45 Leu Ser Leu Phe Ser Phe Leu Ile Val Ala Gly Ala Thr Thr Leu Phe
 35 40 45

Cys Leu Leu His Phe Gly Val Ile Gly Pro Gln Arg Glu Glu Phe Pro
 50 55 60

50 Arg Asp Leu Ser Leu Ile Ser Pro Leu Ala Gln Ala Val Arg Ser Ser
 65 70 75 80

Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val Val Ala Asn Pro
 85 90 95

55 Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu
 100 105 110

Leu Ala Asn Gly Val Glu Leu Arg Asp Asn Gln Leu Val Val Pro Ser
 115 120 125
 5 Glu Gly Leu Tyr Leu Ile Tyr Ser Gln Val Leu Phe Lys Gly Gln Gly
 130 135 140
 Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile Ser Arg Ile Ala
 145 150 155 160
 10 Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala Ile Lys Ser Pro
 165 170 175
 Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys Pro Trp Tyr Glu
 180 185 190
 15 Pro Ile Tyr Leu Gly Gly Val Phe Gln Leu Glu Lys Gly Asp Arg Leu
 195 200 205
 Ser Ala Glu Ile Asn Arg Pro Asp Tyr Leu Asp Phe Ala Glu Ser Gly
 210 215 220
 20 Gln Val Tyr Phe Gly Ile Ile Ala Leu
 225 230

<210> 9
 <211> 1250
 25 <212> DNA
 <213> Mus musculus
 <220>
 <221> CDS
 30 <222> (13)..(795)
 <400> 9

35

40

45

50

55

EP 1 809 737 B9

	ctttcagtc	gc	atg	ata	gaa	aca	tac	agc	caa	cct	tcc	ccc	aga	tcc	gtg	51	
			Met	Ile	Glu	Thr	Tyr	Ser	Gln	Pro	Ser	Pro	Arg	Ser	Val		
			1				5						10				
5	gca	act	gga	ctt	cca	gcg	agc	atg	aag	att	ttt	atg	tat	tta	ctt	act	99
	Ala	Thr	Gly	Leu	Pro	Ala	Ser	Met	Lys	Ile	Phe	Met	Tyr	Leu	Leu	Thr	
		15					20					25					
10	ggt	ttc	ctt	atc	acc	caa	atg	att	gga	tct	gtg	ctt	ttt	gct	gtg	tat	147
	Val	Phe	Leu	Ile	Thr	Gln	Met	Ile	Gly	Ser	Val	Leu	Phe	Ala	Val	Tyr	
	30					35					40				45		
15	ctt	cat	aga	aga	ttg	gat	aag	gtc	gaa	gag	gaa	gta	aac	ctt	cat	gaa	195
	Leu	His	Arg	Arg	Leu	Asp	Lys	Val	Glu	Glu	Glu	Val	Asn	Leu	His	Glu	
					50					55					60		
20	gat	ttt	gta	ttc	ata	aaa	aag	cta	aag	aga	tgc	aac	aaa	gga	gaa	gga	243
	Asp	Phe	Val	Phe	Ile	Lys	Lys	Leu	Lys	Arg	Cys	Asn	Lys	Gly	Glu	Gly	
				65					70					75			
25	tct	tta	tcc	ttg	ctg	aac	tgt	gag	gag	atg	aga	agg	caa	ttt	gaa	gac	291
	Ser	Leu	Ser	Leu	Leu	Asn	Cys	Glu	Glu	Met	Arg	Arg	Gln	Phe	Glu	Asp	
			80					85					90				
30	ctt	gtc	aag	gat	ata	acg	tta	aac	aaa	gaa	gag	aaa	aaa	gaa	aac	agc	339
	Leu	Val	Lys	Asp	Ile	Thr	Leu	Asn	Lys	Glu	Glu	Lys	Lys	Glu	Asn	Ser	
		95					100					105					
35	ttt	gaa	atg	caa	aga	ggt	gat	gag	gat	cct	caa	att	gca	gca	cac	gtt	387
40																	
45																	
50																	
55																	

	Phe	Glu	Met	Gln	Arg	Gly	Asp	Glu	Asp	Pro	Gln	Ile	Ala	Ala	His	Val	
	110					115					120					125	
5	gta	agc	gaa	gcc	aac	agt	aat	gca	gca	tcc	gtt	cta	cag	tgg	gcc	aag	435
	Val	Ser	Glu	Ala	Asn	Ser	Asn	Ala	Ala	Ser	Val	Leu	Gln	Trp	Ala	Lys	
					130					135					140		
10	aaa	gga	tat	tat	acc	atg	aaa	agc	aac	ttg	gta	atg	ctt	gaa	aat	ggg	483
	Lys	Gly	Tyr	Tyr	Thr	Met	Lys	Ser	Asn	Leu	Val	Met	Leu	Glu	Asn	Gly	
				145					150					155			
15	aaa	cag	ctg	acg	gtt	aaa	aga	gaa	gga	ctc	tat	tat	gtc	tac	act	caa	531
	Lys	Gln	Leu	Thr	Val	Lys	Arg	Glu	Gly	Leu	Tyr	Tyr	Val	Tyr	Thr	Gln	
			160					165					170				
20	gtc	acc	ttc	tgc	tct	aat	cgg	gag	cct	tcg	agt	caa	cgc	cca	ttc	atc	579
	Val	Thr	Phe	Cys	Ser	Asn	Arg	Glu	Pro	Ser	Ser	Gln	Arg	Pro	Phe	Ile	
		175					180					185					
25	gtc	ggc	ctc	tgg	ctg	aag	ccc	agc	agt	gga	tct	gag	aga	atc	tta	ctc	627
	Val	Gly	Leu	Trp	Leu	Lys	Pro	Ser	Ser	Gly	Ser	Glu	Arg	Ile	Leu	Leu	
		190				195				200					205		
30	aag	gcg	gca	aat	acc	cac	agt	tcc	tcc	cag	ctt	tgc	gag	cag	cag	tct	675
	Lys	Ala	Ala	Asn	Thr	His	Ser	Ser	Ser	Gln	Leu	Cys	Glu	Gln	Gln	Ser	
					210					215				220			
35	gtt	cac	ttg	ggc	gga	gtg	ttt	gaa	tta	caa	gct	ggt	gct	tct	gtg	ttt	723
	Val	His	Leu	Gly	Gly	Val	Phe	Glu	Leu	Gln	Ala	Gly	Ala	Ser	Val	Phe	
				225					230					235			
40	gtc	aac	gtg	act	gaa	gca	agc	caa	gtg	atc	cac	aga	gtt	ggc	ttc	tca	771
	Val	Asn	Val	Thr	Glu	Ala	Ser	Gln	Val	Ile	His	Arg	Val	Gly	Phe	Ser	
			240					245					250				
45	tct	ttt	ggc	tta	ctc	aaa	ctc	tga	acagtgcgct	gtcctaggct	gcagcagggc	825					
	Ser	Phe	Gly	Leu	Leu	Lys	Leu										
		255					260										
50	tgatgctggc	agtcttccct	atacagcaag	tcagttagga	cctgccctgt	gttgaaactgc	885										
	ctatttataa	ccctaggatc	ctcctcatgg	agaactatct	attatgtacc	cccaaggcac	945										
	atagagctgg	aataagagaa	ttacagggca	ggcaaaaatc	ccaagggacc	ctgctcccta	1005										
55	agaacttaca	atctgaaaca	gcaaccccac	tgattcagac	aaccagaaaa	gacaaagcca	1065										
	taatacacag	atgacagagc	tctgatgaaa	caacagataa	ctaatagagca	cagttttggt	1125										
	gttttatggg	tgtgtcgttc	aatggacagt	gtacttgact	taccagggaa	gatgcagaag	1185										
	ggcaactgtg	agcctcagct	cacaatctgt	tatggttgac	ctgggctccc	tgcggcccta	1245										
	gtagg						1250										

<210> 10
 <211> 260
 <212> PRT
 <213> Mus musculus

 <400> 10

Met Ile Glu Thr Tyr Ser Gln Pro Ser Pro Arg Ser Val Ala Thr Gly

EP 1 809 737 B9

<213> Artificial Sequence

<220>

<223> synthetic primer

5

<400> 12

ctattatgaa gactcccagc g 21

<210> 13

10

<211> 915

<212> DNA

<213> Artificial Sequence

<220>

15

<223> optimized human CD40L

<400> 13

20

gggcgaattg ggccctctag atctgcagaa ttcggcttgc atgatcgaaa catacaacca 60

aacttctccc cgatctgcgg ccaactggact gcccatcagc atgaaaattt ttatgtattt 120

acttactggt tttcttatca cccagatgat tgggtcagca ctttttgctg tgtatcttca 180

25

tagaaggttg gacaagatag aagatgaaag gaatcttcat gaagattttg tattcatgaa 240

aacgatacag agatgcaaca caggagaaag atccttatcc ttactgaact gtgaggagat 300

taaaagccag tttgaaggct ttgtgaagga tataatgtta aacaaagagg agacgaagaa 360

30

agaaaacagc tttgaaatgc aaaaagggtga tcagaatcct caaattgcgg cacatgtcat 420

aagtgaggcc agcagtaaaa caacatctgt gttacagtgg gctgaaaaag gatactacac 480

catgagcaac aacttggtaa ccctggaaaa tgggaaacag ctgaccgtta aaagacaagg 540

35

actctattat atctatgccc aagtcacctt ctgttccaat cgggaagctt cgagtcaagc 600

tccatttata gccagcctct gcctaaagtc ccccggtaga ttcgagagaa tcttactcag 660

agctgcaaat acccacagtt ccgccaacc ttgctgggcaa caatccattc acttgggagg 720

40

agtatttgaa ttgcaaccag gtgcttcggt gtttgtcaat gtgactgatc caagccaagt 780

gagccatggc actggcttca cgtcctttgg cttactcaaa ctctgaacag tgtcaccttg 840

caggctgtgg tggagctgac gctgggagtc ttcataatac aagccgaatt ccagcacact 900

45

ggcggccggt actag 915

<210> 14

<211> 251

<212> DNA

50

<213> Artificial Sequence

<220>

<223> CD40 Receptor 3'UTR

55

<400> 14

	ggctgcaccc acccaggagt gtggccacgt gggcaaacag gcagttggcc agagagcctg	60
	gtgctgctgc tgctgtggcg tgagggtgag gggctggcac tgactgggca tagctccccg	120
5		
	cttctgcctg caccctgca gtttgagaca ggagacctgg cactggatgc agaaacagtt	180
	caccttgaag aacctctcac ttcaccctgg agcccatcca gtctcccaac ttgtattaaa	240
10	gacagaggca g	251
	<210> 15	
	<211> 597	
15	<212> DNA	
	<213> Homo sapiens	
	<400> 15	
20	gCGGactatg acttagttgc gttacaccct ttcttgacaa aacctaactt gcgcagaaaa	60
	caagatgaga ttggcatggc tttatttgtt tttttgttt tgttttggtt tttttttttt	120
	ttttggcttg actcaggatt taaaaactgg aacgggtgaag gtgacagcag tcggttggag	180
25	cgagcatccc ccaaagttca caatgtggcc gaggactttg attgcacatt gttgtttttt	240
	taatagtcac tccaaatatg agatgcgctg ttacaggaag tcccttgcca tcctaaaagc	300
	cacccccactt ctctctaagg agaatggccc agtcctctcc caagtccaca caggggaggt	360
30	gatagcattg ctttcgtgta aattatgtaa tgcaaaattt ttttaacttt cgccttaata	420
	cttttttatt ttgttttatt ttgaatgatg agccttcgtg ccccccttc cccctttttt	480
	gtcccccaac ttgagatgta tgaaggcttt tggctccct gggagtgggt ggaggcagcc	540
35	agggcttacc tgtacactga cttgagacca gttgaataaa agtgcacacc ttaaaaa	597
	<210> 16	
	<211> 381	
40	<212> DNA	
	<213> Homo sapiens	
	<400> 16	
45	tttgattgca cattgttggt tttttaatag tcattccaaa tatgagatgc gttgttacag	60
	gaagtccctt gccatcctaa aagccacccc acttctctct aaggagaatg gcccagtcct	120
	ctccaagtc cacacagggg aggtgatagc attgctttcg tgtaaattat gtaatgcaaa	180
50	atTTTTTaa tcttcgcctt aatacttttt tattttgttt tattttgaat gatgagcctt	240
	cgTgcccccc cttccccctt ttttgtcccc caacttgaga tgtatgaagg cttttggctt	300
	ccctgggagt gggTggaggc agccagggct tacctgtaca ctgacttgag accagttgaa	360
55	taaaagtgca caccttaaaa a	381
	<210> 17	

EP 1 809 737 B9

<211> 139
 <212> DNA
 <213> simian rotavirus

5 <400> 17

gaccaagcta acaacttggg atccaacttt ggtgagtatg tagctatatc aagctgtttg 60
aactctgtaa gtaaggatgc gtatacgcat tcgctacact gagttaatca ctctgatggg 120
atagtgagag gatgtgacc 139

15 <210> 18
 <211> 65
 <212> DNA
 <213> simian rotavirus

20 <400> 18

gaccaagcta acaacttggg atccaacttt ggtgagtatg tagctatatc aagctgtttg 60
aactc 65

25 <210> 19
 <211> 179
 <212> DNA
 <213> Homo sapiens

30 <400> 19

tacctttttc gagagtgact cccggtgtcc caaggcttcc cagagcgaac ctgtgaggct 60
gcaggcaccg gcgcgtcgag tttccggcgt ccggaaggac cgagctcttc tcgaggatcc 120
agtgttccgt ttccagcccc caatctcaga gcggagccga cagagagcag ggaaccggc 179

40 <210> 20
 <211> 1014
 <212> DNA
 <213> Mus musculus

45 <400> 20

50

55

EP 1 809 737 B9

agcgcagagg cttggggcag ccgagctgca gcgagcgcgc ggcaactgggg gcgagctgag 60
 cggcggcagc ggagctctgt cgcgagacgc agcgacaagg cagactatca gcggactcac 120
 5 cagcccggga gtctgtgctc tgggatttga tattcaaacc tcttaatttt tttttcttaa 180
 actgtattgt tttacgcttt aatttatattt tgcttcctat tcccctctta aatcgtgcca 240
 acggtttgag gaggttggtt cttcactccc tcaaatcact tcggattgtg gaaatcagca 300
 10 gacgaaagag gtatcaagag ctccagagag aagtcaagga agagagagag agaccgggtca 360
 gagagagcgc gctggcgagc gaacagagag agggacaggg gcaaagtga cttgaccttg 420
 cttttggggg tgaccgccag agcgcggcgt gacctcccc ttcgatcttg catcggacca 480
 15 gtcgcgctga cggacagaca gacagacacc gccccagcc ccagcgccca cctcctcgcc 540
 ggcgggctgc cgacggtgga cgcggcggcg agccgagaaa ccgaagcccg cgcccggagg 600
 cgggtggagg gggtcggggc tcgcgggatt gcacggaaac ttttcgtcca acttctgggc 660
 20 tcttctcgct ccgtagtagc cgtggtctgc gccgcaggag acaaaccgat ccggagctgg 720
 gagaaggcta gctcggccct ggagaggccg gggcccgaga agagagggga ggaaggaaga 780
 ggagaggggg ccacagtggg cgctcggctc tcaggagccg agctcatgga cgggtgaggc 840
 25 ggccgtgtgc gcagacagtg ctccagccgc gcgcgcgccc caggccccgg cccgggcctc 900
 ggttccagaa gggagaggag cccgccaaagg cgcgcaagag agcgggctgc ctcgcagtcc 960
 ggagccggag agagggagcg cgagccgccg cggccccgga cggcctccga aacc 1014

30
 <210> 21
 <211> 163
 <212> DNA
 <213> Mus musculus
 35
 <400> 21

agcgcagagg cttggggcag ccgagcggca gccaggcccc ggcccgggccc tcggttccag 60
 40 aagggagagg agcccgcaa ggcgcgcaag agagcgggct gcctcgcagt ccgagccgga 120
 gagggagcgc gagccgcgcc ggccccggac ggcctccgaa acc 163

45
 <210> 22
 <211> 180
 <212> DNA
 <213> spleen necrosis virus
 50
 <400> 22

ttgctcggcc tcgaggtcgg ggtcgcctgc ctacacattg ttggttgac gtgcggccca 60
 55 gattcgaatc tgtaataaaa cttttttttt tctgaatcct cagattggca gtgagaggag 120
 attttgttcg tggtggtggc tggcctactg ggtgggcgca gggatcttgg tggcgtgaaa 180

EP 1 809 737 B9

<210> 23
 <211> 143
 <212> DNA
 <213> Tobacco etch virus

5
 <400> 23
 aaataacaaa tctcaacaca acatatacaa aacaaacgaa tctcaagcaa tcaagcattc 60
 10 tacttctatt gcagcaattt aaatcatttc ttttaaagca aaagcaattt tctgaaaatt 120
 ttcaccattt acgaacgata gca 143

15 <210> 24
 <211> 9
 <212> PRT
 <213> Artificial Sequence

20 <220>
 <223> synthetic peptide

<400> 24

25 Leu Ala Gly Ile Gly Ile Leu Thr Val
 1 5

30 <210> 25
 <211> 9
 <212> PRT
 <213> Artificial Sequence

35 <220>
 <223> synthetic peptide

<400> 25

40 Ala Ala Gly Ile Gly Ile Leu Thr Val
 1 5

45 <210> 26
 <211> 10
 <212> PRT
 <213> Artificial Sequence

50 <220>
 <223> Synthetic peptide

<400> 26

55 Phe Leu Thr Pro Lys Lys Leu Gln Cys Val
 1 5 10

Claims

1. An *in vitro* method for preparing mature dendritic cells (DCs), comprising the sequential steps of:
 - 5 (a) signaling isolated immature dendritic cells (iDCs) with an interferon gamma receptor (IFN- γ R) agonist and a TNF- α R agonist, to produce signaled mature CD83⁺ dendritic cells; and
 - (b) signaling said mature CD83⁺ dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7⁺, CD83⁺ mature dendritic cells wherein the signaling with the second transient signal is initiated 12 to 30 hours after the initiation of signaling the DCs with the IFN- γ R agonist and the TNF- α R agonist, wherein said second signal is effected upon translation of an mRNA encoding a CD40 agonist, and further wherein said cell is transfected with said mRNA.
2. The method of claim 1, further comprising contacting said iDCs or said signaled DCs with PGE₂.
- 15 3. The method of claim 1 or claim 2, wherein steps (a) and (b) further comprise contacting said cells with GM-CSF and at least one of IL-4 or IL-13.
4. The method of claim 1 or claim 2, wherein the signaled mature CD83⁺ dendritic cells of step (a) are CCR7⁻.
- 20 5. The method of any preceding claim, wherein the CD40 agonist is selected from an agonistic antibody to CD40, an aptamer that binds to CD40 and a CD40L polypeptide.
6. The method of claim 5, wherein said CD40L polypeptide is selected from the group consisting of:
 - 25 a) a polypeptide comprising SEQ ID NO:2;
 - b) a fragment of the polypeptide of (a) wherein said fragment binds CD40, or

wherein said CD40L polypeptide is a polypeptide having at least 77% sequence identity to a polypeptide selected from the group consisting of:

 - 30 a) a polypeptide comprising SEQ ID NO:2;
 - b) a fragment of the polypeptide of (a) wherein said fragment binds CD40.
7. The method of any preceding claim, wherein the signal with an IFN- γ R agonist is effected upon translation of an mRNA encoding a IFN- γ R agonist, and/or upon contacting said iDCs with a IFN- γ R agonist.
- 35 8. The method of claim 1, wherein said dendritic cell is transfected using electroporation.
9. The method of claim 1, wherein step (a) comprises adding the IFN- γ R agonist and TNF- α R agonist to a culture comprising said iDCs, and step (b) comprises electroporating said mature CD83⁺ dendritic cells with an mRNA encoding a CD40 agonist to produce the CCR7⁺ mature dendritic cells, wherein said electroporation is performed approximately 12 to 30 hours after the addition of the IFN- γ R agonist and the TNF- α R agonist to the iDCs.
- 40 10. The method of any preceding claim, wherein said mRNA encodes a CD40L polypeptide and comprises a polynucleotide selected from the group consisting of:
 - a) a polynucleotide of SEQ ID NO:1;
 - b) a polynucleotide comprising nucleotides 40 to 822 of SEQ ID NO:1;
 - c) a polynucleotide having at least 80% sequence identity with any polynucleotide of (a) or (b);
 - 50 d) a polynucleotide hybridizing under stringent conditions to any polynucleotide of (a) through (c); and
 - e) a polynucleotide of (a) through (d), further comprising a 3' untranslated sequence selected from the group consisting of the nucleic acids of SEQ ID NO:14, 15, 16, 17 or 18, and/or a 5' untranslated sequence selected from the group consisting of the nuclei acids of SEQ ID NO:19, 20, 21, 22, or 23.
- 55 11. The method of any preceding claim, wherein the CCR7⁺ mature DCs secrete from 0 to 500 pg IL-10 per 10⁶ DCs, and/or secrete IL-12 p70 protein.
12. The method of any preceding claim, wherein the immature dendritic cells are prepared from one of the following,

- (a) CD34⁺ hematopoietic stem or progenitor cells;
- (b) peripheral blood mononuclear cells (PBMCs), or
- (c) by contacting said PBMCs with GM-CSF in the presence of IL-4 and/or IL-13.

- 5 13. The method of any preceding claim, further comprising introducing into said iDCs, signaled DCs or CCR7⁺ mature DCs one or more antigens or a polynucleotide(s) encoding one or more antigens to produce an antigen-loaded CCR7⁺ mature DCs.
- 10 14. The method of claim 13, wherein the antigen is selected from pathogens, pathogen lysates, pathogen extracts, pathogen polypeptides, cancer cells, cancer cell lysates, cancer cell extracts and cancer cell specific polypeptides.
- 15 15. The method of claim 13 or claim 14, wherein a polynucleotide(s) encoding the antigen(s) is introduced into said iDCs, signaled DCs or CCR7⁺ mature DCs.
16. The method of claim 15, wherein said polynucleotide is introduced by electroporation.
17. The method of claim 15 or claim 16, wherein the polynucleotide is an mRNA.
18. The method of any of claims 14 to 17, wherein the antigen encoding polynucleotide, which is optionally an mRNA, is introduced together with the mRNA encoding a CD40 agonist.
19. The method of any of claims 14 to 18, wherein the antigen or polynucleotide is introduced,
- (a) prior to said first signal;
 - (b) subsequent to said first signal and prior to said second signal;
 - (c) subsequent to said second signal; and/or
 - (d) substantially concurrent with said second signal.
20. The method of any preceding claim, wherein said TNF- α R agonist is TNF- α .
21. The method of any of preceding claim, further comprising contacting said immature dendritic cells with PGE₂.
22. The method of any preceding claim, wherein the IFN- γ R agonist is IFN- γ or a biologically active fragment thereof.
23. The method of claim 22, wherein the IFN- γ has the sequence of SEQ ID NO:6.
24. The method of any of claims 1 to 21, wherein said IFN- γ R agonist comprises a polypeptide having at least 80% sequence identity with SEQ ID NO:6.
25. The method of any preceding claim, further comprising contacting said immature dendritic cells, said signaled dendritic cells, or said CCR7⁺ dendritic cells with a NKT cell ligand, wherein optionally said NKT cell ligand is a compound selected from the group consisting of: α -galactosylceramides, α -glucosylceramides, α -6-deoxygalactosylceramides, α -6-deoxygalactofuranosylceramides, β -6-deoxygalactofuranosylceramides, β -arabinosylceramides, α -C-galactosylceramides and α -S-galactosylceramides, and further optionally wherein said compound is (2S, 3S, 4R)-1-O-(alpha-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol (KRN7000).

Patentansprüche

- 50 1. In-vitro-Verfahren zur Herstellung reifer dendritischer Zellen (DCs) umfassend die aufeinanderfolgenden Schritte:
- (a) signalmäßiges Ausstatten isolierter unreifer dendritischer Zellen (iDCs) mit einem Interferon-Gamma-Rezeptor (IFN- γ R)-Agonist und einem TNF- α R-Agonist unter Herstellen signalmäßig ausgestatteter reifer CD83⁺ dendritischer Zellen; und
 - (b) signalmäßiges Ausstatten der reifen CD83⁺ dendritischen Zellen mit einem zweiten transienten Signal, umfassend eine wirksame Menge eines CD40-Agonisten unter Produktion reifer CCR7⁺, CD83⁺-dendritischer Zellen, worin das signalmäßige Ausstatten mit dem zweiten, transienten Signal 12 bis 30 Stunden nach der Initiierung des signalmäßigen Ausstattens der DCs mit dem IFN- γ R-Agonist und dem TNF- α R-Agonist initiiert
- 55

EP 1 809 737 B9

wird, worin das zweite Signal bewirkt wird bei Translation einer mRNA, die für einen CD40-Agonist kodiert, und weiter worin die Zelle mit der mRNA transfektiert wird.

- 5 2. Verfahren nach Anspruch 1, weiter umfassend ein In-Kontakt-Bringen der iDCs oder der signalmäßig ausgestatteten DCs mit PGE₂.
3. Verfahren nach Anspruch 1 oder Anspruch 2, worin die Schritte (a) und (b) weiter umfassen ein In-Kontakt-Bringen der Zellen mit GM-CSF und wenigstens einer der Verbindungen IL-4 oder IL-13.
- 10 4. Verfahren nach Anspruch 1 oder Anspruch 2, worin die signalmäßig ausgestatteten reifen CD83⁺-dendritischen Zellen von Schritt (a) CCR7⁻ sind.
- 15 5. Verfahren nach irgendeinem vorangehenden Anspruch, worin der CD40-Agonist gewählt ist aus einem Agonist-Antikörper zu CD40, einem Aptamer, das an CD40 bindet, und einem CD40L-Polypeptid.
- 20 6. Verfahren nach Anspruch 5, worin das CD40L-Polypeptid gewählt ist aus der Gruppe, die besteht aus:
 - a) einem die SEQ.-ID-Nr. 2 umfassenden Polypeptid;
 - b) einem Fragment des Polypeptids von (a) worin das Fragment CD40 bindet, oder worin das CD40L-Polypeptid ein Polypeptid ist, das wenigstens 77 % Sequenz-Identität zu einem Polypeptid aufweist, das gewählt ist aus der Gruppe, die besteht aus:
 - 25 a) einem SEQ.-ID-Nr. 2 umfassenden Polypeptid;
 - b) einem Fragment des Polypeptids von (a) worin das Fragment CD40 bindet.
- 30 7. Verfahren nach irgendeinem vorangehenden Anspruch, worin das signalmäßige Ausstatten mit einem IFN- γ R-Agonisten bewirkt wird bei Translation einer mRNA, die für einen IFN- γ R-Agonist kodiert, und/oder bei In-Kontakt-Bringen der iDCs mit einem IFN- γ R-Agonist.
- 35 8. Verfahren nach Anspruch 1, worin die dendritische Zelle unter Anwendung von Elektroporation transfektiert wird.
9. Verfahren nach Anspruch 1, worin Schritt (a) ein Zusetzen des IFN- γ R-Agonisten und des TNF- α R-Agonisten zu einer die iDCs umfassenden Kultur umfasst, und Schritt (b) ein Elektroporieren der reifen CD83⁺-dendritischen Zellen mit einer mRNA, die für einen CD40-Agonisten kodiert, unter Herstellung der reifen CCR7⁺-dendritischen Zellen umfasst, worin die Elektroporation durchgeführt wird etwa 12 bis 30 Stunden nach der Zugabe des IFN- γ R-Agonisten und des TNF- α R-Agonisten zu den iDCs.
- 40 10. Verfahren nach irgendeinem vorangehenden Anspruch, worin die mRNA für ein CD40L-Polypeptid kodiert und ein Polynukleotid umfasst, das gewählt ist aus der Gruppe, die besteht aus:
 - a) einem Polynukleotid von SEQ.-ID-Nr. 1;
 - b) einem die Nukleotide 40 bis 822 von SEQ.-ID-Nr. 1 umfassenden Polynukleotid;
 - c) einem Polynukleotid, das wenigstens 80 % Sequenz-Identität mit irgendeinem der Polynukleotide von (a) oder (b) aufweist;
 - 45 d) einem Polynukleotid, das unter stringenten Bedingungen zu einem Nukleotid von (a) bis (c) hybridisiert; und
 - e) einem Polynukleotid von (a) bis (d), weiter umfassend eine 3'-untranslatierte Sequenz, die gewählt ist aus der Gruppe, die besteht aus den Nukleinsäuren von SEQ.-ID-Nr. 14, 15, 16, 17 oder 18, und/oder einer 5'-untranslatierten Sequenz, gewählt aus der Gruppe, die besteht aus den Nukleinsäuren von SEQ.-ID-Nr. 19, 20, 21, 22 oder 23.
- 50 11. Verfahren nach irgendeinem vorangehenden Anspruch, worin die reifen CCR7⁺-DCs von 0 bis 500 pg IL-10 pro 10⁶ DCs abscheiden und/oder IL-12p70-Protein abscheiden.
- 55 12. Verfahren nach irgendeinem vorangehenden Anspruch, worin die unreifen dendritischen Zellen aus irgendeinem der folgenden hergestellt werden:
 - (a) hematopoietische CD34⁺-Stammzellen oder -Vorläuferzellen;
 - (b) mononukleäre Zellen aus peripherem Blut (PBMCs); oder

(c) durch In-Kontakt-Bringen der PBMCs mit GM-CSF in Gegenwart von IL-4 und/oder IL-13.

- 5 13. Verfahren nach irgendeinem vorangehenden Anspruch, weiter umfassend ein Einführen eines oder mehrerer Antigen(e) oder eines oder mehrerer Polynukleotid(e), die für ein oder mehrere Antigen(e) kodieren, in die iDCs, signalmäßig ausgestatteten DCs oder reifen CCR7⁺-DCs unter Herstellung reifer, mit einem Antigen beladener CCR7⁺-DCs.
- 10 14. Verfahren nach Anspruch 13, worin das Antigen gewählt ist aus Pathogenen, Pathogenlysaten, Pathogenextrakten, Pathogenpolypeptiden, Krebszellen, Krebszell-Lysaten, Krebszell-Extrakten und Krebszellen-spezifischen Polypeptiden.
- 15 15. Verfahren nach Anspruch 13 oder Anspruch 14, worin ein oder mehrere Polynukleotid(e), das/die für das/die Antigen(e) kodiert/kodieren, in die iDCs, signalmäßig ausgestatteten DCs oder reifen CCR7⁺-DCs eingeführt wird/werden.
17. Verfahren nach Anspruch 15, worin das Polynukleotid durch Elektroporation eingeführt wird.
17. Verfahren nach Anspruch 15 oder Anspruch 16, worin das Polynukleotid eine mRNS ist.
- 20 18. Verfahren nach irgendeinem der Ansprüche 14 bis 17, worin das für ein Antigen kodierende Polynukleotid, das gegebenenfalls eine mRNS ist, zusammen mit der für einen CD40-Agonisten kodierenden mRNS eingeführt wird.
19. Verfahren nach irgendeinem der Ansprüche 14 bis 18, worin das Antigen oder Polynukleotid eingeführt wird
- 25 (a) vor dem ersten signalmäßigen Ausstatten;
 (b) im Anschluss an das erste signalmäßige Ausstatten und vor dem zweiten signalmäßigen Ausstatten;
 (c) im Anschluss an das zweite signalmäßige Ausstatten; und/oder
 (d) im Wesentlichen gleichzeitig mit dem zweiten signalmäßigen Ausstatten.
- 30 20. Verfahren nach irgendeinem vorangehenden Anspruch, worin der TNF- α R-Agonist TNF- α ist.
21. Verfahren nach irgendeinem vorangehenden Anspruch, weiter umfassend ein In-Kontakt-Bringen der unreifen dendritischen Zellen mit PGE₂.
- 35 22. Verfahren nach irgendeinem vorangehenden Anspruch, worin der IFN- γ R-Agonist IFN- γ oder ein biologisch aktives Fragment davon ist.
23. Verfahren nach Anspruch 22, worin das IFN- γ die Sequenz SEQ.-ID-Nr. 6 hat.
- 40 24. Verfahren nach irgendeinem der Ansprüche 1 bis 21, worin der IFN- γ R-Agonist ein Polypeptid umfasst, das wenigstens 80 % Sequenz-Identität mit SEQ.-ID-Nr. 6 hat.
- 45 25. Verfahren nach irgendeinem vorangehenden Anspruch, weiter umfassend ein In-Kontakt-Bringen der unreifen dendritischen Zellen, der signalmäßig ausgestatteten dendritischen Zellen oder der CCR7⁺-dendritischen Zellen mit einem NKT-Zell-Liganden, worin gegebenenfalls der NKT-Zell-Ligand eine Verbindung ist, die gewählt ist aus der Gruppe, die besteht aus: α -Galactosylceramiden, α -Glucosylceramiden, α -6-Deoxygalactosylceramiden, α -6-Deoxygalactofuranosylceramiden, β -6-Deoxygalactofuranosylceramiden, β -Arabinosylceramiden, α -C-Galactosylceramiden und α S-Galactosylceramiden, und weiter gegebenenfalls worin die Verbindung ist: (2S, 3S, 4R)-1-O-(α -D-Galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecantriol (KRN7000).

Revendications

- 55 1. Un procédé *in vitro* pour la préparation de cellules dendritiques matures (DCs), comprenant les étapes séquentielles suivantes :
- (a) marquage de cellules dendritiques non matures isolées (iDCs) avec un agoniste du récepteur d'interféron gamma (IFN- γ R) et un agoniste du TNF- α R, pour produire des cellules dendritiques CD83⁺ matures marquées; et
 (b) marquage des dites cellules dendritiques CD83⁺ matures avec un second marqueur transitoire comprenant

EP 1 809 737 B9

une quantité efficace d'un agoniste du CD40 pour produire des cellules dendritiques matures CCR7⁺, CD83⁺ où le marquage avec le second marqueur transitoire est initié 12 à 30 heures après l'initiation du marquage des DCs avec l'agoniste du IFN- γ R et l'agoniste du TNF- α R, où ledit second marquage est effectué lors de la translation d'un mRNA codant un agoniste du CD40, et où en outre ladite cellule est transfectée avec ledit mRNA.

- 5
2. Le procédé selon la revendication 1, consistant en outre à mettre en contact lesdites iDCs ou lesdites DCs marquées avec de la PGE₂.
- 10
3. Le procédé selon l'une des revendications 1 et 2, où les étapes (a) et (b) consistent en outre à mettre en contact lesdites cellules avec des GM-CSF et au moins une des IL-4 ou IL-13.
4. Le procédé selon l'une des revendications 1 et 2, où les cellules dendritiques CD83⁺ matures marquées de l'étape (a) sont des CCR7⁻.
- 15
5. Le procédé selon l'une quelconque des revendications précédentes, où l'agoniste du CD40 est choisi parmi un anticorps agonistique du CD40, un aptamer qui se lie au CD40 et un polypeptide CD40L.
6. Le procédé selon la revendication 5, où ledit polypeptide CD40L est choisi dans le groupe :
- 20
- a) un polypeptide comportant la SEQ ID NO: 2 ;
b) un fragment du polypeptide selon (a) où ledit fragment se lie au CD40, ou
- où ledit polypeptide CD40L est un polypeptide ayant au moins 77% d'identité de séquence d'un polypeptide choisi dans le groupe :
- 25
- a) un polypeptide comportant la SEQ ID NO: 2 ;
b) un fragment du polypeptide selon (a) où ledit fragment se lie au CD40.
- 30
7. Le procédé selon l'une quelconque des revendications précédentes, où le marquage avec un agoniste du IFN- γ R est effectué lors de la translation d'un mRNA codant un agoniste du IFN- γ R, et/ou lors de la mise en contact des dites iDCs avec un agoniste du IFN- γ R.
8. Le procédé selon la revendication 1, où ladite cellule dendritique est transfectée par électroporation.
- 35
9. Le procédé selon la revendication 1, où l'étape (a) consiste à ajouter l'agoniste du IFN- γ R et l'agoniste du TNF- α R à une culture comprenant lesdites iDCs, et où l'étape (b) consiste en une électroporation des dites cellules dendritiques CD83⁺ matures avec un mRNA codant un agoniste du CD40 pour produire les cellules dendritiques matures CCR7⁺, où ladite électroporation est effectuée approximativement 12 à 30 heures après l'addition, aux iDCs, de l'agoniste du IFN- γ R et de l'agoniste du TNF- α R.
- 40
10. Le procédé selon l'une quelconque des revendications précédentes, où le mRNA code un polypeptide du CD40L et comprend un polynucléotide choisi dans le groupe :
- 45
- a) un polynucléotide de SEQ ID NO:1 ;
b) un polynucléotide comprenant les nucléotides 40 à 822 de la SEQ ID NO: 1 ;
c) un polynucléotide ayant au moins 80% d'identité de séquence avec n'importe quel polynucléotide de (a) ou (b) ;
d) un polynucléotide s'hybridant dans des conditions sévères en n'importe quel polynucléotide de (a) à (c) ; et
e) un polynucléotide de (a) à (d), comprenant en outre une séquence non traduite 3' choisie dans le groupe des acides nucléiques de SEQ ID NO:14, 15, 16, 17 ou 18, et/ou une séquence non traduite 5' choisie dans le groupe des acides nucléiques de SEQ ID NO:19, 20, 21, 22, ou 23.
- 50
11. Le procédé selon l'une quelconque des revendications précédentes, où les DCs matures CCR7⁺ sécrètent de 0 à 500 pg IL-10 par 10⁶ DCs, et/ou sécrètent la protéine IL-12 p70.
- 55
12. Le procédé selon l'une quelconque des revendications précédentes, où les cellules dendritiques non matures sont préparées à partir de l'une des :
- (a) cellules de tige hématopoïétiques ou progénitrices CD34⁺ ,

EP 1 809 737 B9

- (b) cellules mononucléaires du sang périphérique (PBMCs), ou
(c) par mise en contact des dites PBMCs avec du GM-CSF en présence de IL-4 et/ou de IL-13.

- 5 13. Le procédé selon l'une quelconque des revendications précédentes, consistant en outre à introduire, dans lesdites iDCs, DCs marquées ou DCs matures CCR7⁺, un ou plusieurs antigènes ou un (des) polynucléotide(s) codant un ou plusieurs antigènes pour produire un DCs mature CCR7⁺ chargé d'antigènes.
- 10 14. Le procédé selon la revendication 13, où l'antigène est choisi parmi des pathogènes, des lysats pathogènes, des extraits de pathogènes, des polypeptides de pathogènes, des cellules cancéreuses, des lysats de cellules cancéreuses, des extraits de cellules cancéreuses et des polypeptides spécifiques de cellules cancéreuses.
- 15 15. Le procédé selon l'une des revendications 13 et 14, où un (des) polynucléotide(s) codant le (les) antigène(s) est (sont) introduit(s) dans lesdites iDCs, DCs marquées ou DCs matures CCR7⁺.
17. Le procédé selon la revendication 15, où ledit polynucléotide est introduit par électroporation.
17. Le procédé selon l'une des revendications 15 et 16, où le polynucléotide est un mRNA.
- 20 18. Le procédé selon l'une quelconque des revendications 14 à 17, où l'antigène codant le polynucléotide, qui est optionnellement un mRNA, est introduit en même temps que le mRNA codant l'agoniste du CD40.
19. Le procédé selon l'une quelconque des revendications 14 à 18, où l'antigène ou le polynucléotide est introduit,
- 25 (a) avant ledit premier marquage ;
(b) à la suite du dit premier marquage et avant ledit second marquage;
(c) à la suite du dit second marquage ; et/ou
(d) sensiblement en même temps que ledit second marquage.
- 30 20. Le procédé selon l'une quelconque des revendications précédentes, où ledit agoniste du TNF- α R est du TNF- α .
21. Le procédé selon l'une quelconque des revendications précédentes, consistant en outre à mettre en contact lesdites cellules dendritiques non matures avec de la PGE₂.
- 35 22. Le procédé selon l'une quelconque des revendications précédentes, où l'agoniste du IFN- γ R est du IFN- γ ou un fragment biologiquement actif de celui-ci.
23. Le procédé selon la revendication 22, où le IFN- γ a la séquence de SEQ ID NO:6.
- 40 24. Le procédé selon l'une quelconque des revendications 1 à 21, où ledit agoniste du IFN- γ R comprend un polypeptide ayant au moins 80% d'identité de séquence avec la SEQ ID NO:6.
- 45 25. Le procédé selon l'une quelconque des revendications précédentes, consistant en outre à mettre en contact lesdites cellules dendritiques non matures, lesdites cellules dendritiques marquées, ou lesdites cellules dendritiques CCR7⁺ avec un ligand des cellules NKT, où optionnellement ledit ligand des cellules NKT est un composé choisi dans le groupe : α -galactosylcéramides, α -glucosylcéramides, α -6-déoxygalactosylcéramides, α -6-déoxygalactofuranosylcéramides, β -6-déoxygalactofuranosylcéramides, β -arabinosylcéramides, α -C-galactosylcéramides et α -S-galactosylcéramides, et où en outre optionnellement ledit composé est du (2S, 3S, 4R)-1-O-(alpha-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadécane-1,3,4-triol (KRN7000).

50

55




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5a




FIG. 5b




FIG. 5c

FIG. 6A






FIG. 6B

FIG. 6C






FIG. 7




FIG. 8




FIG. 9




FIG. 10

FIG. 11a





FIG. 11b






FIG. 12




FIG. 13




FIG. 14

FIG. 15a

Expansion of NKT-cells in DC/PBMC co-cultures




FIG. 15b

Expansion of MART-1 reactive CTL by MART-1 transfected, KRN7000 pulsed CD40L base process matured DCs




FIG. 16a

```

# Program: needle
# Rundate: Tue Oct 05 21:36:57 2004
# Align_format: srspair
# Report_file: /ebi/extserv/old-work/needle-20041005-21365334534448.output
#####
#=====
#
# Aligned_sequences: 2
# 1: EMBOSS_001
# 2: EMBOSS_001
# Matrix: EDNAFULL
# Gap_penalty: 10.0
# Extend_penalty: 0.5
#
# Length: 1836
# Identity: 1033/1836 (56.3%)
# Similarity: 1033/1836 (56.3%)
# Gaps: 606/1836 (33.0%)
# Score: 4085.5
#
#
#=====

HUMAN CD40L      1 cttctctgccagaagataccatttcaactttaacacagcatgatcgaaac      50
                                     |||||.||.|||||||||.|||||
MOUSE CD40L      1                               ctttcagtcagcatgatagaaac      23

EMBOSS_001      51 atacaaccaaacttctccccgatctgcccactggactgcccac-agc      99
   |||||.|||||.|||||.|||.|||||.|||||.|||||.|||||.|||
EMBOSS_001      24 atacagccaaccttccccagatccgtggcaactggact-tccagcgagc      72

EMBOSS_001      100 atgaaaatttttatgtatttacttactgtttttcttatcaccagatgat      149
   |||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||
EMBOSS_001      73 atgaagatttttatgtatttacttactgttttccttatcaccctaaatgat      122

EMBOSS_001      150 tgggtcagcactttttgctgtgtatcttcatagaagggtggacaagatag      199
   |||.|||.|||.|||||.|||||.|||||.|||||.|||||.|||||.|||
EMBOSS_001      123 tggatctgtgctttttgctgtgtatcttcatagaagattggataaggctg      172

EMBOSS_001      200 aagatgaaaggaatcttcatgaagattttgtattcatgaaaacgatacag      249
   |||||.|||||.|||.|||||.|||||.|||||.|||||.|||||.|||||.|||
EMBOSS_001      173 aagaggaagtaaaccttcatgaagattttgtattcataaaaaagctaaag      222

EMBOSS_001      250 agatgcaacacaggagaaaagatccttatccttactgaactgtgaggagat      299
   |||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||
EMBOSS_001      223 agatgcaacaaaggagaaggatctttatccttgctgaactgtgaggagat      272

EMBOSS_001      300 taaaagccagtttgaaggctttgtgaaggatataatgttaacaaagagg      349
   .|.|||.|||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||
EMBOSS_001      273 gagaaggcaatttgaagaccttgtcaaggatataacgttaacaaagaag      322

EMBOSS_001      350 agacgaagaaagaaaacagcttgaatgcaaaaaggatgatcagaatcct      399
   |.|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||||.|||
EMBOSS_001      323 a---gaaaaaagaaaacagcttgaatgcaaaggatgatgaggatcct      369

```





Figure 18

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 52251204 P [0001]
- WO 9528479 A [0009]
- EP 0922758 A [0010]
- EP 0633930 B [0011]
- WO 20040152191 A [0012]
- RU 41740 [0012]
- US 20040146492 A [0013]
- US 20040038398 A [0014]
- WO 9527071 A [0055]
- WO 9500655 A [0055]
- WO 9511984 A [0055]
- US 6475483 B [0073]
- JP 3068910 B [0076]
- US 5767092 A [0076]
- US 5936076 A [0076] [0078]
- US 5849716 A [0077]
- US 5780441 A [0077]
- US 09721768 B [0077]
- US 6531453 B [0077]
- WO 03105769 A [0080]
- US 20040127429 A [0080]
- WO 03016326 A [0081]
- US 6635622 B [0082]
- US 5981724 A [0095]
- US 5962406 A [0095]
- US 4683195 A [0099]
- US 4800159 A [0099]
- US 4754065 A [0099]
- US 4683202 A [0099]
- US 20040072347 A [0102]
- US 20030235908 A [0102]
- US 0532710 W [0119]
- WO 2006031870 A [0119]
- US 5199942 A [0140]
- WO 9729182 A [0146]
- US 6075181 A, Kucherlapati [0155]
- US 4816567 A [0157]
- EP 404097 A [0158]
- WO 9311161 A [0158]
- US 6632926 B, Chen [0158]
- US 4603102 A [0161]
- WO 9710365 A [0166]
- US 5405783 A [0166]
- US 5412087 A [0166]
- US 5445934 A [0166]
- US 5578832 A [0166]
- US 5631734 A [0166]
- US 60522512 B [0217]

Non-patent literature cited in the description

- **Jonuleit et al.** *Exp. Med.*, 2000, vol. 192, 1213 [0006]
- **Dhodapkar et al.** *Exp. Med.*, 2001, vol. 193, 233 [0006]
- **Jonuleit et al.** *Eur J Immunol*, 1997, vol. 12, 3135-3142 [0008]
- **Macatonia et al.** *Immunol.*, 1995, vol. 154, 507 1 [0015]
- **Ahuja et al.** *Immunol.*, 1998, vol. 161, 868 [0015]
- **Unintford et al.** *Immunol.*, 1999, vol. 97, 588 [0015]
- **Schmidt et al.** *Immunol.*, 1999, vol. 163, 2561 [0015]
- **Mosca et al.** *Blood*, 2000, vol. 96, 3499 [0016]
- **Koya et al.** *J. Immunother*, 2003, vol. 26 (5), 451 [0017]
- **Mackey et al.** *J. Immunol.*, 1998, vol. 161, 2094 [0018]
- **Kuniyoshi, J.S. et al.** *Cell Immunol.*, 1999, vol. 193, 48 [0018]
- **Kalady, M.F. et al.** *J. Surg. Res.*, 2004, vol. 116, 24 [0018]
- **Faries et al.** *Blood*, 15 October 2001, vol. 98 (8) [0018]
- **Hwu et al.** *J. Immunol.*, 2000, vol. 164, 3596 [0018]
- **Grohmann et al.** *Trends Immunol.*, 2003, vol. 24, 242 [0018]
- **Sambrook et al.** MOLECULAR CLONING: A LABORATORY MANUAL. 1989 [0028]
- CURRENT PROTOCOLS IN MOLECULAR BIOLOGY. 1987 [0028]
- METHODS IN ENZYMOLOGY. Academic Press, Inc, [0028]
- **M. MacPherson et al.** PCR: A PRACTICAL APPROACH. IRL Press at Oxford University Press, 1991 [0028]
- PCR 2: A PRACTICAL APPROACH. 1995 [0028]
- ANTIBODIES, A LABORATORY MANUAL. 1988 [0028]
- USING ANTIBODIES, A LABORATORY MANUAL. 1999 [0028]
- ANIMAL CELL CULTURE. 1987 [0028]

- **Steinman.** *Ann. Rev. Immunol.*, 1991, vol. 9, 271-296 [0037]
- **Schwartz, R.H.** *Science*, 1990, vol. 248, 1349-1356 [0044]
- **Jenkins, M.K.** *Immunol. Today*, 1992, vol. 13, 69-73 [0044]
- **Liu, Y. et al.** *3. Exp. Med.*, 1992, vol. 175, 437-445 [0044]
- **Naujokas, M.F. et al.** *Cell*, 1993, vol. 74, 257-268 [0044]
- **Van Seventer, G.A.** *Immunol.*, 1990, vol. 144, 4579-4586 [0044]
- **Schwartz, R.H.** *Cell*, 1992, vol. 71, 1065-1068 [0044]
- **Freeman et al.** *Science*, 1993, vol. 262, 909-911 [0044]
- **Young et al.** *Clin. Invest.*, 1992, vol. 90, 229 [0044]
- **Nabavi et al.** *Nature*, 1992, vol. 360, 266-268 [0044]
- **Schlesinger ; Dubensky.** *Curr. Opin. Biotechnol.*, 1999, vol. 5, 434-439 [0053]
- **Zaks et al.** *Nat. Med.*, 1999, vol. 7, 823-827 [0053]
- **Hermonat ; Muzyczka.** *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 6466-6470 [0055]
- **Lebkowski et al.** *Mol. Cell. Biol.*, 1988, vol. 8, 3988-3996 [0055]
- **Martin.** REMINGTON'S PHARM. SCI. Mack Publ. Co, 1990 [0069]
- **Wierda et al.** *Blood*, 2000, vol. 96, 2917 [0071]
- **Ajdary et al.** *Infection and Immunity*, 2000, vol. 68, 1760 [0071]
- **Romani et al.** *Exp. Med.*, 1994, vol. 180, 83 [0072]
- **Caux, C. et al.** *Exp. Med.*, 1996, vol. 184, 695 [0072]
- **Shimieg J. et al.** *J. Exp. Med.*, 2003, vol. 198, 1631-1641 [0080]
- **Bach et al.** *Ann. Rev. Immunol.*, 1997, vol. 15, 563-591 [0084]
- **Lammas ; Casanova ; Kumararatne.** *Clin Exp Immunol*, 2000, vol. 121, 417-425 [0084]
- **Thiel et al.** *Structure*, 2000, vol. 8, 927-936 [0084]
- **Magro et al.** *Br J Pharmacol*, 26 July 2004 [0085]
- **Schonbeck ; Libby.** *Cell Mol. Life Sci.*, 2001, vol. 58, 4 [0093]
- **Gauchat et al.** *FEBS Lett.*, 1993, vol. 315, 259 [0094]
- **Graf et al.** *Eur. J. Immunol.*, 1992, vol. 22, 3191-3194 [0094]
- **Graf et al.** *Eur. J. Immunol.*, 1995, vol. 25, 1749 [0094]
- **Ludewig et al.** *Eur. J. Immunol.*, 1996, vol. 26, 3137 [0094]
- **Wykes et al.** *Eur. J. Immunol.*, 1998, vol. 28, 548 [0094]
- **Ledbetter, J.A. et al.** *Crit. Reviews in Immunol.*, 1997, vol. 17, 427 [0097]
- **Stewart et al.** *Solid Phase Peptide Synthesis.* Pierce Chemical Co, 1984 [0118]
- **Qin ; Gunning.** *Journal of Biochemical and Biophysical Methods*, 1997, vol. 36, 63-72 [0129]
- **Yang.** *Archives of Virology*, 2004, vol. 149, 303-321 [0130]
- **Stein et al.** *Molecular and Cellular Biology*, 1998, vol. 18, 3112-3119 [0132]
- **Roberts ; Boris-Lawrie.** *Journal of Virology*, 2000, vol. 74, 8111-8118 [0133]
- **Gallie et al.** *Gene*, vol. 165, 233-238 [0134]
- **Niepel ; Gallie.** *Journal of Virology*, 1999, vol. 73, 9080-9088 [0134]
- **Gallie.** *Journal of Virology*, 2001, vol. 75, 12141-12152 [0134]
- **Hruby.** *Life Sciences*, 1982, vol. 31, 189-199 [0139]
- **Hruby et al.** *Biochem J*, 1990, vol. 268, 249-262 [0139]
- **Inaba et al.** *3. Exp. Med.*, 1992, vol. 176, 1693-1702 [0141]
- **Paczesny et al.** *3 Exp Med.*, 2004, vol. 199, 1503-11 [0141]
- **Ho et al.** *Stem Cells*, 1995, vol. 13 (3), 100-105 [0141]
- **Yu et al.** *PNAS*, 1995, vol. 92, 699-703 [0141]
- **Sallusto ; Lanzavecchia.** *J. Exp. Med.*, 1994, vol. 179, 1109 [0146]
- **Romani et al.** *J. Exp. Med.*, 1994, vol. 180, 83 [0146]
- **Romani et al.** *J. Immunol. Methods*, 1996, vol. 196, 137 [0146]
- **Romani et al.** *Immunol. Methods*, 1996, vol. 196, 137 [0146]
- **Bender et al.** *J. Immunol. Methods*, 1996, vol. 196, 121 [0146]
- *Basic and Clinical Immunology.* 1991 [0150]
- *Enzyme Immunoassay.* CRC Press, 1980 [0151]
- *Practice and Theory of Enzyme Immunoassays.* **Ti-jan.** *Laboratory Techniques in Biochemistry and Molecular Biology.* Elsevier Science Publishers B.V, 1985 [0151]
- *Immunoassay: A Practical Guide.* Academic Press, 1987 [0151]
- *Principles and Practice of Immunoassays.* Stockton Press, 1991 [0151]
- *Non-isotopic Immunoassays.* Plenum Press, 1988 [0151]
- **Abbas et al.** *Cellular and Molecular immunology.* W.B. Saunders Company, 1991 [0152]
- **Kuby.** *Immunology.* W.H. Freeman and Company, 1992 [0152]
- **Russel et al.** *Infection and Immunity*, April 2000, 1820-1826 [0155]
- **Gallo et al.** *European J. of Immun.*, 2000, vol. 30, 534-540 [0155]
- **Green.** *J. of Immun. Methods*, 1999, vol. 231, 11-23 [0155]
- **Yang et al.** *J. of Leukocyte Biology*, 1999, vol. 66, 401-410 [0155]
- **Yang.** *Cancer Research*, 1999, vol. 59 (6), 1236-1243 [0155]
- **Jakovovits.** *Advanced Drug Delivery Reviews*, 1998, vol. 31, 33-42 [0155]

- **Green ; Jakobovits.** *Exp. Med.*, 1998, vol. 188 (3), 483-495 [0155]
- **Jakobovits.** *Exp. Opin. Invest. Drugs*, 1998, vol. 7 (4), 607-614 [0155]
- **Tsuda et al.** *Genomics*, 1997, vol. 42, 413-421 [0155]
- **Sherman-Gold.** *Genetic Engineering News*, 1997, vol. 17, 14 [0155]
- **Mendez et al.** *Nature Genetics*, 1997, vol. 15, 146-156 [0155]
- **Jakobovits.** WEIR'S HANDBOOK OF EXPERIMENTAL IMMUNOLOGY, THE INTEGRATED IMMUNE SYSTEM. 1996, vol. IV, 194.1-194.7 [0155]
- **Jakobovits.** *Current Opinion in Biotechnology*, 1995, vol. 6, 561-566 [0155]
- **Mendez et al.** *Genomics*, 1995, vol. 26, 294-307 [0155]
- **Jakobovits.** *Current Biology*, 1994, vol. 4, 761-763 [0155]
- **Arbones et al.** *Immunity*, 1994, vol. 1, 247-260 [0155]
- **Jakobovits.** *Nature*, 1993, vol. 362, 255-258 [0155]
- **Jakobovits et al.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 2551-2555 [0155]
- **Hollinger et al.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 6444-6448 [0158]
- **Zapata et al.** *Protein Eng.*, 1995, vol. 8 (10), 1057-1062 [0158]
- **Velculescu et al.** *Science*, 1995, vol. 270, 484-487 [0163]
- **MacPherson et al.** PCR: A PRACTICAL APPROACH. IRL Press at Oxford University Press, 1991 [0165]
- LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGY. Hybridization with Nucleic Acid Probes. Elsevier, 1993, vol. 24 [0166]
- **Korbling et al.** *Blood*, 1986, vol. 67, 529-532 [0173]
- **Haas et al.** *Exp. Hematol.*, 1990, vol. 18, 94-98 [0173]
- **Ware et al.** *Immunol.*, March 1983, vol. 131, 1312 [0180]
- **Fujihashi et al.** *J. Immunol. Meth.*, 1993, vol. 160, 181 [0180]
- **Tanquay ; Killion.** *Lymphokine Cytokine Res.*, 1994, vol. 13, 259 [0180]
- **Parkhurst et al.** *Immunol.*, 1996, vol. 157, 2539 [0180]
- **Shirai et al.** *J. Immunol.*, 1995, vol. 154, 2733 [0180]
- **Mosier et al.** *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 2443 [0180]
- **Caruso et al.** *Cytometry*, 1997, vol. 27, 71 [0180]
- **Bertoni et al.** *Immunol.*, 1998, vol. 161, 4447 [0180]
- **Salazar et al.** *Tnt. J. Cancer*, 2000, vol. 85, 829 [0180]
- **Isakov et al.** *J. Exp. Med.*, 1995, vol. 181, 375 [0180]
- **Luft et al.** *Blood*, 2002, vol. 100, 1362 [0207]
- **Scandella et al.** *Blood*, 2002, vol. 100, 1354 [0207]
- **Valmori, D et al.** *J. Immunol.*, 1998, vol. 160, 1750 [0210]